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Abstract
The function of the human endometrium is to accept the implanting embryo and provide an 
environment for its subsequent growth and development by forming the maternal side of the placenta. 
The endometrium undergoes rapid cyclic changes of cell proliferation, differentiation and renewal and 
briefly becomes receptive to the embryo allowing its attachment and subsequent invasion during the 
implantation window. These processes are controlled systemically by steroid hormones which are 
thought to activate and control local molecular effectors including chemotatic cytokines known as 
chemokines. Chemokines are known to recruit leukocytes by chemotaxis, but also have a wider 
multifunctional in the control of cell function.
Limited studies have shown expression of the chemokine ligand CXCL12 and its receptor CXCR4 in the 
human endometrium. However, little is known about the precise role of these molecules in endometrial 
function. To investigate this further, real-time RT-PCR was used to measure the expression of CXCL12 
and CXCR4 mRNA in endometrial biopsies throughout the menstrual cycle. Both CXCR4 and CXCL12 
were expressed by the endometrium at all stages of the cycle. Expression of CXCL12 mRNA was 
relatively low and did not change throughout the menstrual cycle. However, CXCR4 mRNA significantly 
increased during the early proliferative phase of the cycle, with a second slight increase during the mid 
secretory phase.
Expression of CXCL12 and CXCR4 in cultured human endometrial epithelial and stromal cells was 
investigated using real-time RT-PCR used to measure levels of CXCL12 and CXCR4 mRNA expression. 
CXCL12 expression was found to be higher in stromal cells compared to epithelial cells, while expression 
of CXCR4 was highest in the endometrial epithelial cells. Expression of CXCR4 mRNA was also 
investigated in Ishikawa and HEC-l-B cell lines. Both cell lines were found to express CXCR4 mRNA, 
though levels were higher in Ishikawa cells compared to HEC-l-B cells, which was more comparable to 
their primary epithelial cell counterparts.
Although the functions of CXCL12 in the endometrium remain unknown, CXCL12 has been shown to 
increase the expression of interleukin 6 (IL6), interleukin8 (IL8), matrix metalloproteinase 2 (MMP2), 
matrix metalloproteinase 9 (MMP9) and vascular endothelial growth factor A (VEGFA) in various non- 
endometrial cell types. As all of these factors have previously been shown to be of potential importance 
to endometrial function, their basal mRNA expression was quantified in primary epithelial and stromal 
endometrial cells and Ishikawa and HEC-l-B cell lines using real-time RT-PCR. To investigate effects of 
CXCL12 on these endometrial factors, all four endometrial cell types were incubated with CXCL12 and 
the expression of IL6, IL8, MMP2, MMP9 and VEGFA was measured using real-time RT-PCR. Basal levels 
of IL8 and MMP9 mRNA were found to be significantly higher in endometrial epithelial cells in 
comparison to stromal cells, while VEGFA was significantly higher in stromal cells in comparison to 
epithelial cells. Expression of IL6, IL8, MMP2 and MMP9 was several orders of magnitude lower in the 
Ishikawa and HEC-l-B cell lines in comparison to their primary epithelial counterparts suggesting that 
these cell lines are not good models to investigate endometrial function. Incubation with CXCL12 had 
no significant effect on the expression of any of these factors, in primary epithelial, stromal, Ishikawa or 
HEC-l-B cells, which suggests CXCL12 may not regulate their expression in the endometrium.
To investigate the potential wider effects of CXCL12 on the expression of endometrial factors, a 
genome-wide microarray expression analysis was carried out in Ishikawa cells. Incubation of these cells 
with CXCL12 resulted in the identification of fifty one mRNA transcripts that were shown to be 
significantly and reproducibly up-regulated by CXCL12. Fourteen of these transcripts were produced by 
unknown genes, but thirty seven transcripts could be identified and potential functions attributed to 
them. Several of these genes have previously been shown to be of potential importance to endometrial 
function or to be known components of the CXCR4 signaling pathways.
Overall, the results of this study have increased our knowledge of the expression and cellular 
distribution of CXCL12 and CXCR4 in the endometrium. This study has also identified several potential 
roles for CXCL12 and CXCR4 in endometrial function which would warrant further investigation.
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Chapter 1 
General Introduction
1.1 The human female reproductive tract
The functions of the human female reproductive tract are to facilitate fertilisation of 
the oocyte by spermatozoa and to provide a suitable environment to allow 
implantation and the subsequent development of the resulting embryo (Johnson and 
Everitt, 1995, Chapter 5). The morphology of the human female reproductive tract is 
shown in Figure 1.1 and can be divided into distinct components. The ovaries are 
responsible for the cyclic release of oestrogen and progesterone which control female 
reproductive function and are the sites of episodic oocyte maturation and release. The 
function of the fallopian tubes (oviducts) is to transport released oocytes from the 
ovaries to the uterus. They consist of the fimbria, which are adjacent to the ovaries 
followed by the ampullary and isthmus regions of the tube which connects to the 
uterus. The ampullary region is the site of fertilisation where spermatozoa travel to 
meet the oocyte following their deposition in the vagina. The fallopian tube is also the 
site of early embryonic development that occurs prior to implantation.
The processes of implantation and placentation take place in the uterus. It is the site 
of embryonic and fetal growth and development (Johnson and Everitt, 1995, Chapter 
5). The upper portion of the uterus is termed the body and the fundus, which is the 
part of the uterine body that extends above the junctions of the fallopian tubes. The 
lower portion of the uterus is termed the cervix. The uterus is covered with a 
connective tissue layer called the peritoneum which extends laterally to form the 
broad ligaments from which the ovaries are suspended. The wall of the uterus is 
composed of a thick smooth muscle layer termed the myometrium and a vascular 
mucosal layer called the endometrium which varies in thickness through the phases of 
the menstrual cycle and is the first point of maternal contact for the implanting 
embryo. Adjacent to the cervix is the vagina, which are the sites of spermatozoa 
deposition and capacitation but also allows the delivery of the fully developed infant.
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Figure 1.1: Anatomy of the female reproductive tract (Taken from Johnson and 
Everitt, 1995, Chapter 5)
The major components of the female reproductive tract showing; the ovaries, fallopian 
tubes, uterus, endometrium and cervix.
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1.1.1 The ovaries and oocyte maturation and release
The adult human ovary contains an inner vascular medulla containing blood vessels 
which branch off into smaller blood vessels that penetrate the surrounding outer 
cortex (Sadow, 1980). The cortex is composed of stromal cells and contains the 
primordial follicles. The follicles are the site of oocyte maturation and are considered 
the fundamental functional unit of the ovary. The primordial follicle consists of 
flattened mesenchymal cells known as granulosa cells, condensed around a primordial 
germ cell which becomes the primary oocyte.
At birth each ovary contains approximately 2xl06 primary oocytes, the majority of 
which undergo atresia during infancy (Jonhson and Everitt, 1995, Chapter 5). By the 
onset of puberty approximately only 40,000 oocytes remain. Following the onset of 
puberty, a small number of follicles are recruited daily into further growth resulting in 
a process of continuous follicular growth and maturation. Between the onset of 
puberty and menopause the ovarian cycle allows the release of one mature oocyte 
from the ovarian follicle approximately every 28 days, a process that will occur 
approximately 400 times in a human females reproductive life (Chabbert-Buffet and 
Bouchard, 2002). Figure 1.2 illustrates the process of follicular development, which 
occurs during the ovarian cycle. The first half of this cycle is termed the follicular 
phase and is the period during which ovarian follicles mature leading to ovulation. The 
latter half of the cycle is termed the luteal phase in which the corpus luteum forms.
When a primordial follicle is selected to recommence growth, it passes through three 
developmental phases prior to ovulation (Johnson and Everitt, 1995, Chapter 5). It first 
becomes a primary preantral follicle before developing into a secondary antral follicle 
and finally becomes a mature tertiary follicle just prior to ovulation itself. The duration 
of these phases varies with the preantral phase being the longest and the preovulatory 
phase the shortest. The preantral phase is characterised by an increase in the 
diameter of the primordial follicle. The primary oocyte is responsible for much of this 
growth as it reaches its final size. The oocyte remains in a state of meiotic prophase 
but synthesises large amounts of mRNA and rRNA to facilitate protein production, 
which is vital for the later stages of
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Figure 1.2: Maturation of human o\/arian follicles (Taken from  Findlay, 1984) 
Shows the transition from the primordial follicle to the mature follicle prior to oocyte 
release.
4
oocyte maturation and the first days of development of the fertilised oocyte. In the 
preantral to antral transition, granulosa cells continue to proliferate resulting in a 
further increase in follicular size. This is accompanied by the appearance of follicular 
fluid between the granulosa cells. This is comprised partly of granulosa cell secretions 
and partly of serum transudate. The fluid coalesces to form a single follicular antrum 
marking the onset of the antral phase.
When the maturing antral follicle is ready to enter the preovulatory phase, the 
pituitary hormones, luteinising hormone (LH) and follicle-stimulating hormone (FSH) 
are required to complete the development of the maturing oocyte (Johnson and 
Everitt, 1995, Chapter 5). Follicular receptors for LH and FSH first appear on cells in the 
late preantral and early antral phases. In the early antral phase, only cells of the theca 
interna bind LH while the granulosa cells bind FSH. The antral follicles produce 
increasing amounts of steroids as they grow under the influence of the gonadotrophins 
LH and FSH. The main oestrogens produced by the antral follicles are oestradiol 173 
and oestrone. The antral follicles also account for the production of 30-70% of the 
androgens, androstenedione and testosterone that circulate in human females, with 
the remaining androgen production coming from the adrenal gland. Thecal cells are 
thought to synthesise androgens and oestrogens from acetate and cholesterol and LH 
is known to stimulate this process. Granulosa cells are capable of the aromatization of 
androgens to produce oestrogens, a process stimulated by FSH. The oestrogens, 
progestagens and androgens can all be detected in the follicular fluid as well as 
systemically in the blood and are thought to have intrafollicular roles as well as 
implementing their wider effects. A positive feedback mechanism in which oestrogens 
produced in the follicle bind receptors on granulosa cells causing their proliferation 
and leading to further conversion of androgens to oestrogens, leads to further 
granulosa cell proliferation. This process culminates towards the end of antral 
expansion in a surge of circulating oestrogens produced by the most advanced follicles. 
This surge in circulating oestrogens causes a rapid increase in FSH levels by acting on 
the pituitary and hypothalamus by a positive feedback mechanism. The FSH surge 
occurs on approximately day 14 of the menstrual cycle with levels peaking 
approximately 18 hours before ovulation.
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Just prior to the onset of the preovulatory phase, receptors for LH appear on the outer 
layer granulosa cells in response to increased levels of oestrogen and FSH. 
Approximately 18 hours prior to oocyte release there is a rapid surge in LH levels that 
is responsible for causing ovulation. LH binds LH receptors on both the granulosa cells 
and the thecal cells, causing the antral follicle to enter the preovulatory phase. If this 
does not happen the antral follicle dies.
The LH surge causes a rapid preovulatory growth phase in the oocyte and its 
subsequent release into the fallopian tube at ovulation, which leaves the follicle to 
become a corpus luteum once the oocyte is released at ovulation (Johnson and Everitt, 
1995, Chapter 5). As the length of the follicular phase can vary and ovulation does not 
always occur precisely on day 14 of the menstrual cycle, a more precise means of 
describing the day of ovulation is to refer to it as LH+0 (day of the LH surge) with 
subsequent days numbered accordingly (e.g. day 20 of the 'ideal' menstrual cycle 
would be termed LH+6) (Li e ta l, 1988).
Corpus luteum formation occurs during the luteal phase of the ovarian cycle (Jones 
and Lopez, 2006). The post-ovulatory follicle becomes a collapsed sac. The initial post­
ovulatory structure is termed the corpus haemorrhagicum due to blood clot formation 
on its surface. The luteinised granulosa cells within the collapsed follicle begin to 
divide and enter the antral cavity to form the corpus luteum. This is penetrated by 
blood vessels from the thecal layer which grows into the central luteal cell mass. LH is 
essential for corpus luteum function in human females and cells of the corpus luteum 
secrete high amounts of progesterone and moderate amounts of estradiol. The corpus 
luteum begins to degenerate just prior to menstruation but if pregnancy occurs it does 
not die and continues to function in the first trimester of pregnancy.
1.1.2 The human uterus
The uterus is an inverted pear-shaped organ situated in the pelvic cavity of the human
female (Jones and Lopez, 2006). The uterus is supported by bands of connective tissue
known as the uterine ligaments, which attaches the uterus to the pelvic wall on each
side. Paired uterosacral ligaments attach the lower end of the uterus to the sacrum.
Lateral cervical ligaments connect the cervix and vagina to the pelvic wall and round
ligaments attach near the entrance of the oviducts to the lower pelvic wall. These
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ligaments carry blood vessels and nerves to the uterus and serve to support the uterus 
and other pelvic organs in their normal position. The walls of the uterine cavity are 
composed of three layers of tissue. The external surface of the uterus is covered by a 
thin membrane called the perimetrium, a continuous layer, which covers the oviducts 
and other peritoneal organs. Inside the perimetrium is a thick layer of smooth muscle 
known as the myometrium. The myometrium is capable of undergoing strong 
contractions during labour and also exhibits contractile patterns throughout the 
menstrual cycle. The final innermost layer of tissue within the uterus lines the 
myometrium and is known as the endometrium.
1.1.3 The human endometrium
The human endometrium is composed of two layers which form the innermost walls of 
the uterine cavity. It is composed of two major cell types: epithelial cells and stromal 
cells (Jones and Lopez, 2006). The epithelial layer is composed of a mixture of ciliated 
and secretory simple columnar epithelial cells on the endometrium's inner surface 
which fold inwards to form the luminal epithelium and is the first point of contact for 
the implanting blastocyst. Glandular epithelium is formed by the budding of luminal 
epithelium into distinct structures. The endometrial glands secrete a wide range of 
proteins and other factors that are thought to contribute to the function of the 
endometrium and provide nutrition to the embryo in the earliest stages of pregnancy 
(Gray et o/., 2001). Stromal fibroblasts are found beneath the luminal epithelial layer 
and surround the glandular epithelium to form the main body of the endometrium 
(Sadow, 1980). A population of endometrial leukocytes is present in the endometrial 
stroma. The upper layer of endometrium is known as the stratum functional and acts 
as the functional layer of the endometrium. It is this layer of the endometrium that is 
shed during menstruation. It contains characteristic spiral arteries which provide 
blood supply. The stratum basale is the basal layer of the endometrium and is 
connected to the uterine smooth muscle layer known as the myometrium. This layer 
of the endometrium is not shed during menstruation but provides the base for 
endometrial proliferation following menses at the beginning of a new menstrual cycle. 
Endometrial blood supply is provided by the uterine arteries. Basal arteries provide 
the stratum basale with a continuous supply of blood while spiral arteries permeate
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the stratum functionalis and are shed with the rest of this layer during menstruation. 
Steroid hormones produced within the ovaries tightly regulate the proliferation and 
cellular activity of the endometrium to facilitate its function, which is to allow the 
implantation of the embryo during the implantation window (Figure 1.3).
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Figure 1.3: The structure of the human endometrium (Taken from Sadow, 
1980)
Showing the layers of the endometrium, spiral and basal arteries and the smooth 
muscle myometrium.
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1.1.4 The Menstrual cycle
The human endometrium is dynamic. Endometrial morphology and function undergo 
characteristic changes with each menstrual cycle (Chabbert-Buffet and Bouchard, 
2002; Jabbour et al., 2006 and Johnson and Everitt, 1995, Chapter 5). The human 
female menstrual cycle lasts for approximately 28 days with a range of 25 to 35 days 
considered to be normal. Changes in ovarian oestrogen and progesterone levels are 
responsible for the regulation of a cascade of locally acting factors within the 
endometrium which controls both endometrial thickness and its receptivity to 
implantation by the embryo. Endometrial thickening occurs in response to the 
oestrogen surge in the latter half of the follicular phase of the ovarian cycle. 
Oestrogens bind receptors found throughout the endometrium and causes 
endometrial thickening due to a proliferation of stromal cells. This is often termed the 
proliferative phase of the menstrual cycle (days 0-14). Endometrial thickening must 
occur to provide an adequate environment for the implanting embryo with a suitable 
blood and nutrient supply for further development (Figure 1.4).
One of the molecular effects of the oestrogen surge is to increase the expression of 
endometrial progesterone receptors in the endometrium, which bind progesterone 
during the luteal phase of the ovarian cycle (Chabbert-Buffet and Bouchard, 2002; 
Jabbour et ol., 2006 and Johnson and Everitt, 1995, Chapter 5). Progesterone acts on 
the endometrium to cause cellular differentiation and initiates the release of 
endometrial mucosal secretions by the epithelial cells in the endometrial glands. 
These secretions are rich in glycoproteins, sugars and amino acids. Progesterone also 
acts to increase the proliferation and size of the stromal cells and stimulates full 
development of the spiral arteries. This latter phase of the menstrual cycle is often 
termed the secretory phase (days 15-28) and acts to allow the endometrium to receive 
the implanting blastocyst. If pregnancy does not occur and under the influence of 
falling progesterone levels the death of endometrial tissue occurs. Shedding of the 
secretory epithelium and stratum functionalis occurs along with blood from ruptured 
spiral arteries via the cervix and vagina in the process termed menstruation. 
Menstruation marks the beginning of a new menstrual cycle following a brief rise in 
FSH which is thought to initiate the new ovarian and therefore endometrial cycles.
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Figure 1.4: Effects of cyclic hormonal changes on the menstrual and ovarian 
cycles (Taken from Jones and Lopez; 1984)
Effective human female reproductive function relies on coordinated hormone release 
to control the progression of the ovarian and uterine cycles.
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1.1.5 Morphological changes in the endometrium throughout the cycle
Microscopy has revealed that the cellular structure of the endometrium changes 
throughout the menstrual cycle in a characteristic manner (Noyes et ol., 1950). During 
the early proliferative phase of the menstrual cycle (days 4-7), the epithelial surface is 
observed as very thin prior to its regeneration following menstruation. The epithelial 
glands are generally short, straight and narrow and the surrounding stromal cells 
appear as compact and spindle shaped with large nuclei. As the endometrium 
develops into the mid-proliferative phase (days 8-10) the surface epithelium becomes 
columnar and the endometrial glands become longer, there is also evidence of stromal 
oedema. The late proliferative phase (days 11-14) is characterised by active growth 
and pseudostratification of the epithelium and an increase in stromal density.
The secretory epithelial cells are either elongated or polygonal and vary in size. The 
microvilli are short but develop as the endometrium moves through the proliferative 
phase (Nikas et a i, 1999a). By day 16 the epithelial glands have increased in size and 
tortuosity and by day 17 the microvilli are long, thick and upright. The appearance of 
subnuclear vacuoles by the nucleus of the glandular epithelium is also important for 
dating endometrial samples at this time (see B and C, Figure 1.5). By day 18 the 
microvilli appear to be swollen and by day 19 they begin to fuse and disappear and are 
replaced by smooth membrane projections which fold in on themselves to form 
pinopodes which appear on day 20 (Nikas et al., 1999b). Pinopodes are progesterone 
dependent organelles which are visible between days 20 and 21 of the menstrual 
cycle. The functional significance of pinopodes appearing during the implantation 
window still remains unclear but they are thought to possibly play a role in the 
adhesion of the blastocyst to the endometrial epithelium. Following their appearance 
for 24-48 hours the pinopodes are replaced by reappearing microvilli (Cavanga and 
Mantese, 2003). It is at this time in the menstrual cycle that intraluminal secretory 
material peaks and there is the onset of massive stromal oedema. On day 23, the 
spiral arteries have become more prominent which indicates the predecidualisation of 
the stroma and by day 24 there are collections of predecidual cells around the 
arterioles with continued stromal proliferation. Differentiation of the predecidua 
continues into day 26 by which time the cells have developed into decidual cells. If by 
day 24, pregnancy has not occurred, the glandular secretions cease and the epithelium
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undergoes involution while the glands dilate. There is a characteristic increase in the 
abundance of polymorphonuclear leukocytes by day 27 (Bulmer et al., 1991) and areas 
of focal necrosis and haemorrhage become apparent a few hours prior to the onset of 
menses (Noyes etal., 1950).
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Figure 1.5: Morphological changes o f the endometrium through the menstrual 
cycle (Images courtesy o f Dr Susan Laird)
Characteristic changes in endometrial cell morphology can be observed through the 
menstrual cycle, (a) During the proliferative phase of the cycle the endometrial glands 
are compact with the majority of the endometrial tissue composed of stromal cells, 
(b) Following the LH surge and under the influence of progesterone the endometrial 
glands become visibly larger occupying more of the endometrial tissue space, (c) By 
LH+3 the presence of secretary vesicles within the glandular epithelial cells can be 
noticed, (d) By LH+6 secretory material is released from the glandular epithelial cells 
and accumulates within the lumen of the endometrial glands, (e) Following the end of 
the implantation window and providing pregnancy does not occur; oedema occurs in 
the stromal compartment. The epithelial cell layer collapses and along with cells of the 
stratum functionalis start to die as menses begins.
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1.2 Implantation
Human embryo implantation is a complex process and requires synchronous 
development of a receptive endometrium and activated blastocyst (Hannan et ol., 
2006).
1.2.1 Gamete transport to the site of fertilisation
Following coitus and spermatozoa deposition in the vagina, spermatozoa travel into 
the cervix and uterus under their own propulsion and aided by currents of fluid 
created by the action of uterine cilia (Johnson and Everitt, 1995, Chapter 10). 
Spermatozoa migrate to the isthmus of the oviduct and have been identified in the 
oviduct as soon as 2-7 hours post-coitus. The number of living spermatozoa found in 
the oviduct rarely exceeds several hundred. Although it is not known how the flow of 
spermatozoa to the oviduct is regulated it is thought the cervical crypts may act as a 
reservoir to control sperm release into the uterus and that the uterotubal junction may 
regulate entry into the oviduct by action as an intermittent sphincter. Upon reaching 
the isthmus of the oviduct, spermatozoa become immotile and linger only re-acquiring 
motility at ovulation where they swim to the ampullary-ishthmic junction, the site of 
potential fertilisation.
While spermatozoa are moving towards the oviducal ampulla, the ovulated oocyte is 
picked up from the ovary surface in the peritoneal cavity by the fimbriated ostium of 
the oviduct and swept by oviducal cilia along the ampulla towards the junction of the 
isthmus.
It is only when spermatozoa reach the uterus and oviduct that they reach their full 
capacity to fertilise the oocyte (Johnson and Everitt, 1995, Chapter 10). This process is 
called capacitation and involves the stripping of glycoprotein molecules from the 
spermatozoa surface. Providing spermatozoa are present when the oocyte reaches 
the ampullary-ishthmic junction, a capacitated spermatozoon can fertilise the occyte 
causing maternal and paternal chromosomes to come together to form the zygote.
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1.2.2 Blastocyst Development
Upon zygote formation cell cleavage occurs to form a two-cell stage embryo which 
remains in the oviduct for 3-4 days where each of the two cells undergoes a series of 
divisions (Johnson and Everitt, 1995, Chapter 10). Once the 8-16 cell stage is reached 
the embryo undergoes compaction resulting in the formation of a morula, which is 
complete by the time the developing embryo reaches the uterine cavity. The morula 
becomes polarised following the minimising of intracellular contacts and two cell types 
are formed. This initial cellular differentiation allows the formation of the inner cell 
mass and the trophoectoderm cells. This process occurs at the 32-64 cell stage and it 
is at this stage that the embryo is termed the blastocyst.
The trophoectoderm forms an outer rim of cells. This is the first extra-embryonic 
tissue and it is termed the trophoblast. The cells that form the trophoblast are 
responsible for the initial contact at the feto-maternal interface which continues to 
develop to become the fetal component of the placenta. The trophoblast cells 
surround a blastocoelic cavity which contains blastocoelic fluid and the inner cell mass, 
the inner cell mass moves to reside within the trophoblastic wall. It is this part of the 
trophoblast that makes contact with the endometrium at the luminal epithelium.
The blastocyst enters the uterine cavity approximately 3-4 days after ovulation. It then 
floats freely within the uterine cavity for a further 3-4 days before implanting (Johnson 
and Everitt, 1995, Chapter 10). Nutritional support for the blastocyst is provided by 
secretions from the glandular epithelium of the endometrium promoted by 
progesterone during the secretory phase of the menstrual cycle. Approximately 6 days 
post-ovulation (LH+6), the zona pellucida of the blastocyst comes away and exposes 
the trophoblast allowing the inner cell mass of the embryo to implant into the 
endometrial epithelium (Figure 1.6).
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Figure 1.6: Diagram showing the development o f the embryo prior to 
endometrial implantation (Taken from  Dey et a i, 2010)
Showing oocyte release following the LH surge, fertilisation in the fallopian tube and 
subsequent development prior to implantation in the receptive endometrium leading 
to placental formation and subsequent parturition.
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1.2.3 Endometrial receptivity to implantation
For successful human embryo implantation to take place, the endometrium must be 
receptive to the apposition, adhesion and invasion of the blastocyst (Achache and 
Revel, 2006 and Cavanga and Mantese, 2003). The endometrium is only receptive to 
these processes for a short period of time which is termed the 'implantation window'. 
In humans, the implantation window is approximately four days long and occurs 
between days 20 and 24 of the menstrual cycle (LH+7 to LH+10). The preparation of 
the endometrial tissues to facilitate this process occurs under the influence of the 
steroid hormones as the endometrium develops through the proliferative phase under 
the influence of oestrogens and enters the secretory phase under the influence of 
progesterone. Steroid hormones bring about their effects in the endometrium by 
affecting the expression of many cytokines and growth factors that finely control the 
cyclic cellular processes of proliferation, differentiation and apoptosis within the 
endometrium. This is thought to be achieved using autocrine, paracrine and endocrine 
mechanisms. These factors must act together during the implantation window to 
facilitate a synchronised cross-talk between the functional blastocyst and receptive 
endometrium to allow successful blastocyst attachment to the endometrium's 
mucosal epithelium and subsequent invasion into the stroma.
1.2.4 The implantation process
The process of implantation consists of three distinct phases. The first phase is the 
apposition, in which the blastocyst correctly orientates itself towards the endometrial 
epithelium so that the inner cell mass faces the epithelial surface (Johnson and Everitt, 
1995, Chapter 10). Following this, the zona pellucida (ZP) of the blastocyst is shed 
exposing the trophoblast cells. The process of ZP shedding is thought to be aided by 
two serine proteases named implantation serine protease 1 (ISP1) and ISP2. ISP1 is 
produced by the blastocyst while ISP2 is secreted from the glands of the endometrium. 
The blasotcyst itself undergoes metabolic activation at this stage, increasing mRNA 
production and preparing it for implantation and subsequent development (O'Sullivan 
et ol., 2001). As no direct contact between the blastocyst and endometrial epithelial 
surface occurs during the process of apposition, crosstalk must occur between the two
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via soluble mediators including growth factors and cytokines such as LIF and IL11 
(Hannan etol., 2006) (Figure 1.7).
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Figure 1.7: The implantation process (taken from Fitzgerald et at., 2008)
The figure shows a proposed scheme of blastocyst attachment and stromal invasion 
during the implantation window including implicated morphological and biochemical 
markers: (1) Representation of the free floating blastocyst (BL) surrounded by the zona 
pellucida (ZP). (2) Blastocyst hatching from the zona pellucida. (3) Gradual apposition 
of blastocyst to the endometrium during the onset of the implantation window 
accompanied by the presence of two biomarkers of implantation; Pinopode (P) 
formation and maximal endometrial expression of LIF (blue) which binds to its receptor 
on the surface of the blastocyst (green). (4) The blastocyst adheres to the 
endometrium. The endometrium itself secretes gpl30 (red) and expresses the LIF 
receptor. (5) The syncytiotrophoblast (ST) invades the luminal epithelium of the 
endometrium and secretes cytokines such as IL1 which in turn stimulates LIF 
expression in the glandular epithelium (GE). (6) The implantation window is complete. 
The blastocyst has invaded the decidualising stroma and the epithelium of the 
endometrium has been restored (Fitzgerald etol., 2008).
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The second phase of implantation is the adhesion of the trophoblast cells of the 
blastocyst to luminal epithelial surface of the endometrium. It is at this time that the 
characteristic morphological markers of implantation, such as the presence of 
pinopodes and biochemical markers, including cellular adhesion molecules (CAMs), 
integrins and selectins are thought to be of greatest importance (Diedrich et ol., 2007) 
(see section 1.2.6). These adhesion molecules allow the trophectoderm to make and 
maintain contact with the endometrial epithelium, while cytokines such as Leukemia 
inhibitory factor (LIF), interleukin 1 (IL1) and interleukin 11 (IL11) are thought to 
maintain crosstalk between the trophoblast and decidualising stromal cells.
The final phase of the implantation process is invasion. Within a few hours following 
the attachment of the blastocyst to the endometrial epithelium, the epithelial cells 
that lie beneath the trophoblast cells become eroded allowing trophoblast invasion to 
occur (Johnson and Everitt, 1995). To facilitate the invading trophoblast and support 
subsequent development of the embryo the stromal fibroblasts undergo 
transformation to decidual cells (Fazleabas and Strakova, 2002). Morphologically the 
fibroblast-like stromal cells become polygonal and begin to express decidual proteins. 
This process is thought to be central to controlling the invasion of the trophoblast, 
providing the necessary nutrional support and protecting the embryo from maternal 
immune rejection.
Trophoblast is an embryonic tissue which plays a crucial role in the processes of 
implantation and placentation (Hannan et a!., 2006 and Lunghi et al., 2007). The 
implanting embryo begins to form floating and anchoring villi which expands as 
pregnancy develops. The villi are composed of specialised trophoblast cell types 
named the syncytiotrophoblast (ST). The initial function of the ST is lytic and mediates 
early invasion. Later the ST acts as a barrier through which nutrient exchange can take 
place. Other trophoblast cells retain their phenotype and line the chorionic villi. These 
are known as cytotrophoblast (CT) cells and act as stem cells for the production of 
further ST cells. ST fuse cells together to form an external layer of non-proliferative 
multinucleated ST, which grows due to the steady incorporation of new cells provided 
by the CT and occurs as EVTs invade the maternal arteries. The ST functions to 
mediate the exchange of nutrients, gas and waste products between the fetal and 
maternal blood.
21
The ST possesses endocrine activity and releases hormones required for successful 
pregnancy including chorionic gonadotrophin (CG) and placental lactogen (PL). CG is 
known to directly contribute to corpus luteum rescue and also modulates the uterine 
environment (Cameo et al., 2004 and Lunghi et al., 2007). At approximately 14 days 
post implantation, CT cells penetrate through the syncytium, some cells remain at the 
tips of the villi as a solid core and are known as the cytotrophoblast cell column (CC). 
This anchors the placental villi to the decidua, establishing a physical connection 
between the fetus and mother. These columns spread laterally and form the CT shell 
from which, invading extravillous cytotrophoblast (EVT) cells originate (Hannan et al., 
2006 and Lunghi etal., 2007).
CT cells break through the ST layer and differentiate into extravillous trophoblast (EVT) 
cells which begin to invade the uterine stroma as trophoblastic cell columns. At the 
distal portion of the cell column, cytotrophoblast cells differentiate into an invasive 
phenotype and then either invade the maternal blood vessels and become vascular 
EVTs (vEVTs) or migrate through the decidua as interstitial EVTs (iEVTs). The iEVTs 
invade the maternal spiral arteries where they contribute critically, to extensive 
remodeling. The vEVTs invade the maternal arteries at the point where the shell 
contacts the opening of the maternal vessels and aggregate to form plugs (Hannan et 
al., 2006 and Lunghi etal., 2007).
1.2.5 Decidualisation and placentation
Evidence found in rodents shows, within a few hours following the attachment of the 
blastocyst to the endometrial epithelium, the immediately underlying stroma 
undergoes an increase in vascular permeability, displays oedema and changes in 
extracellular matrix structure and stromal cell morphology (Johnson and Everitt, 1995, 
Chapter 10). This is accompanied by a progressive sprouting and ingrowth of 
capillaries. These stromal cell changes in response to blastocyst attachment are 
collectively called the primary decidualisation reaction. In the next 2-3 days following 
the initiation of the primary decidualisation reaction, further secondary decidualisation 
spreads throughout the endometrial stroma.
The process of decidualisation involves functional and morphological changes in
endometrial stromal cells, uterine glands and vessels as well as endometrial leukocyte
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populations (Lunghi et al., 2007). In humans, decidualisation is independent of the 
blastocyst's presence in the uterine cavity and begins in the late secretory phase of the 
menstrual cycle and is thought to be evoked by progesterone.
Decidualisation continues during early pregnancy and is thought to regulate 
subsequent trophoblast invasion and formation of the placenta by altering expression 
of regulatory factors including; matrix metalloproteinases (MMPs), cytokines, surface 
integrins and major histo-compatibility (MHC) molecules (Hess et al., 2006). The 
trophoblast releases paracrine signals in response to this, including cytokines, 
chemokines and angiogenic growth factors, which further modulates decidual stromal 
cell gene expression. Decidual stromal cell morphology changes to show 
ultrastructural similarities with myofibroblast and epithelial cells (King, 2000). They 
are known to release several factors including; prolactin, relaxin, rennin, insulin-like 
growth factor binding protein (IGFBP1) and specific extracellular matrix proteins such 
as laminin and fibronectin. The decidualised stromal cells themselves produce various 
growth factors and cytokines such as IL6 and IL8 and MMPs, which regulate 
trophoblast invasion under the general control of progesterone (Brar et al., 2001 and 
Hess et al., 2006). In vitro studies have demonstrated that this event correlates to 
changes in steroid hormone receptor expression and steroid metabolism, remodeling 
of the extracellular matrix (ECM) and cytoskeleton, altered expression of enzymes, 
growth factors and cytokines and also induction of apoptosis modulators and specific 
transcription factors.
Elongation of the maternal spiral arteries occurs through endometrial angiogenesis 
(Lunghi et al., 2007). The decidual tissue that surrounds the invading trophoblast acts 
as a nutrient reservoir for the embryo which survives from using maternal secretions 
provived by the glandular epithelial glands of the decidualising endometrium (Burton 
et al., 2002.) Maternal blood flow to the developing placenta is not fully established 
until the third month of gestation. This strongly suggests that initial fetal nutrition is 
histiotrophic in nature. The maternal uterine glands are present and remain active 
until at least week 10 of pregnancy during which time, their secretions are freely 
delivered freely into the placental intervillous space. Initial organogenesis of the fetus 
therefore occurs when metabolism is essentially anaerobic. However, this process of
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histiotrophic nutrition soon becomes inadequate to support the growing embryo 
(Johnson and Everitt, 1995, Chapter 10).
To supply the developing fetus with the nutrients it requires as it grows, the 
decidualised endometrium develops a region of highly specialised and vascularised 
tissue (Johnson and Everitt, 1995, Chapter 10). The embryo also develops a 
corresponding vasculature and this zone of contact between the mother and the 
embryo is called the placenta. The endometrial epithelium becomes incorporated into 
the developing placenta which provides haemotrophic nutrition to the embryo by 
allowing the rapid exchange of materials between two distinct maternal and 
embryonic vasculatures. Placental formation is characterised by extensive proliferation 
of embryonic tissue to give a large surface area for material exchange, the presence of 
a highly developed vasculature between the fetal and maternal components and an 
intimately composed, but physically separate fetal and maternal blood flows.
1.2.6 Role of adhesion molecules in the implantation process
The endometrium's capacity to be receptive to the implantation of the blastocyst 
during the implantation window is associated with the expression of genes encoding 
proteins which function to aid the implantation process and can therefore act as 
biomarkers for the normal functioning of the receptive endometrium and the onset of 
the implantation window (Achache and Revel, 2006).
During blastocyst apposition, trophoblast cells adhere to the receptive endometrial 
epithelium. This process is thought to be facilitated by the presence of cellular 
adhesion molecules (CAMs) on the surfaces of the epithelial and trophoblast cells and 
provides an obvious target for the identification of implantation markers.
The CAM family consists of four subtypes of adhesion molecule; the integrins, 
selectins, cadherins and the immunoglobulin-like receptors. The classical function of 
these cell surface ligands includes; maintenance of tissue integration, wound healing 
and cellular migration. Both the integrins and selectins are thought to be of direct 
importance to the implantation process, while cadherins and immunoglobulin-like 
receptors are known to be expressed in the endometrium throughout the cycle and at
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the implantation window yet their functional significance is still not fully understood in 
process of implantation itself.
Integrins are a family of transmembrane glycoproteins formed by the association of 
two non-covalently linked a and (3 subunits. Approximately 18 a chains and 8 p chains 
have been identified to date and can form 24 distinct integrin heterodimers which 
differ in function. The extracellular domain of integrins acts as a receptor to 
extracellular matrix (ECM) components, complement and other cells. The intracellular 
domain of integrins are able to interact with the cytoskeleton (Achache and Revel, 
2006). A variety of integrins have been described within the luminal and glandular 
epithelium of the endometrium and the majority of them have been shown to be 
constitutively expressed throughout the menstrual cycle (Lessey et al., 1992). 
However, the integrins a lp l  and a4p i have been shown to be elevated during the 
implantation window and the integrin aVP3 showed increased p3 subunit mRNA 
expression following day 19 and was undetectable beforehand. Due to its increased 
expression at the implantation window and its cellular location on the endometrial 
luminal epithelial surface, integrin aVP3 has been proposed as a potential receptor for 
the attachment of the blastocyst (Apparao etal., 2001 and Lessey, 2003).
Selectins are a family of glycoproteins that include P-selectin, L-selectin and E-selectin. 
Human L-selectin has been demonstrated to be of importance in the implantation 
process. It consists of a large highly glycosylated extracellular domain, a single 
transmembrane domain and a small cytoplasmic tail. L-Selectins are expressed on 
leukocytes and are known to interact with carbohydrate ligands expressed on inflamed 
vascular endothelium allowing the rolling of leukocytes over the endothelium before 
firm adhesion and transmigration. A parallel between this phenomena and blastocyst 
apposition can be made. Strong L-selectin staining over the embryo surface has been 
observed at the time of implantation (Genbacev et al., 2003) and maternal expression 
of L-selectin ligands such as MECA-79 or HECA-452 is upregulated during the 
implantation window allowing the trophoblast cells to contact the endometrial 
epithelial surface. This process may constitute the initial step of the implantation 
process (Genbacev et al., 2003 and Lai etal., 2005).
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1.2.7 Cytokines and growth factors involved in implantation
Cytokines and growth factors are cell derived polypeptides and proteins that have the 
capacity to bind cell surface receptors specifically and have the potential to act as 
intracellular signals that regulate the function of endometrial cells (Achache and Revel,
2006). They regulate cell proliferation, differentiation and apoptosis by autocrine, 
paracrine and endocrine mechanisms. Many cytokines are produced by the uterine 
mucosa and the embryo and may play a role in the maternal-embryonic interactions, 
enhancing endometrial receptivity by controlling the expression of adhesion 
molecules.
Classically cytokines have been classified according to the immune cell type from 
which they are produced and the effects their expression brings about (Laird et al., 
2003). CD4+ T cells are the major class of immune cells responsible for cytokine 
production and can be divided into three functional subsets based on their cytokine 
production. T helper 1 (Thl) cells produce interferon gamma (IFNT) and tumour 
necrosis factor beta (TNFp) and contribute to the control of the cell-mediated 
response. Th2 cells produce IL4, IL5, IL6, and IL10 and contribute to the control the 
antibody mediated response. ThO cells are precursor cells that can transform to either 
Thl or Th2 cells and produce both types of cytokines as well as tumour necrosis factor 
alpha (TNFa) and granulocyte-macrophage colony stimulating factor (GM-CSF). 
Additional to the Thl/Th2 cytokines, the proinflammatory cytokines constitute another 
cytokine group which includes I LI, TNFa, IL6 and leukaemia inhibitory factor (LIF). 
They are produced by macrophages and are important in mediating responses to 
tissue damage and repair.
It has become clear that all these cytokines can be produced by non-immune cell types 
including epithelial and stromal cells of the endometrium and also decidual and 
cytotrophoblast cells (Laird et al., 2003). As cytokines act locally and as T helper cells 
are a minor immune-cell population within the first trimester placental tissues, this 
suggests they are not the main source of cytokines present within the feto-placental 
unit. It is thought the Th2 type response is the predominant human maternal immune 
response during pregnancy (Wegmann etal., 1993).
26
The cytokines I LI, LIF and IL11 have all been shown to be of importance in the process 
of implantation (Achache and Revel, 2006). LIF (Stewart et al. 1992) and IL11 (Robb et 
al., 1998) are thought to be of particular importance as they have been shown to be 
the only two cytokines essential for successful implantation in mouse models. In 
humans, LIF and IL11 are thought to be involved in the control of early blastocyst 
interactions with the luminal epithelial surface of the endometrium and in the 
processes of decidualisation and the invasion of EVT (Achache and Revel, 2006). LIF 
(Arid et al., 1995; Charnock-Jones et al., 1994; Kojima et al., 1994 and Sharkey et al., 
1995) and IL11 (Cork et al., 2001 and Dimitriadis et al., 2000) are maximally expressed 
in the glandular and luminal epithelium during the mid secretory phase of the 
menstrual cycle. IL11 (Cork et al., 2001) and LIF (Kojima et al., 1994) are also 
expressed in the stroma. In-vitro studies have identified a role for LIF and IL11 in the 
adhesion of the blastocyst to the endometrial epithelium by differentially affecting the 
expression of integrins (Achache and Revel, 2006). LIF and IL11 are also thought to 
play roles in the regulation of EVT invasion and decidualisation under the general 
control of progesterone potentially by modulating matrix metalloproteinase activity. 
LIF has also been shown to be produced by uterine natural killer cells (uNK) cells and 
may facilitate EVT trophoblast invasion via LIF receptor expression present on the cell 
surface of EVTs (Saito et al., 1993).
The growth factors heparin binding-epidermal growth factor, colony-stimulating 
factor-1, insulin-like growth factor binding protein-1 and keratinocyte growth factor 
have all been shown to be of potential importance to the implantation process 
(Achache and Revel, 2006). Many other additional factors such as the mucins and 
prostaglandins are thought to be of importance in controlling endometrial receptivity 
at the time of implantation.
1.3 The endometrial leukocyte population
Effective ovarian and uterine function relies on a complex interplay between the 
endocrine and immune systems (Lea and Sandra, 2007). Ovarian leukocyte release has 
been shown to be central to ovarian follicle development, ovulation and corpus luteum 
formation. In the uterus, sex steroids cyclically regulate the number and distribution 
of endometrial and decidual immune cells and other immune factors. It is generally
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accepted that oestrogens have a typical pro-inflammatory immune-reproductive effect 
while progesterone initiates an anti-inflammatory response (Wegmann et al., 1993). 
The uterine mucosa is unique; it must tolerate the presence of commensal organisms, 
sperm and the allogenic blastocyst but not compromise immune surveillance against 
potential pathogens (Lea and Sandra, 2007).
The leukocyte population that exists within the endometrium and decidua is distinctly 
different to that of the peripheral blood (Laird et al., 2003). Within the population 
there are essentially no B cells and very few neutrophils (Bulmer et al., 1991; Johnson 
et al., 1999 and Salamonsen and Lathbury, 2000). Instead, the endometrial and 
decidual leukocyte population consists of T cells, macrophages and uterine natural 
killer (uNK) cells (large granular lymphocytes). Figure 1.8 summarises the process of 
leukocyte migration.
The most predominant leukocyte in the endometrium and decidua are uNK cells. They 
are phenotypically different to those found in the peripheral blood (Bulmer et al., 1991 
and Laird et al., 2003). They express CD56 and CD38 cell markers but not the classical 
T cell or NK cell markers; CD3, CD4, CD8, CD16 and CD57. However, a small proportion 
of uNK cells show similarity to peripheral blood NK cells and express minimal levels of 
CD56 and CD16. These cells are referred to as CD56dimuNK cells while the majority of 
the uNK cell population is CD56bnght.
The numbers and proportions of the endometrial and decidual leukocytes population 
varies throughout the menstrual cycle and in early pregnancy (Bulmer et al., 1991). T 
cells make up approximately 45% of leukocytes found in the proliferative 
endometrium. Their numbers remain relatively constant throughout the menstrual 
cycle and in early pregnancy but their relative numbers decrease in comparison to the 
uNK cells as the cycle progresses. Macrophages make up 15-20% of endometrial 
leukocytes. Their numbers increase slightly during the secretory phase of the 
menstrual cycle and early pregnancy comprising 20% of the leukocytes found in the 
placental bed (Laird et al., 2003).
It is the uNK cells that show the most dramatic changes in numbers through the 
menstrual cycle (Bulmer et al., 1991 and Jabbour et al., 2006). During the proliferative 
phase, their numbers are approximately equal to the T cell population but by the mid
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secretory phase, they comprise 70% of the endometrial leukocyte population and are 
found in close contact with endometrial glands and spiral arteries. Numbers continue 
to increase further into early pregnancy.
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Figure 1.8: Summary o f the process o f leukocyte migration (Taken from  Ley et 
a l 2007)
The process of leukocyte migration, including the stages of leukocyte capture, rolling 
and extravasation through the endothelial cells of blood vessels such as the spiral 
arteries of the endometrium.
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1.3.1 uNK cell proliferation and trafficking
It has not yet been determined whether the increase in uNK cell number is solely due 
to in situ proliferation or due to de novo migration from the peripheral circulation. In 
mice there strong evidence that self-renewing proginators of uNK cells are derived 
from trafficking precursors which are found in peripheral lymphoid sites such as the 
spleen and lymph nodes (Chantakru et al., 2002). In humans there is evidence for both 
the trafficking of uNK cells from the peripheral circulation and in situ differentiation 
and proliferation (Bulmer et al., 2010). It has been shown that in late secretory phase 
endometrium and early pregnancy decidua, that uNK cells are found predominantly in 
the stratum functional and often form aggregates around spiral arteries and glands 
(Bulmer et al., 1991). This perivascular distribution of uNK cells has been considered to 
be evidence of the trafficking of uNK cells or their precursors from the peripheral 
circulation (Trundley and Moffett, 2004). Some studies have focused on whether 
factors produced by the trophoblast may play a role in the trafficking of uNK cells. 
Molecules such as macrophage inhibitory protein la  (M IPla) (Drake et al., 2001), 
MIP1(3 (Kitaya et al., 2003) and CXCL12 (Hanna et al., 2003), which are all expressed by 
trophoblast have all been shown to potentially fulfill this role. There are also 
arguments against the trophoblast playing a role in recruiting the uNK cells to the 
endometrium. uNK cells are known to be prominent in the endometrium in the 
absence of trophoblast in pre-menstrual endometrium and in intrauterine decidua in 
ectopic pregnancy. This suggests trophoblast does not recruit uNK cells as they are not 
found at the site of the tubal pregnancy (Von Rango et al., 2001). uNK cells are most 
prominent in the endometrium in the progesterone dependent secretory phase of the 
menstrual cycle and are likely to respond to exogenous progesterone. Further to this, 
if the trophoblast played a role in the recruitment of uNK cells into the endometrium, 
it would be expected that uNK cell numbers would differ consistently between the 
decidua basalis in the presence of extravillous trophoblast and the decidua parietalis 
which lacks trophoblast (Bulmer et al., 2010). This has not been observed to be the 
case.
If uNK cells are trafficked from the peripheral blood, it is possible and likely that the 
endometrium releases factors to control their recruitment. Several studies have 
shown that cytokines and chemokines released by the endometrium may be
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responsible for the recruitment of uNK cells to the endometrium including 
macrophage derived chemokine (MDC), monocyte chemoattractant protein (MCP)3, 
fractalkine, 6Ckine, MIPlp (Jones et al., 2004), CXCL10, CXCL11 (Sentman, 2004) and 
IL15 (Kitaya et al., 2005). In some cases, studies have shown cyclical changes in 
expression suggesting potential regulation by the steroid hormones. While the 
endometrium secretes many factors which may cause uNK cell recruitment, 
endometrial uNK cells themselves have been shown to lack some of the chemokine 
receptors which would allow uNK cells to respond via chemotaxsis (Manaster et al., 
2008).
Recruitment of cells from the peripheral blood into the endometrial tissues does not 
exclude the possibility of local differentiation of precursor cells which could first be 
recruited into the endometrium before differentiating to display their uNK phenotype 
in response to local stimuli (Bulmer et al., 2010). Evidence for this occurring has 
mainly been observed in the mouse (Bilinski et al., 2008 and Lynch et al., 2007). This 
hypothesis is supported in the human by the identification of the presence of CD34+ 
CD56+ leukocyte stem cells in the secretory phase endometrium and the local 
proliferation of CD56+ uNK cells in secretory phase endometrium and early pregnancy 
decidua (Pace et al., 1989). While it is possible that uNK cells may differentiate from 
precursor cells found in the peripheral blood, it is also possible that they may 
differentiate into their uterine specific phenotype from typical peripheral blood NK 
cells. uNK cells are phenotypically distinct and to date, similar cells have not been 
described in substantial numbers in other organs. It is also the case that no typical 
peripheral blood NK cells have been identified in the endometrium in significant 
numbers at any stage of the cycle or in early pregnancy (Bulmer et al., 2010). 
Incubation of peripheral blood NK cells with transforming growth factor (TGF)|31 has 
been shown to lead to the conversion of these cells to a uNK phenotype (Keskin et al.,
2007). However, if this was the case in vivo, it would be expected at some stage of the 
menstrual cycle or early pregnancy that peripheral type NK cells could be indentified in 
the endometrium (Bulmer etal., 2010).
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1.3.2 uNK cell function
uNK cells are the major endometrial leukocyte population during the onset of the 
implantation window and early pregnancy. For this reason, the study of endometrial 
leukocyte function has focused on this cell type. The identification of this cell 
population as a NK cell type has led studies to investigate their cytotoxic nature in 
relation to their endometrial function (Bulmer et al., 2010 and Bulmer and Lash, 2005). 
CD56+ cells isolated from non-pregnant endometrium during various stages of the 
menstrual cycle (Jones et al., 1997) and in early pregnancy decidua (King et al., 1989) 
have been shown to exhibit cytotoxic activity against the NK cell target K562. 
However, this cytotoxic activity has been demonstrated to be lower than peripheral 
blood NK cells (Kopcow et al., 2005). It has been suggested that uNK cells cytotoxic 
potential may play a role in vivo in controlling the invasion of trophoblast into the 
decidua but extravillous trophoblast has been shown to be protected from uNK cell 
cytotoxicity. This may be due interactions between inhibitory receptors on the NK 
cells and MHC molecules present on the trophoblast cells (Manaster and Mandelboim,
2008). Abnormal expression of these molecules has been associated with 
preeclampsia and recurrent miscarriage (Hiby et al., 2004 and Hiby et al., 2008). uNK 
cells are a rich source of many different cytokines and It has been suggested that they 
may mediate the action of uNK cells in trophoblast invasion. The cytokines TNFa, 
TGFpi and IFNT have all been shown to inhibit trophoblast invasion in placental 
explants lending support to this idea (Lash et al., 2006a and Otun et al., 2003).
It has also been shown that uNK cells are a major source of angiogenic growth factors 
in early pregnancy (Hanna et al., 2006 and Lash 2006b). A role for uNK cells in 
trophoblast independent spiral artery remodeling has been proposed (Pijnenborg et 
al., 2006), though it has been demonstrated that complete remodeling of the uterine 
spiral arteries requires a contribution from the trophoblast and uNK cells alone may 
only be involved in the early stages (Kam et al., 1999). A study which investigated 
infiltration of leukocytes into decidual arteries showed infiltration of uNK cells and 
macrophages into smooth muscle of the deciduas basalis via endothelial cells (Smith et 
al., 2009). Early vascular changes were shown to be independent of vascular 
trophoblast strongly suggesting a role for the uNK cells and macrophages found to be 
present at this time. Most recently, a study which used a placental-decidual co-culture
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model to investigate remodeling showed that presence of placenta was required to 
intiate spiral artery remodeling but uNK cells and macropahges were shown to 
mediate this process at a cellular level during the early stages of this process (Hazan et 
al., 2010).
While the presence of uNK cells aggregates around the spiral arteries has been 
suggested to be evidence of uNK cell trafficking from the peripheral blood, it may be 
the case that this occurs because uNK cells play an important role in vascular 
remodeling during pregnancy (Bulmer et al., 2010).
Quantitative real-time RT-PCR and protein studies show an absence of the oestrogen 
receptor ERa and the progesterone receptor (PR) in uNK cells but the oestrogen 
receptor ERp isoform and glucocorticoid receptor (GR) mRNA and protein has been 
identified, raising the possibility that oestrogens and glucocorticoids can act directly on 
uNK cells to affect cell and endometrial function (Henderson et al., 2003). Indirectly, 
oestrogens and progesterone may also exert effects on uNK cells via stimulation of 
cytokines such as IL-15 and prolactin and other soluble factors by endometrial cells. 
Progesterone is thought to be central to these effects, due to the location of uNK cells 
within the endometrial stroma where most of these factors are released and the 
retention of the PR expression in stromal cells during the secretory phase of the 
menstrual cycle (Jabbour etal., 2006 and Lea and Sandra, 2007).
1.3.3 uNK cells and reproductive failure
While the precise functions of uNK cells remains unknown, their importance in 
endometrial and placental function is suggested by the presence of abnormal numbers 
or populations in women with reproductive failure such as recurrent miscarriage (RM) 
or implantation failure after in vitro fertilisation (IVF) (Laird etal., 2003).
There have been several studies of uNK and peripheral NK cells in the decidua and 
peripheral blood in women with recurrent and sporadic miscarriage (Laird etal., 2003). 
Differences in the numbers of uNK cells and their state of activation have been 
implicated in the aetiology of RM. Several studies have showed increased numbers of 
CD56+ uNK cells in the peripheral blood of women with RM prior to and during 
pregnancy compared to healthy controls (Aoki et al., 1995 and Kwak et al., 1995).
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CD56+ uNK cell activity has been shown to decrease in the first trimester of pregnancy 
in normal women but the activity of these cells in women with RM remains high 
(Higuchi et al., 1995). It has also been shown that CD56+ uNK cell number and activity 
is only seen in RM women with chromosomally normal fetuses suggesting they are a 
cause of RM rather than an immunological response to chromosomally abnormal 
fetuses (Coulam et al., 1995 and Yamada et al., 2001).
Other studies however have contradicted these findings. While an increased number 
of CD56+ NK cells have been observed in the peripheral blood, a decreased number of 
decidual CD56+ uNK cells have been reported in the placental tissue from women who 
underwent spontaneous miscarriage in comparison to those who requested 
terminations (Quack et al., 2001 and Yamamoto et al., 1999b). Several reports have 
also shown increased numbers of uNK cells in secretory phase endometrium of both 
women with unexplained RM and recurrent implantation failure using 
immunohistochemistry (Clifford et al., 1999; Laird et al., 2005; Quenby et al., 1999 and 
Tuckerman et al., 2007).
Differences in the activation state of uNK cells may be important in their function or 
potential reproductive pathogenesis (Laird et al., 2003). The activation status of both T 
cells and CD56+ NK cells has been investigated by measurement of CD25 (IL2Ra) (T cell 
activation marker) and CD69 (NK cell activation marker). Increased expression of CD69 
on peripheral CD56+ (both CD56bnght and CD56dim) NK cells has been observed in 
women with unexplained recurrent miscarriage in contrast to normal controls and cells 
from women with RM showed significantly higher CD69 expression when co-cultured 
with trophoblast cell lines compared to cells from normal controls (Ntrivalas et al., 
2001).
1.4 Endometrial receptivity and female reproductive failure
The endometrium plays an important role in successful pregnancy outcome and 
abnormalities in endometrial function lead to reproductive failure, which can manifest 
itself as a failure to conceive (infertility), repeated failure to establish implantation in 
women undergoing IVF and recurrent miscarriage in women who successfully conceive 
(Laird et al., 2006).
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1.4.1 Endometrial receptivity and repeated implantation failure (RIF)
The pregnancy rate following one cycle of IVF and embryo transfer can be as high as 
60%. Embryonic reasons for RIF include; genetic abnormalities of the male or female, 
sperm defects, embryonic aneuploidy or zona hardening. Various uterine pathologies 
such as hyperplasia, polyps, endometritis, synechiae and leiomyomata have been 
associated with RIF in up to approximately 30% of cases (Demirol and Gurgan, 2004). 
This still leaves a significant proportion of cases in which the cause of RIF is undefined 
and no morphological pathology of the endometrium can be observed despite the 
transfer of 'good quality' embryos. The altered expression of specific endometrial 
factors may be responsible for altering endometrial function and negatively affecting 
endometrial receptivity.
Endometrial dysregulation of numerous factors has been implicated in RIF including 
the abnormal levels of cytokines; IL12, IL15 and IL18 (Ledee-Bataille et al., 2005). 
Increased ILlp and decreased IFNT and IL10 expression in uterine fluid has also shown 
to be of potential importance in the aetiology of RIF along with increased levels of the 
MMPs 2 and 9 (Inagaki et al., 2003). Adhesion molecules found to be expressed on the 
epithelium of the endometrium at the time of implantation are an obvious target for 
investigation in RIF. Absence of the integrin-aVp3 during the implantation window in 
cases of RIF has been shown and may suggest a potential mechanism in which the 
blastocyst is unable to attach to the endometrial epithelial surface (Inagaki et al., 
2003). Mucins have also been shown to be potentially involved in RIF and the 
increased expression of MUC1 glycans has been demonstrated using
immunohistochemistry (Horne et al., 2005).
1.4.2 Endometrial receptivity and recurrent miscarriage
Recurrent miscarriage (RM) affects 1% of women and is defined as three or more 
consecutive first trimester losses of pregnancy. RM has both maternal and embryonic 
aetiologies, with known probable causes including; parental and foetal chromosome 
abnormalities, thrombophilia, metabolic disorders and anatomical causes. Despite this 
knowledge, around 50% of RM cases remain unexplained. Successful implantation 
requires concerted actions between the blastocyst, leukocyte populations and the 
endometrial epithelia and stroma. The expression of key molecules by the
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endometrium at the time of implantation implies its importance in allowing the 
blastocyst to attach to the endometrial surface and invade into the decidual stroma 
Laird et al., 2006).
Previous work has suggested that abnormal endometrial development may be 
associated with recurrent miscarriage (Li et al., 2002). This may be identified by 
morphological analysis, which has shown that the endometrium of a sub-group of 
women with recurrent miscarriage at day LH+7 is retarded and would be dated at least 
2 days earlier using the Noyes criteria. Immunohistochemical studies have also shown 
decreased expression of a number of endometrial proteins, such as MUC1 (Hey et al., 
1995), IL6 and LIF (Cork et al., 1999) and av|33 integrin expression (Lessey et al., 1996) 
in the peri-implantation period. Levels of the endometrial marker protein placental 
protein 14 are also reduced in women with recurrent miscarriage (Dalton et al., 1995).
It is thought a proportion of unexplained RM may be due to abnormal maternal 
immunological function leading to destruction of the foetus. While it is clear that 
leukocyte populations such as uNK cells may play pivotal roles in the pathology of 
unexplained RM, the identification of the expression of 'immune' and other factors by 
the endometrium itself may be centrally important (Laird etal., 2006).
1.4.3 Role of cytokines in successful pregnancy outcome
It has been shown in murine models that rejection of pregnancy is mediated by Thl 
cytokines such as IL2 and IFNT, while successful pregnancy depends on the presence of 
Th2 cytokines such as IL4, IL6 and IL10 (Wegmann et al., 1993). While cytokines are 
expressed by CD4+ T helper cells in the endometrium and have traditionally been 
divided into such families based on the immunological effects they bring about it, 
seems clear that the endometrial epithelium is a major source of cytokines in the non­
pregnant endometrium. Stromal and decidual cells have also been shown to produce 
cytokines (Linjawi et al., 2004 and Tuckerman et al., 2004).
It has been shown that women with RM have higher levels of Thl cytokines (IFNT, IL2, 
IL12 and TNFp) and lower levels of Th2 cytokines such as IL6 in comparison to the 
endometrium and blood of normal controls (Lim et al., 2000). Another study showed 
reduced expression of IL6 and LIF in RM endometrium in comparison to normal
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controls (Cork et al., 1999). The chemotatic cytokine (chemokine) IL8 (CXCL8) has been 
shown to be elevated in samples from the cervical mucus from RM patients (Hattori et 
al., 2007). However, this study also showed increased levels of IL6 which is in 
disagreement with the study by Lim et al. (2000), which suggested decreased 
expression of IL6.
While the importance of LIF and IL11 in normal pregnancy is well established (see 
section 1.2.5), there is also evidence for abnormal expression of these cytokines 
playing a role in pregnancy failure due to RIF or RM (Laird etal., 2006). Some studies 
have shown decreased production of LIF in endometrial samples obtained from 
women with unexplained infertility (Delage et al., 1995 and Laird et al., 1997), but 
other studies have shown no observable difference compared to normal controls 
(Sherwin et al., 2002). Decreased secretion of LIF in women with multiple IVF failures 
has been shown (Hambartsoumian, 1998) and high levels of LIF expression at times in 
the menstrual cycle when it would be expected to be decreasing in women with 
multiple IVF failure has also been shown (Ledee-Bataille et al., 2002). Decreased 
expression of LIF in peri-implantation endometrium of non-pregnant women with RM 
has been demonstrated suggesting the importance of LIF in preventing pregnancy loss 
(Cork et al., 1999).
Investigations into the expression of IL11 in the endometrium of women with 
implantation and pregnancy failure is limited, but it has been shown that IL11 is 
reduced in stromal and epithelial cells from women with infertility in comparison to 
normal controls (Karpovich et al., 2005 and Linjawi et al., 2004).
1.4.4 Trophoblast invasion and preeclampsia
Failure of the trophoblast to invade the endometrium successfully and remodel the
maternal environment, including the spiral arteries is thought to be an aetiological
factor for preeclampsia. This leads to restricted blood flow to the developing foetus.
The disorder occurs in approximately 3-5% of pregnancies and is a cause of both foetal
and maternal morbidity and mortality (Weiss et al., 2007). Preeclampsia is
characterised by hypertension and proteinuria in previously normal subjects, which
can progress to eclampsia, which is characterised by convulsions. The superficial
trophoblast invasion seen with preeclampsia has been associated with abnormal
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genetic polymorphism, vascular endothelial cell activation, immune responses by the 
maternal immune system and exaggeration of a systemic imflammatory response 
(Schiesssl, 2007). Immuno-competent cells such as neutrophils, monocytes, NK cells, T 
and B cells have been found to activated in preeclampsia and hypoxic conditions, 
excessive inflammation or oxidative stress induces necrosis or aponecrosis of 
trophoblasts (Weiss et al., 2009). Syncytiotrophoblast apoptotic debris, which is shed 
into the maternal circulation in increased amounts in preeclampsia, may be the 
stimulus for inducing the observed inflammatory response.
While failure of the trophoblast to correctly invade and remodel the maternal 
environment could occur due to the trophoblast's inability to correctly implant, it is 
possible that pathological endometrial receptivity or function may contribute. Recent 
studies have shown abnormally increased expression of endometrial factors including 
IL11 and MMP9 in cases of preeclampsia in decidualised endometrial cells (Basar etal., 
2010 and Lockwood et al., 2008). This adds support to this idea and again highlights 
the importance of the tightly regulated crosstalk that must occur between the 
endometrium and blastocyst to achieve a successful pregnancy.
1.5 Chemokines
Chemoattractant cytokines (chemokines) are a family of small proteins (8-14 kDa) that 
are traditionally known to be involved in the recruitment of leukocytes during the 
inflammatory process acting on neutrophils, monocytes, lymphocytes and eosinophils. 
It has become clear however that chemokines and their receptors are central to the 
activity of many biological processes and affect the function of non-immune cell types 
(Taub and Oppenheim, 1994; Wells et al, 1998 and Zlotnik and Yoshie, 2000). 
Advances in cloning and bioinformatic research strategies have led to the identification 
of a large number of chemokines and their G protein coupled receptors. Chemokines 
can be divided into four subfamilies based on the presence or absence of amino acid 
residues between the first two of four conserved cysteines at the N-terminus of the 
protein (Figure 1.9). At least twenty eight CC, seventeen CXC, two C chemokines and a 
CX3C chemokine have been identified (Wells etal, 1998 and Zlotnik etal., 2006). Table 
1.1 summarises the known chemokines and their receptors according to their subtypes 
and systematic name.
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Figure 1.9: Structural differences of chemokine ligands (Taken from Townson 
and Liptak, 2003).
Shows the structural differences between the chemokine ligand subtypes and their 
regions of ligand/receptor binding.
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Family Other names Chromosome Function Receptor
CXC family
CXCL1 Melanoma growth 
stimulating activity alpha 
(Groa)
4ql3.3 l CXCR2, CXCR1
CXCL2 Melanoma growth 
stimulating activity beta 
(Grop)
4ql3.3 1 CXCR2
CXCL3 Melanoma growth 
stimulating activity gamma 
(GroT)
4ql3.3 l CXCR2
CXCL4 Platelet factor 4 (PF4) 4ql3.3 u CXCR3B
CXCLV1 4ql3.3 u Unknown
CXCL5 Epithelial-derived neutrophil- 
activating peptide-78 (ENA- 
78)
4ql3.3 1 CXCR2
CXCL6 Granulocyte chemotactic 
protein 2 (GCP-2)
4ql3.3 1 CXCR1,CXCR2
CXCL7 Pro-platelet basic protein 4q l3.3 1 Unknown
CXCL8 Interleukin 8 (IL-8) 4ql3.3 1 CXCR1/CXCR2
CXCL9 Mig receptor (MIGR) 4q21.1 1 CXCR3, CXCR33
CXCL10 Interferon gamma-produced 
protein (IP-10)
4q21.1 1 CXCR3, CXCR33
CXCL11 Interferon-inducible T-cell 
alpha chemoattractant (1- 
TAC)
4q21.1 1 CXCR3, CXCR3P, 
CXCR7+
CXCL12 Stromal cell-derived factor 
(SDF-la/P)
1 0 q ll.2 1 H CXCR4, CXCR7+
CXCL13 B lymphocyte 
chemoattractant (BLC)
4q21.1 H CXCR5
CXCL14 Chemokine breast and kidney 5q31.1 1 Unknown
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(BRAK), Bolekine
CXCL16 1713.2 1 CXCR6
CXCL17 Dendritic ceil and monocyte 
chemokine-like protein 
(DMC)
19ql3.2 U Unknown
CC family
CCL1 1 7 q ll.2 1 CCR8
CCL2 Monocyte chemoattractant 
protein-1 (MCP-1)
1 7 q ll.2 1 CCR2
CCL3 Macropahge inflammatory 
protein-1 alpha (M IP-la)
1 7 q ll.2 1 CCR1,CCR5
CCL3L1 17ql2 1 Unknown
CCL3L3 17ql2 1 Unknown
CCL4 Macrophage inflammatory 
protein 1 beta (MIP-ip)
17ql2 1 CCR5
CCL4L1 Lymphocyte activation gene 1 
protein (LAG-1)
17ql2 1 Unknown
CCL4L2 Lymphocyte activation gene 1 
protein (LAG-1)
17ql2 1 Unknown
CCL5 Regulated on activation 
normal T expressed and 
secreted (RANTES)
17ql2 1 CCR1,CCR3,CCR5
CCL7 Monocyte chemoattractant 
protein 3 (MCP-3)
1 7 q ll.2 1 CCR1,CCR2,CCR3
CCL8 Monocyte chemoattractant 
protein 2 (MCP-2)
1 7 q ll.2 1 CCR1/CCR2/CCR3
;CCR5
CCL11 Eotaxin 1 7 q ll.2 1 CCR3
CCL13 Monocyte chemoattractant 
protein-4 (MCP-4)
1 7 q ll.2 1 CCR1,CCR2,CCR3
CCL14 Haemofiltrate CC chemokine- 
1 (HCC-1)
17ql2 H CCR1
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CCL15 Haemofiltrate CC chemokine- 
2 (HCC-2)
17ql2 H CCR1,CCR3
CCL15 Haemofiltrate CC chemokine- 
2 (HCC-2)
17ql2 H CCR1,CCR3
CCL16 Haemofiltrate CC chemokine- 
4 (HCC-4)
17ql2 H CCR1,CCR2,CCR5
,HRH4
CCL17 Thymus and activation- 
regulated chemokine (TARC)
16ql3 D CCR4
CCL18 Pulmonary and activation- 
regulated chemokine (PARC)
17ql2 H Unknown
CCL19 Macrophage inflammatory 
protein 3-beta (MIP3P)
9pl3.3 H CCR7
CCL20 Macrophage inflammatory 
protein 3-alpha (MIP3a)
2q36.3 D CCR6
CCL21 Secondary lymphoid-tissue 
chemokine (SCL)
9pl3.3 D CCR7
CCL22 Macrophage derived 
chemokine (MDC)
16ql3 D CCR4
CCL23 Myeloid progenitor inhibitory 
factor-1 (MPIF-1)
17ql2 1 CCR1, FPRL-1
CCL24 Eotaxin 2 7 q ll.2 3 1 CCR3
CCL25 Thymus expressed 
chemokine (TECK)
19pl3.2 H CCR9
CCL26 Eotaxin 3 7 q ll.2 3 1 CCR3
CCL27 Cutaneous T-cell attracting 
chemokine (CTACK)
9pl3.3 H CCR10
CCL28 Mucosae-associated 
epithelial chemokine (MEC)
5p l2 U CCR10, CCR3
Other classes
XCLl Lymphotactin lq24.2 D XCR1
XCL2 Small inducible cytokine 
subfamily (SCM-1P)
lq24.2 D Unknown
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CX3CL1 Fractalkine 1 6 q l3 CX3CR1
Table 1.1: The known human chemokines and receptors (Adapted from Zlotnik 
et a l 2006
Systematic symbols for chemokine ligands are derived by the position of conserved N- 
terminus cystiene residues. For example, CXCL1 is: Chemokine (C-X-C motif) ligand 1. 
Chemokine receptors use 'R' to denote receptor status, e.g. CXCR1 is: Chemokine (C-X- 
C motif) receptor 1.
Functions: I, inflammatory; H, homeostatic; D, dual (homeostatic and inflammatory); 
U, unknown. The lists of alternative names are not fully comprehensive, t  Binding has 
been reported but signaling is still controversial.
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1.5.1 Chemokine ligands and receptor
Chemokines act as ligands for chemokine receptors. Chemokine receptors belong to 
the G protein-coupled receptor (GPCR) super-family which contains receptors for a 
wide range of ligands including hormones, neurotransmitters and inflammatory 
mediators (Murdoch and Finn, 2000 and Zlotnik and Yoshie, 2000). They all 
structurally consist of seven trans-membrane protein domains with an extracellular N- 
terminus and an intracellular C-terminus (Figure 1.10).
Secreted chemokine ligands bind the extracellular N-terminus region of its target 
chemokine receptor causing activation of an intracellular signaling cascade potentially 
in both a G protein dependent and independent manner causing a cellular response 
(Busillo and Benovic, 2007). Chemokine ligands and receptors exhibit promiscuity with 
many of the chemokine receptors binding multiple ligands (see Table 1.1) (Zlotnik et 
al., 2006), which in one part is due to their similar tertiary protein structures and 
binding properties (Figure 1.9) (Townson and Liptak, 2003). Expression of chemokines 
and their receptors are subject to transcriptional control with the identification of 
mRNA and protein splice variants and other forms of control such as DNA 
hypermethylation and regulation by microRNAs also playing roles (Asirvatham et al., 
2008 and Busillo and Benovic, 2007).
The effects of chemokines within a wide range of human tissues has been observed. 
Chemokines were initially studied for their ability to act as molecular attractants, 
recruiting leukocytes to sites of inflammation via chemotaxis. Since these findings, it 
has become clear that chemokines have the ability to carry out a wide range of 
functions (Onuffer and Horuk, 2002 and Shao et al., 2008). These functions are 
thought to include roles in leukocyte, dendritic cell and stem cell migration and 
function, mediation of the Th l and Th2 responses, organogenesis and control of 
developmental processes, cell adhesion, angiogenesis and angiostasis.
Chemokine function has been implicated in a number of human diseases in a range of 
different cell types, tissues and systems (Busillo and Benovic, 2007). The two most 
studied diseases in which chemokines have been implicated, HIV and numerous types 
of cancer metastases, both involve the chemokine receptor CXCR4 and its ligand 
CXCL12.
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Figure 1.10: Representation of the chemokine receptor CXCR1 situated in the 
cell membrane (Taken from Murdoch and Finn, 2000).
Showing the seven transmembrane domains, the extracellular N-terminus and 
intracellular C-terminus characteristic of G protein-coupled receptors.
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1.5.2 Evidence for the role of chemokines in endometrial function
Chemokines have been implicated in playing a role in the control of female 
reproductive function including in the endometrium and ovaries. Recruitment and 
control of leukocyte populations within the ovaries and endometrium is thought to be 
controlled by chemokine chemotaxis. It has been shown that several chemokines and 
their receptors are expressed in the endometrium and are potentially involved in the 
recruitment of endometrial leukocytes including uNK cells. Expression of a number of 
different chemokine mRNAs was generally up-regulated during the implantation 
window. Protein expression of these chemokines was found to be localised to 
endometrial epithelial cells leading up to implantation, while differentiated stromal 
cells were found to be a major source of chemokines following decidualisation (Jones 
et al., 2004). Another study demonstrated concordance between the expression of 
chemokines ligands in the uterus and expression of their receptors on decidual 
leukocytes suggesting a possible mechanism for leukocyte recruitment during 
pregnancy (Red-Horse et al., 2001).
Beyond acting as a simple chemoattractant, there is evidence that chemokine ligands 
act as signal molecules between cells and tissues where receptor activation leads to 
changes in intracellular signaling and gene expression. This is particularly relevant in 
the endometrium where there is potentially a complex and rapidly changing crosstalk 
between the endometrial epithelium and stroma, implanting blastocysts and 
leukocytes such as uNK cells all of which may be involved in the control of 
implantation, decidualisation, placentation and menses (Dominguez et al., 2003 and 
Garcia-Valesco and Arid, 1999). The identification of mRNA expression of chemokine 
transcripts CX3CL1 and CCL7, along with their receptors CX3CR1, CCR1, CCR2, CCR3 
and CCR5 has been demonstrated in human endometrium and first-trimester placenta. 
Immuno-reactive CCR1, CCR3 and CX3CR1 was also shown in human first-trimester 
implantation sites, lending support to the involvement of endometrial chemokines in 
the crosstalk that occurs at the feto-maternal interface (Hannan et al., 2006).
There is evidence that chemokine production is under the influence of steroid
hormone control within the endometrium, where it is thought they may play centrally
important roles in many processes of this highly dynamic tissue throughout the
menstrual cycle (Dominguez et al., 2003 and Garcia-Valesco and Arici, 1999). The
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chemokine ligands IL8, MCP-1 and RANTES (CXCL8, CCL2 and CCL5) and the chemokine 
receptors CXCR1, CXCR4, CCR5 and CCR2B have been identified in human 
endometrium and their expression has been shown to change throughout the normal 
menstrual cycle and in a steroid hormone dependent manner in women undergoing 
hormone replacement therapy (HRT) (Dominguez et al., 2003). IL8 mRNA expression 
has been found to peak in the late secretory and early proliferative human 
endometrium, where IL8 expression was found predominantly in the surface 
epithelium and glands of the endometrium (Arici et al., 1998 and Dominguez et al., 
2003). MCP-1 has also been shown to be localised to the epithelium and glands of the 
endometrium and expression would appear to increase during the onset of the 
implantation window. RANTES expression has been shown to be localised to the 
endometrial stroma and perivascular cells during the implantation window (Arici et al., 
1995; Arici et al., 1998; Dominguez et al., 2003a).
Several studies have demonstrated that the expression of some chemokines can be 
induced by steroid hormones. Estradiol and progesterone treatment has been shown 
to increase CXCL10 and CXCL11 protein expression in cultured human endometrium 
and CD56brightuNK cells have been shown to express the receptor CXCR3, the receptor 
for these chemokine ligands (Sentman et al., 2004).
17 P-estradiol has been shown to increase CXCL12 and CXCR4 mRNA transcript 
expression in oestrogen receptor positive Ishikawa adenocarcinoma cell lines (Kubarek 
and Jagodzinski, 2007) and oestrogen induced CXCL12 expression has been shown in 
the uterus of rats (Glace et al., 2009). In primary cell cultures of decidual stromal cells 
(DSCs); oestrogen, progesterone and hCG was shown to increase the level of CCL2 (He 
et al., 2007).
Analysis of the chemokine receptors CXCR1, CXCR4, CCR2B and CCR5 mRNA transcript 
levels in endometrial samples obtained from normal fertile women throughout the 
menstrual cycle showed hormone dependent changes in expression (Dominguez et al., 
2003). CXCR1 and CCR5 mRNA was shown to be highest during the late secretory 
phase of the menstrual cycle while CXCR4 mRNA was apparently increased during the 
implantation window. Immunohistochemical staining for CXCR4, CCR2B and CCR5 was 
shown to be located within the epithelium and glands of the endometrium but was
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weak in HRT patients receiving oestrogen suggesting a suppressive effect. CXCR1 
staining was shown to increase in the glands of the endometrium approaching and 
during the implantation window. An in vitro model of blastocyst apposition, showed 
an increase in endometrial cell expression of CXCR1, CXCR4 and CCR5 in the presence 
of a blastocyst in comparison to its absence. Tables 1.2 and 1.3 summarise the known 
expression of chemokine ligands and receptors in the endometrium.
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Chemokine
ligand
(systematic
name)
Endometrial expression Proposed functions and regulation
CXCL1 Stroma/decidua, increased 
during secretory phase (Nasu 
etal., 2001)
Regulated by thrombin via MAP kinases 
(Kawano et al., 2011)
CXCL2 First trimester decidua (Huang 
etal., 2006)
Increased expression in response to ILlp 
(Huang et al., 2006)
CXCL3 First trimester decidua (Huang 
etal., 2006)
Increased expression in response to ILlp 
(Huang et al., 2006)
CXCL5 Stroma (Nasu etal., 2001) Regulated by progesterone and pro- 
inflammatory mediators (Nasu et al., 2001)
CXCL6 Cultured stromal cells (Mine et 
al., 2003)
Regulated by inflammatory cytokines (Mine 
etal., 2003)
CXCL8 Highest in epithelium, present 
in stroma (Caballero-Campo et 
al., 2002), Peaks during the 
secretory phase (Arici et al.,, 
1998a)
Regulated by steroid hormones (Kelly et al., 
1994) and cytokines (Arici etal., 1993). 
Potential functions in neutrophil migration 
prior to menses (Kelly et al., 1994) and 
angiogenesis (Arici etal., 1998a)
CXCL10 Epithelium (Paiva etal., 2011) Regulated by hCG, involved in blastocyst 
migration and adhesion (Paiva et al., 2011)
CXCL11 Epithelium (Hirota et al., 2006) Regulated by pro inflammatory cytokines 
(Hirota etal., 2006)
CXCL12 Epithelium and stroma 
throughout the menstrual 
cycle (Laird et al., 2011)
Potential regulation by steroid hormones 
(Tsutsumi etal., 2011), potential function in 
uNK cell recruitment (Kitaya etal., 2004)
CXCL14 Glandular epithelium, 
increased during mid 
secretory phase (Mokhtar et 
al., 2011)
Potential implantation role (Mokhtar etal., 
2011)
CCL2 Stroma (Huang etal., 2006) Regulated by ILlp (Huang etal., 2006)
CCL3 Epithelium (Akiyama etal., 
1999)
Potentially involved in monocyte chemotaxis 
(Akiyama etal., 1999)
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CCL4 Epithelium and stroma 
(Hannan et al., 2006)
Promotes trophoblast m igration at feto- 
maternal interface (Hannan etal., 2006)
CCL5 Stroma and endothelial cells 
(Caballero-Campo etal., 2002)
Potentially involved in implantation, 
regulated by ILlp via NF kappa B (Caballero- 
Campo etal., 2002)
CCL8 Epithelium, no differential 
expression through cycle 
(Hampton etal., 2001)
Unlikely to be involved in macrophage 
recruitment (Hampton etal., 2001)
CCL14 Epithelium, decidua and 
vasculature (Hannan etal., 
2008)
Promotes trophoblast m igration (Hannan et 
al., 2008)
CCL16 Epithelium (Chand etal., 
2007)
Regulated by inflammatory cytokines (Chand 
et al., 2007)
CCL19 Epithelium and stroma 
throughout the menstrual 
cycle (Daikoku etal., 2004)
Not involved in chemotaxis (Daikoku et al., 
2004)
CCL20 Endometrial Cell lines (Sun et 
al., 2002)
Potential function in regulating/trafficking 
dendritic and T memory cells (Sun et al., 
2002)
CCL21 Epithelium and perivascular 
stroma (Nakayama et al., 
2003)
Increased during the mid secretory phase, 
may be involved in uNK cell chemotaxis 
(Nakayama etal., 2003)
Table 1.2: Summary of endometrial chemokine expression, regulation and 
function
The known chemokine ligand expression in the human endomtrium, including potential 
regulation and function.
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Chemokine
receptor
(systematic
name)
Endometrial expression Proposed functions and 
regulation
CXCR1 Epithelium and stroma, peak 
expression during mid 
secretory (Mulayim et al., 
2003)
Potential steroid hormone 
regulation (Dominguez etal., 
2003)
CXCR2 Epithelium and stroma 
(Mulayim etal., 2003)
CXCR3 Epithelial and stromal cell 
lines (Hirota et al., 2006)
MAP kinase signalling (Hirota 
et al., 2006)
CXCR4 Throughout the 
endometrium, highest in 
epithelium during 
proliferative phase (Laird et 
al., 2011).
Potential role during 
proliferative phase (Laird et 
al., 2011) and in 
implantation during the MS 
phase (Dominguez et al., 
2003)
CCR1 Found at first trimester 
implantation sites (Hannan 
et al., 2006)
Potential role in 
implantation (Hannan etal., 
2006)
CCR2 Decidual stromal cells (He et 
al., 2007)
Roles in the maternal-fetal 
interface (He et al., 2007)
CCR3 Epithelial cells (Zhang etal., 
2000)
Role in leukocyte 
recruitment/implantation 
(Zhang etal., 2000)
CCR7 Stromal cell cultures (Shi et 
al., 2007)
CCR8 Stromal cell cultures (Shi et 
al., 2007)
Potential regulation by 
oestrogen (Shi et al., 2007)
Table 1.3: Summary of endometrial chemokine receptor expression, regulation 
and function
The known chemokine ligand expression in the human endomtrium, including potential 
regulation and function.
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1.5.3 CXCL12
CXCL12 is an 8 kDa chemokine which was named stromal cell-derived factor 1 (SDF-1) 
after identification of its constitutive expression in bone-marrow derived stromal cells. 
It exhibits several features which distinguish it from other chemokines (Holmes et al., 
2001). Genes encoding the CXC and CC chemokines are generally found on 
chromosomes 4 and 17 respectively. However, the CXCL12 gene is found on 
chromosome 10. CXCL12 is expressed in a broad range of tissues while other 
chemokines appear to be more restricted in where they are expressed. The nucleotide 
and amino acid sequences for CXCL12 are highly conserved between humans and 
murine models indicating it is of core importance for mammalian cell function. Until 
recently it was believed that CXCL12 exclusively bound the chemokine receptor CXCR4. 
However, it has been shown that CXCL12 can bind to what was originally thought to be 
an orphan receptor named RDC1 (Thelen and Thelen, 2008). This receptor has since 
been renamed CXCR7 and while signal transduction via the receptor remains 
controversial, strong CXCL12 binding has been shown and a possible scavenging role 
proposed. Interestingly, CXCR7 has been shown not to play roles in leukocyte 
trafficking.
CXCL2 was chosen as the focus for this study due to its unique attributes, such as the 
location of its gene on chromosome 10 and not chromosomes 4 and 17, its widespread 
expression in human tissues (Holmes etal., 2001) and limited evidence for its presence 
and potential functional importance in the endometrium (Kitaya et al., 2004). 
Complementary protein studies in our laboratory also showed the presence of CXC12 
in non-pregnant endometrium. CXCL12,s receptor CXCR4 has also been shown to be 
expressed in the endometrium and its expression characterised throughout the 
menstrual cycle (Dominguez et al., 2003). As CXCR7 was only very recently discovered 
as a potential receptor to CXCL12 with potentially significant functioning, the 
expression of this new receptor could not be investigated in this study.
Two alternatively spliced isoforms of CXCL12 were originally isolated and termed SDF-
la  and SDF-10. SDF-la is composed of 89 amino acids and is the predominantly
expressed isoform. SDF-lp contains a four amino acid extension at the carboxyl
terminus. Both isoforms bind CXCR4 with comparable affinity. More recently, an
additional four splice variants have been identified which vary in length at the carboxyl
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terminus. While these isoforms are functional and have differential tissue 
distributions, their functional significance remains unknown (Busillo and Benovic, 2007 
and Yu et al., 2006).
1.5.4 CXCR4
CXCR4 is a 352 amino acid rhodopsin-like GPCR and selectively binds the CXC 
chemokine CXCL12 (Busillo and Benovic, 2007). Mice lacking either CXCR4 or CXCL12 
exhibit an almost identical phenotype of late gestational lethality and defects in B cell 
lymphopoesis, bone marrow colonisation and cardiac septum formation. These 
findings and other studies have confirmed CXCR4 is essential for development, 
hematopoiesis, organogenesis and vascularisation as well as functioning as a classical 
chemokine receptor in the adult. CXCR4 has been shown to be expressed in a number 
of tissues in addition to the leukocytes from which it was originally cloned.
1.5.5 Transcriptional control of CXCR4
The CXCR4 promoter region contains a number of predicted regulatory consensus 
sequences and is thought to be positively regulated by Nuclear Respiratory Factor-1 
(NRF-1) (Moriuchi et al., 1997 and Wegner et al., 1998), with a potential negative 
upstream element that may be mediated by Ying Yang 1 (YY1). Roles for other 
transcription factors have also been suggested (Moriuchi etal., 1999). Transcriptional 
expression of CXCR4 is thought to be affected by a number of signaling molecules. An 
increase in CXCR4 expression has been observed in response to intracellular second 
messengers such as calcium and cyclic AMP in addition to a number of cytokines such 
as IL2, IL4, IL7, IL8, IL10, IL15 and TGF-ip (Busillo and Benovic, 2007). Simultaneous 
CD3 and CD28 engagement (Moriuchi et al., 1997) as well exposure to growth factors 
such as basic fibroblast growth factor (bFGF), vascular endothelial growth factor 
(VEGF) (Salcedo et al., 1999) and epidermal growth factor (EGF) (Philips et al., 2005) 
have also been shown to increase CXCR4 transcription. Pro-inflammatory cytokines 
such as tumour necrosis factor a (TNFa), interferon T (IFNT) and ILlp have been shown 
to decrease the expression of CXCR4 (Gupta et al., 1998 and Han et al., 2001).
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1.5.6 Translational control of CXCR4
A number of translational modifications have been shown to contribute to the 
expression of CXCR4 at the protein level (Busillo and Benovic, 2007). The extracellular 
domain of CXCR4 contains two potential N-linked glycosylation sites (Asnll and 
Asnl76) though only A snll appears to be glycosylated in mammalian cells and has 
been shown to inhibit CXCL12 binding (Chabot et al., 2000). CXCR4 can also undergo 
extracellular tyrosine sulfation at Tyr7, Tyrl2 and Tyr21 and this has been shown to 
affect CXCL12 ligand binding (Farzan et al., 2002). CXCR4 is thought to be able to 
homodimerise, which may occur in the absence of CXCL12 (Babcock et al., 2003). It is 
thought that CXCR4 can also heterodimerise with CCR2 and CD4. While little is known 
about the functionality of dimerisation, it is potentially a further explanation for the 
functional heterogeneity of CXCR4 signaling in various cell types and tissues (Issafras et 
al., 2002 and Basmaciogullari etal., 2006).
1.5.7 Binding of CXCL12 to its receptor
The binding of CXCL12 to its receptor CXCR4 is proposed to be a two-step process. 
Initially, an interaction between residues 12 to 17 of CXCL12 and residues 2 to 36 of 
CXCR4 are thought to cause a conformational change in the receptor allowing the first 
eight amino acids of CXCL12 to access a binding pocket in CXCR4's extracellular loop 
structures (Brelot et al., 2000 and Huang et al., 2003). During an inflammatory 
response, proteases have been shown to inhibit CXCL12/CXCR4 binding by cleaving N- 
terminus residues of both the ligand and receptor (Delgado et al., 2001 and 
Valenzuela-Fernandez et al., 2002). CXCL12 is able to interact with glycosaminoglycans 
such as heparin sulphate which may immobilise CXCL12 in vivo aiding gradient 
formation. This association may also allow CXCL12 to oligomerise, a phenomenon 
observed at high CXCL12 concentrations. Recent evidence suggests that inflammatory 
response products may 'prime' the CXCL12 response and enhance hematopoietic 
stem/progenitor cell migration at lower CXCL12 concentrations. This may be due to 
changing membrane localisation of CXCR4 through incorporation into lipid rafts. It has 
been argued that lipid raft localisation is required to allow the proper functioning of 
CXCR4 and it has recently been shown that CXCL12 promotes the incorporation of Src 
tyrosine kinases, focal adhesion kinases, PI3 kinase and the G protein Rac into lipid
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rafts. This ligand promoted clustering of receptor and effectors may ensure activation 
of the appropriate/correct signal pathways (Majka et al., 2000 and Wysoczynski et al., 
2005).
1.5.8 CXCR4 and G protein Signaling
Upon CXCL12 ligand binding to CXCR4, a number of signaling pathways can be 
activated leading to a variety of biological responses. CXCR4 couples to the G,- family of 
proteins (Busillo and Benovic, 2007). This interaction can be disrupted by pertussis 
toxin (PTX) which inhibits GPCR/G,- association by ADP-ribosylation. This interaction 
has been used as a tool to investigate CXCR4 signaling and has demonstrated the 
capability of CXCR4 signaling to occur in both a G protein dependent and independent 
manner. G protein dependent signaling relies on activated G* protein causing 
inhibition of adenylyl cyclase and activating the Src family of tyrosine kinases. 
Liberated GpY activates phospholipase C-p (PLC-p) and phosphoinositide-3 (PI3K). 
These events ultimately lead to regulation of processes such as gene transcription, cell 
migration and cell adhesion (Kucia et al., 2004). G protein independent signaling has 
been proposed to take place through activation of the JAK/STAT pathway in which the 
transient association of JAK2 and JAK4 with CXCR4 causes the activation and nuclear 
translocation of a number of STAT proteins (Vila-Coro et al., 1999). CXCR4 dependent 
signal transduction has also been shown to occur through the activation of the 
MAPK/ERK1/2 and PI3K/Akt pathways leading to the activation of transcription factors 
such as nuclear-factor kappa B (NFKB) and Etsl (Chinni et al., 2006; Huang et al., 2009 
and Tang et al., 2008).
1.5.9 Regulation of CXCR4 signaling
GPCRs are regulated by the processes of desensitisation, internalisation and 
degradation. Homologous desensitisation (decreased receptor activity in response to 
continuous stimuli) occurs due to phosphorylation of serine/threonine residues 
present within the cytoplasmic tail domain of the receptor by G protein-coupled 
receptor kinase (GRK). This phosphorylation event allows subsequent binding of 
arrestin-2 and/or arrestin-3 which uncouples the receptor from further G protein 
activation and potentially targets it for internalisation (Krupnick et al., 1998). Upon
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CXCL12 binding, CXCR4 is rapidly phosphorylated and internalised. Upon 
internalisation, GPCRs can be recycled back to the plasma membrane but this process 
occurs poorly for CXCR4. CXCR4 has been shown to be ubiquinated, sorted to the 
lysosome and degraded in a process mediated by the E3 ubiqutin ligase AIP4. It is 
thought the phoshorylation of specific residues within CXCR4 may dictate the 
receptors fate following its internalisation (Haribabu et al., 1997).
1.6 Evidence for the role of CXCL12 and CXCR4 in the function of the 
endometrium
Although expression of CXCL12 in monkey and bovine endometrium has been reported 
(Ace and Okuliez, 2004 and Mansouri-Attia et al., 2009), studies of CXCL12 and CXCR4 
in human endometrial epithelial and stromal cells are limited. One 
immunohistochemical study showed that CXCL12 could be detected during the 
proliferative phase of the menstrual cycle only (Kitaya et al., 2004). A study which 
investigated the expression of CXCL12 and other chemokines in the human 
endometrium through the menstrual cycle using gene arrays did not detect the 
presence of CXCL12 (Jones et al., 2004). Unpublished data from our laboratory has 
suggested that CXCL12 protein is detectable in the endometrium and is localised 
predominantly to the glandular and luminal epithelium (see Chapter 3, Figure 3.1). A 
study by Dominguez et al. (2003) quantified the expression of CXCR4 mRNA through 
stages of the menstrual cycle from endometrial biopsies. This study found CXCR4 to be 
expressed throughout the menstrual cycle with an apparent decrease in CXCR4 mRNA 
expression through the proliferative phase and a significant increase at the time of 
implantation.
Several studies of CXCL12 and CXCR4 in uNK cells, trophoblast and the blastocyst have 
demonstrated a potential role for the chemokine ligand and its receptor in the 
processes of implantation and uNK cell trafficking. It has been demonstrated that 
decidual uNK cells isolated from elective terminations expressed CXCR4 mRNA as did 
the decidual tissue and placenta. Positive immunohistochemical staining for CXCL12 
was also shown in the placenta and it was demonstrated that CXCL12 (but not CXCL9 
or CXCL10) attracted CD56+ CD16- NK cells. The same group also showed that CXCL12
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protein is expressed in vivo on invasive trophoblast and trophoblast cells lining 
maternal blood vessels (Hanna etol., 2003).
Another study also demonstrated (using RT-PCR and immunohistochemistry) that 
trophoblasts and decidual stromal cells express both CXCL12 and CXCR4. CXCL12 was 
found to induce an apparent increase in the invasiveness of the trophoblast and 
upregulated MMP2 and MMP9 activity in both trophoblast and stromal decidua. It 
was proposed that CXCL12 secreted by human trophoblasts enhances the coordination 
between the trophoblast and the decidual stromal cells via MMP2 and MMP9 (Zhou et 
ol., 2008). It has been shown that CXCR4 and CXCR3 were highly expressed in 
CD56bnght CD16‘ first trimester decidual NK cells (Wu et oi., 2005). The same study 
demonstrated that trophoblast cells spontaneously secrete CXCL12 and showed that 
both recombinant CXCL12 and trophoblast cell supernatents caused the chemotaxsis 
of CD56bright CD16- natural killer cells.
Endometrial biopsies taken from patients undergoing hormone replacement therapy 
showed that when patients were treated solely with estradiol, weak staining for CXCR4 
was seen to be localised to the luminal and glandular epithelium of the endometrium. 
It was also shown in an in vitro apposition model of implantation that in the presence 
of a blastocyst, endometrial cells showed an increase in staining for CXCR4. Staining 
for CXCR4 on the blastocyst was negative (Valles and Dominguez, 2006).
Endometrial and peripheral T lymphocytes taken from RM and fertile women showed 
that endometrial lymphocytes expressed CXCR4 and that its expression was decreased 
by CCL5 (Ramhorst et oi., 2004). CCL5 was also shown to be expressed in the 
endometrium, which was shown to be sensitive to progesterone.
Finally, in an investigation into genome wide mRNA transcript levels between three 
fertility groups subjected to exogenous estradiol and progesterone, microarray 
analysis showed reduced expression of CXCR4 in a group of women who showed 
repeated implantation failure during IVF treatments in comparison to women who 
underwent successful IVF or fertile controls (Tapia et al., 2008). Although expression 
of CXCR4 was decreased in comparison to both the successful IVF treatment and fertile 
control groups, the expression of CXCR4 mRNA was highest in women who had 
undergone successful IVF treatment and not fertile controls.
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1.7 Evidence for the effects of CXCL12 on the expression of other factors
Outside of the endometrium, there is evidence that CXCL12 acts not just as a 
chemotactic agent but also functions to modulate the expression of a number of genes 
and subsequent protein production (Busillo and Benovic, 2007). A number of genes 
that have been shown to be of potential importance in endometrial function have 
been shown to be up-regulated by CXCL12 in non-endometrial cell types. However, 
the effects of CXCL12 on these genes expression levels remains unstudied in human 
endometrial cells.
CXCL12 increases IL6 expression in human microglia, basal carcinoma cells and 
prostate cancer cell lines. It is proposed that is achieved by activation of the PI3K/Akt, 
ERK and NF Kappa B signal transduction pathways (Chu et al.t 2009; Lu et al., 2009 and 
Wang et al., 2005). CXCL12 increases IL8 expression in prostate cancer and mast cell 
lines (Lin et al., 2000 and Wang et al., 2005) and expression of IL8 has been shown to 
be inhibited following treatment with a CXCR4 antagonist in malignant human glioma 
cells. This was also demonstrated for vascular endothelial growth factor (VEGF) 
expression in the same study (Ping et al., 2007). VEGF expression has been shown to 
be increased by CXCL12 in human breast carcinoma cells via the Akt signaling pathway 
(Liang et al., 2007) and in human prostate cancer cell lines (Wang et al., 2005). Matrix 
metalloproteinases MMP2 and MMP9 have been shown to be increased by CXCL12 
treatment in prostate cancer cell lines (Singh et al., 2004), bone marrow proginator 
cells (Shao et al., 2008) and implicated in transendothelial haematopoietic stem cell 
migration, where CXCL12 increases MMP2 and MMP9 expression (Lapidot et al., 2005).
1.8 Evidence for the functional importance of IL6, IL8, MMP2, MMP9 and 
VEGF in the human endometrium
Various studies have implicated IL6 (Laird et al., 1993; Laird et al., 1994; Margni and
Zenclussen, 2001; Robertson et al., 2000; Tabibzadeh et al., 1995; Vandermolen and
Gu, 1996 and Zenclussen et al., 2003), IL8 (Arici et al., 1998a; Arid et al., 1998b;
Caballero-Campo et al., 2002; Garcia-Valesco and Arici, 1999 and Koch et al., 1992),
MMP2 (Fernandez et al., 1992; Jeziorska et al., 1996 and Salamonsen and Woolley,
1996), MMP9 (Lockwood et al., 2008 and Salamonsen et al., 1997) and VEGF (Ferrara,
2004; Ferrara and Davis-Smyth, 1997; Girling and Rogers, 2005 and Risau, 1997) in a
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range of female reproductive and endometrial functions throughout the menstrual 
cycle and during implantation.
1.8.1 Interleukin 6 (IL6)
Interleukin 6 (IL6) is a multifunctional secreted cytokine that regulates various aspects 
of the immune response, acute phase reaction and haematopoiesis. IL6 deficient mice 
have reduced fertility and a decrease in viable implantation sites (Robertson et oi, 
2000). A report by Tabibzadeh (1989) showed the production of IL6 by human stromal 
endometrial cells which was decreased by incubation with oestradiol, showing that IL6 
production can be modulated by a major controller of endometrial function. Further 
immunolocalisation studies of IL6 expression in the human endometrium showed that 
it was weakly expressed during the proliferative phase of the menstrual cycle but 
highly expressed during the mid secretory phase. The expression was found mainly to 
be in the endometrial glands and to a lesser extent in the stroma (Tabibzadeh et a i, 
1995 and Vandermolen and Gu, 1996). IL6 was also found to be expressed in cultured 
human endometrial cells. Endometrial epithelial cells were shown to produce 
significantly higher levels of IL6 protein than stromal cells and addition of progesterone 
and oestradiol increased IL6 production in these cells (Laird et oi, 1993). Addition of 
I LI to cultured endometrial epithelial cells increased IL6 production (Laird et a i, 1994). 
Inhibition of IL6 production in the Ishikawa cell line following treatment with 170- 
oestradiol potentially through NFKB signaling has also been demonstrated (Ray et oi,
1997). Some studies have shown differences in serum IL6 expression between normal 
fertile females and those that undergo spontaneous abortion in both humans and 
murine models, however uterine levels were not measured (Margni and Zenclussen, 
2001; Zenclussen et a i, 2003). The localisation of IL6 mainly to the glandular and 
luminal epithelium of the endometrium, with expression peaking in the mid-secretory 
phase combined with evidence that IL6 levels differ between fertile and infertile 
individuals suggests a plausible role for IL6 in the implantation process. However, a 
further study which measured levels of IL6 expression in human endometrial biopsies 
obtained between days LH+6 and LH+13 from fertile and infertile human women, 
showed no difference between the two groups of women, suggesting that IL6 does not 
play a direct role in uterine receptivity (Sherwin et a i, 2002).
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IL6 expression has also been identified in the blastocyst (Sharkey et al., 1995) and in 
the trophoblast. Investigations into the role of IL6 in trophoblast growth and placental 
development have shown its capacity to affect the expression of placental hormones 
such as hCG (Nishino et al., 1990). The trophoblast has also been shown to express the 
interleukin 6 receptor (IL6R) and its associated signal transducer, gpl30. It has also 
been shown in an in vitro study that cytotrophoblast cells produce higher levels of IL6 
mRNA than syncytiotrophoblast cells (Stephanou et al., 1995). The IL6R and its 
associated gpl30 signal protein has also been localised to within the trophoblast 
(Nishino et al, 1990). IL6 has been shown to induce the activation of trophoblast 
MMPs 2 and 9 and also to increase trophoblast integrin expression (Das et al., 2002 
and Meisser et al., 1999).
Tissue culture experiments have found that first trimester placenta released IL6 into 
the supernatant, while histochemical studies showed the presence of IL6 in 
trophoblast cells with greater staining intensity found in the syncytiotrophoblast rather 
than the cytotrophoblast (Kameda et al., 1990). Other tissue culture experiments 
found IL6 to be expressed in both the trophoblast and villous core compartments of 
the placenta, with the trophoblast producing significantly higher levels of IL6. It was 
suggested that the regulation of IL6 was post-transcriptional as mRNA levels in the 
villous core and trophoblast did not correlate with the observed differential production 
of IL6 (Kauma et al., 1993). Another study found IL6 to be expressed by both the 
syncytiotrophoblast and extravillous trophoblast and suggested that IL6 produced by 
the trophoblast may account for observed IL6 in coelomic and amniotic fluids. It has 
been suggested that IL6 may play a role in tissue remodeling associated with 
placentation and during the first trimester of pregnancy in the haematopoeitic 
function of the secondary yolk sac and in the generation of new vessels in placental 
villous tissue (Jauniaux eta!., 1996).
1.8.2 Interleukin 8 (IL8) (CXCL8)
IL8 is a secreted chemokine that is known to recruit leukocytes by chemotaxsis. It has
also shown to be involved in non-immune cell function both outside and within the
endometrium (Arici et al., 1998b and Garcia-Valesco and Arici, 1999). IL8 has been
shown to be expressed in the human endometrium, where it has been
immunolocalised mainly to the glandular and luminal epithelium and vascular
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endothelial cells (Caballero-Campo et al., 2002 and Milne et al., 1999). It has been 
suggested that the function of IL8 in the endometrium is to act as a regulator for 
immune cell recruitment, a process which is known to change throughout the 
menstrual cycle (Garcia -Velasco and Arici, 1999). IL8 is expressed in cultured epithelial 
and stromal endometrial cells and addition of the pro-inflammatory cytokines IL1 and 
TNFa increased its expression (Arid et al., 1993). Endometrial IL8 protein levels 
change during the menstrual cycle, with peak levels of expression during the early to 
mid proliferative and late secretory phases (Arici et al., 1998a). It was suggested that 
the increased expression of IL8 in the late secretory phase may regulate the increased 
recruitment of neutrophils into the endometrium prior to menstruation (Milne et al., 
1999), where they are thought to be involved in the degradation and scavenging of 
endometrial tissue. The increased expression of IL8 in the latter early to mid 
proliferative phase of the menstrual cycle may suggest a role in neo-vascularisation of 
growing endometrium, which is a known effect of IL8 (Arici et al., 1998a and Koch et 
al., 1992). Progesterone has been shown to increase IL8 mRNA expression and inhibit 
protein production in cultured endometrial cells and this might account for the lower 
IL8 expression seen in the early luteal phase in vivo. The decrease in progesterone 
during the late luteal phase would allow IL8 expression to increase allowing increased 
neutrophil recruitment into the endometrium (Kelly et al., 1994). This is supported by 
the observation that increased immuno-reactivity to IL8 occurs in premenstrual 
decidua and perivascular cells, which is consistent with IL8 functioning to recruit 
leukocytes from the vasculature at this time (Jones et al., 1997).
IL8 has not only been shown to act as a chemoattractant and angiogenic factor but 
also can stimulate cell growth. It has been shown that IL8 stimulates the proliferation 
of various cells types including endothelial cells (Koch et al., 1992), epidermal cells 
(Tuschil et al., 1992), and smooth muscle cells (Yue et al., 1994). The ability of IL8 to 
act as a growth factor in stromal endometrial cells has been demonstrated previously 
(Arici et al., 1998b).
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1.8.3 Matrix metailoproteinase 2 (MMP2) and 9 (MMP9)
Matrix metalloproteinases (MMPs) are enzymes which degrade components of the 
extracellular matrix (ECM). The MMPs are thought to critically control the degradation 
and remodeling of ECM and collectively can degrade virtually all components of ECM 
including both interstitial matrix and basement membranes (Birkedal-Hansen et al., 
1993; Powell and Matrisan, 1996 and Salamonsen and Woolley, 1999). The MMPs can 
be divided into subfamilies; the collagenases, gelatinases, stromelysins and 
membrane-types. Most MMPs are secreted extracellulary as latent zymogens, which 
have been shown to be activated by a number of proteases such as plasmin, tryptase 
and elastin as well as by other MMPs which can form MMP activation cascades. The 
activation of pro-MMP2 is unusual as it activated at the cell surface by membrane-type 
MMPs (MT-MMPs) (Salamonsen, 1999 and Salamonsen and Woolley, 1996). MMPs 
are inhibited by tissue inhibitors of matrix metalloproteinases (TIMPs) which block the 
activity of the MMPs by the formation of 1:1 complexes. Growth factors, cytokines, 
steroid hormones (including progesterone and androgens) differentially regulate the 
expression of MMPs. This gives the MMPs the ability to act differentially in both a 
tissue and cell specific manner independent of the system to which they belong 
(Salamonsen, 1999 and Salamonsen et al., 1997). Both transcriptional and post- 
transcriptional mechanisms regulate MMP and TIMP production. The promoter 
regions of the MMP and TIMP genes contain an AP-1 and PEA-3 biding site, which 
binds fos and jun and Ets respectively. The fos, jun and Ets proteins have been shown 
to be present in the endometrium (Edwards et al., 1996). The mechanisms by which 
MMP gene transcription is regulated in the endometrium and trophoblast remains 
unknown (Salamonsen, 1999 and Salamonsen and Woolley, 1999).
The expression pattern of MMPs in the normally functioning endometrium during the 
menstrual cycle is consistent with a role in the process of normal menstruation. 
Studies have demonstrated that progesterone has the ability to act as a negative 
regulator of transcription for MMPs 1, 3 and 9 and it has been suggested that falling 
levels of progesterone towards the end of the menstrual cycle may be responsible for 
allowing an increased expression of MMPs at the time of menstruation (Salamonsen et 
al., 1997). However, it has been suggested that this may not reflect the true in vivo 
situation. For example, some cytokines such as IL1 and TNFa, which increase MMP
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production, have been shown to have the ability to override the action of 
progesterone on MMP expression suggesting that transcriptional control of MMP 
expression may be carried out at the local level (Salamonsen et al., 1997; Singer et al., 
1997 and Zhang et al., 1998). M M P1,2 and 3 are expressed by the human endometrial 
stroma at menstruation (Salamonsen and Woolley, 1996).
Studies that have immunolocalised the expression of MMP2 in the human female 
reproductive tract have found it to be expressed in a variety of cell types including 
decidual cells and the trophoblast as well as a variety of leukocytes (Fernandez et al., 
1992). During the secretory phase of the menstrual cycle, MMP9 protein has not been 
detected in the endometrial stroma using immunohistochemistry but MMP9 has been 
shown to be expressed within the luminal and glandular epithelium during the 
postovulatory period. It has been observed that MMP9 protein moves to the apical 
surface of the epithelium and are released into the uterine lumen during the period of 
endometrial receptivity (Jeziorska et al., 1996 and Salamonsen and Woolley, 1996). 
The expression of MMP9 has been shown in subsets of endometrial eosinophils, 
macrophages and neutrophils, while CD4+ T lymphocytes have been shown to express 
MMP2 and 9 during menstruation (Shi e ta l, 1995).
MMP2 and 9 are thought to play role in controlling the invasion of the trophoblast 
into the endometrial stroma (loannidis et al., 2010 and Jovanovic et al., 2010). The 
cytokine LIF, which is known to be involved in the control of implantation has been 
shown to increase the secretion of TIMP1 and 2 in primary first trimester human 
extravillous trophoblast (EVT), but did not affect the expression of MMP2 and 9 (Tapia 
et al., 2008). In preeclampsia, there is shallow EVT invasion and impaired spiral artery 
and arteriole remodeling to reduce uteroplacental blood flow. Studies have shown 
increased expression of MMP9 in decidual cells and adjacent interstitial trophoblasts in 
placental sections taken from preeclamptic women versus normal controls 
demonstrating MMP9's potential importance in successful normal implantation 
(Lockwood et al., 2008).
Proteolytic degradation of the ECM by MMPs and the control of ECM degradation by 
TIMPs appears to be the most obvious reason for the expression of MMPs in the 
endometrium, especially given its highly dynamic nature. Flowever, alternative
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functions of the MMPs have been described for these molecules which may be 
important when considering endometrial function (Salamonsen, 1999). For example, 
several MMPs degrade regulatory molecules including IL1(3 and insulin-like growth 
factor binding protein (Fowlkes et oi, 1994 and Flo et al., 1996). The TIMPs also have 
been shown to have alternative functional activities. For example, TIMP1 and 2 have 
shown to have growth factor activity (Flayakawa etal., 1994).
1.8.4 Vascular endothelial growth factor A (VEGFA)
Angiogenesis is the formation of new blood vessels from pre-existing vasculature and 
is a fundamental process of the human menstrual cycle. The endometrium is 
recognised as one of the few adult human tissues where significant angiogenesis 
occurs on a routine physiological basis due to the endometrium's dynamic cycles of 
tissue growth and breakdown. Abnormal endometrial angiogenesis may contribute to 
several endometrial pathologies including; endometrial cancer, endometriosis, 
menorrhagia and breakthrough bleeding (Girling and Rogers, 2005).
Endometrial growth and differentiation occurs under the control of oestrogen and 
progesterone, but the sex steroids exert the majority of their effects indirectly via a 
variety of growth factors (Girling and Rogers 2005). This includes the process of 
angiogenesis, in which vascular endometrial growth factor (VEGF) is known to act as a 
potent endothelial cell mitogen. It also has the ability to increase vascular 
permeability and plays a central role in inflammation and other pathologies (Ferrara, 
2004; Ferrara and Davis-Smyth, 1997 and Risau, 1997).
The human VEGF gene is organized in eight exons on chromosome 6p21.3 and is 
known to produce four alternatively spliced isoforms (VEGFA-D) which vary in amino 
acid length, protein structure and potential functioning. VEGF acts through tyrosine 
kinase receptors VEGFR1 and VEGFR2 to exert its cellular effects (Ferrara and Davis- 
Smyth, 1997).
There is evidence that oestrogen stimulates angiogenesis by acting directly on
endometrial endothelial cells, which is supported by the identification of the oestrogen
receptors in the endometrial vascular smooth muscle and in endothelial cells both in
vitro and in vivo (Girling and Rogers, 2005). Studies which have investigated the
effects of oestrogen on endometrial epithelial and stromal cells have produced some
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conflicting results. For example, a study which investigated the effects of oestrogen on 
cultured endometrial stromal cells found it to increase the mRNA expression of VEGF 
isoforms (Huang et al., 1998), yet a more recent study which used immunolocalisation 
to demonstrate expression of VEGF in both the endometrial epithelium and stroma 
found that expression of VEGF was decreased under the influence of oestrogen 
(Punyadeera et al., 2006).
While evidence for the direct action of oestrogen on the endometrium and its 
vasculature in relation to angiogenesis and VEGF expression has been identified, it is 
also thought that angiogenesis in the endometrium must also occur indirectly via other 
endometrial cell types. For example, following hormonal withdrawal at the end of the 
secretory phase, the angiogenesis required to repair the vascular bed occurs in the 
absence of steroid hormones (Girling and Rogers, 2005). This is supported by 
observations using human co-cultures of endometrial cells and microvascular 
endothelial cells, which showed that neither oestrogen nor endometrial stromal cells 
promoted angiogenesis in endothelial cells but instead demonstrated increased 
angiogenesis by endothelial cells in the presence of glandular epithelial cells. This led 
to the proposal that oestrogen regulates endometrial angiogenesis by regulating the 
expression and secretion of angiogenic factors such as VEGF by glandular epithelial 
cells in the human endometrium. Expression of VEGF by glandular epithelial cells has 
also been demonstrated in non-human primates (Albrecht et al., 2003 and Albrecht 
and Pepe, 2003).
1.9 Aims and Objectives of the study
This introduction has highlighted that successful reproduction in the human female 
involves the concerted action between different organs, tissues and cell types. The 
endometrium plays a particularly important role in the process as it is the site of 
embryo implantation and develops to form the maternal side of the placenta during 
pregnancy. The endometrium contains many different cell types, including a unique 
population of immune cells and undergoes dynamic changes through the menstrual 
cycle. These highly dynamic processes are systemically regulated by the action of the 
steroid hormones. However, the diverse cellular functions that occur throughout the 
menstrual cycle and during implantation requires fine cellular control. Chemokines
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have the potential to fill many of these roles using their ability to form chemotatic 
gradients and potentially exert wide effects on the expression of many genes and the 
proteins they encode.
The endometrium undergoes rapid changes in tissue development and organisation, 
vascularisation and cell function. Chemokines have been implicated in all of these 
roles and may play vital roles in the paracrine control of endometrial function (Busillo 
and Benovic, 2007). The chemokine ligand CXCL12 and its receptor CXCR4 are unique 
in terms of their genetic locations in respect to other chemokines and receptors, their 
widespread expression and secretion in human tissues and are essential to achieve 
fetal development. The ligand and receptor pair are known to be involved in leukocyte 
chemotaxis and other functions including controlling cell proliferation and 
angiogenesis. All of these effects could be of potential importance in the 
endometrium. While CXCL12 and CXCR4 have been heavily studied in pathological 
roles such as cancer metastases and HIV, their potentially diverse normal functions in 
human tissues have received less attention. Within the endometrium the expression 
of CXCL12 and CXCR4 has been characterised but the expression patterns through the 
menstrual cycle, cellular distribution and functions remain unknown but may 
potentially be of crucial importance to the general functions of the endomtrium 
(Dominguez et a/., 2003 and Kitaya et o/v 2004).
1.9.1 Hypotheses
It is our hypotheses that CXCL12 and CXCR4 may be differentially expressed in the 
endometrium throughout the menstrual cycle and between endometrial cell types, 
which may affect function. Furthermore, CXCL12 may regulate the expression of 
factors important to successful endometrial function such as IL6, IL8, MMP2, MMP9 
and VEGFA, which have all been shown to be regulated by CXCL12 in non-endometrial 
human tissues. CXCL12 may act via CXCR4 to exert completely unknown functional 
changes on endometrial cells.
1.9.2 Aims and objectives
Therefore, it is our aim to quantify CXCL12 and CXCR4 mRNA expression throughout 
the menstrual cycle using endometrial samples obtained from healthy volunteers using
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real-time RT-PCR to identify differential expression throughout the cycle. To 
investigate any potential differences in CXCL12 and CXCR4 mRNA expression between 
different endometrial cell types, we aimed to use real-time RT-PCR to quantify levels of 
CXCL12 and CXCR4 mRNA in primary endometrial cell cultures. To investigate any 
potential regulatory effects of CXCL12 on IL6, IL8, MMP2, MMP9 and VEGFA in the 
endometrium, primary cultures of endometrial cells would be incubated with CXCL12 
and any effects measured using real-time RT-PCR after establishing basal expression. 
As CXCL12 may have effects on endometrial gene expression that are completely 
unknown, we aim to use genome-wide microarray analysis in endometrial cell lines 
incubated with CXCL12 to identify gene transcripts which may respond to the ligands 
presence. The suitability of using cell lines to investigate endometrial cell function will 
also be considered by comparing the gene expression of Ishikawa and HEC-l-B cells to 
primary epithelial counterparts.
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Chapter 2 
Materials and methods
2.1 Human subjects
Endometrial biopsies were obtained from women attending the Jessop Wing, Sheffield 
Teaching Hospitals, to investigate the expression of CXCL12 and CXCR4 through the 
menstrual cycle and for preparation of primary cell cultures. All samples were 
collected with written informed consent from the patient and ethical committee 
approval was obtained for this study (ethics REC reference number: 04/Q2305/23, 
Sheffield Research Ethics Committee). The total number of samples used was 37 and 
all samples were obtained from normal fertile women undergoing surgery for non- 
endometrial pathology. All of the women were aged between 20 and 40 and had 
menstrual cycles of between 25 and 35 days, had normal uterine anatomy and had no 
steroid treatment for at least 2 months prior to the study. The samples were dated 
according to the day of the last menstrual period and confirmed by histological staging.
2.2 Cell culture
All cell culture reagents, media and supplements were obtained from Gibco™, 
Invitrogen UK unless otherwise stated. All cell culture methods were carried out under 
sterile conditions in a class II laminar flow cabinet. Ishikawa endometrial 
adenocarcinoma cells were obtained from the European Collection of Cell Cultures 
(ECACC) through Sigma-Aldrich, UK. HEC-l-B endometrial adenocarcinoma cells were 
obtained from the American Type Culture Collection (ATCC) through LGC Standards, 
UK.
2.2.1 Cell line stocks
Ishikawa and HEC-l-B cells were stored in cryovials immersed in liquid nitrogen until 
required for use. Cells were preserved in 2 ml of fetal bovine serum (FBS) containing 
10% (v/v) dimethyl sulfoxide (Sigma-Aldrich, UK).
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2.2.2 Ishikawa cell line culture
Thawed stocks of adherent Ishikawa adenocarcinoma cells were routinely grown in a 
cell culture incubator at 37°C and 5% C02 in 25 cm2 cell culture flasks bathed in 20 ml 
of Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% (v/v) FBS, 2% 
(v/v) L-glutamine (200 mM) and 2% penicillin-streptomycin to make complete DMEM 
(cDMEM). When cell monolayers were determined to be near-confluent 
(approximately 80%), cells were passaged to new 25 cm2 flasks by removal of culture 
medium followed by washing with 10 ml of IX  phosphate buffered saline (PBS) 
solution. The cells were detached from the flask by incubating at 37°C for 5 minutes in 
5 ml of trypsin/EDTA solution (containing 0.25% trypsin) followed by gentle tapping of 
the flask. The action of the trypsin/EDTA solution was stopped by addition of 5 ml of 
cDMEM. The resulting 10 ml cell solutions were placed into 50 ml Falcon tubes and 
centrifuged for 5 minutes at 300 x g and the supernatant discarded. Cell pellets were 
washed by re-suspension in 10 ml of PBS to remove any remaining trypsin/EDTA. 
Centrifugation was repeated. The supernatant was discarded and the pellet was either 
immediately used for RNA extraction (section 2.2) or re-suspended in 8 ml of cDMEM 
and passaged at a 1:8 ratio into new 25 cm2 flasks by addition of 1 ml of cell/DMEM 
solution to 19 ml of cDMEM. Flasks were placed back into the incubator to allow cells 
to adhere and grow.
2.2.3 HEC-l-B cell line culture
The same procedure as was used for Ishikawa cells was used to culture HEC-l-B cells, 
except that HEC-l-B cells were grown in McCoy's 5A medium (Sigma-Aldrich, UK) 
which was supplemented with 10% FBS, 2% L-glutamine and 2% penicillin- 
streptomycin solution.
2.2.4 Primary cell culture
Primary endometrial epithelial and stromal cell cultures were prepared using an 
established method (Cork et al., 2002; Laird et al., 1993 and Tuckerman et al., 2000). 
Human endometrial tissue was collected and placed in 2.5 ml Hanks balanced salt 
solution (Sigma-Aldrich, UK) containing 100 pi penicillin-streptomycin solution. 20 mg 
of collagenase 1A (Sigma-Alrich, UK) was placed into a sterile Falcon tube and 10 ml of
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cDMEM containing 0.005% (v/v) sodium pyruvate Solution (Sigma-Aldrich, UK) was 
added to the tube and syringe filtered into two 5 ml aliquots in 50 ml Falcon tubes and 
stored at 4°C. Using sterile scissors and forceps, endometrial tissue was removed from 
the Hanks solution and cut into fine pieces in one of the tubes containing the 
collagenase/cDMEM solution.
The sample was incubated at 37°C for 1 hour to allow the collagenase 1A to act on the 
endometrial tissue resulting in separation of epithelial cell glands and stromal cells 
from the tissue. This process was aided by gentle pipetting at 30 minutes and 1 hour 
during the incubation to aid dispersion. After 1 hour, the dispersed cell suspension 
was centrifuged at 100 x g for 5 minutes, the resulting supernatant containing stromal 
cells was removed and centrifuged at 300 x g for 5 minutes to pellet the cells and allow 
removal of collagenase/cDMEM solution. The supernatant was discarded and the 
stromal cell pellet was re-suspended in 5 ml of cDMEM and stored at 37°C. The 
remaining epithelial cell pellet was re-suspended in the second aliquot of 
collagenase/cDMEM and incubated at 37°C and pipetted to disperse cells as previously 
stated. Centrifugation at 100 x g produced a pellet of epithelial cells in glandular 
clumps and the supernatant was placed into the previously removed and stored 
stromal cell suspension which was centrifuged at 300 x g to produce a pellet.
Density gradient separation was performed to further purify epithelial and stromal cell 
cultures. Two 15 ml sterile Falcon tubes were labeled epithelial gradient and stromal 
gradient. 8 ml of cDMEM was placed into the epithelial gradient tube and 8 ml of 50% 
cDMEM and 50% Nutrient Mixture F-12 Ham medium (F-12) supplemented in the 
same manner as cDMEM (section 2.2.2). 2 ml of cDMEM was used to re-suspend the 
epithelial cells and was layered over its gradient. 2 ml of cDMEM/F-12 was used to re­
suspend the stromal cells, which were also layered over its respective gradient. Both 
gradients were left for 30 minutes to allow separation. The larger epithelial cell gland 
fragments fall to the bottom of the tube, the top 8 ml of the epithelial tube was 
discarded and the remaining 2 ml was retained for cell counting. The smaller stromal 
cells remain in the upper 8 ml of the tube which was removed and retained. The lower 
2 ml of the media was discarded.
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Previous immunocytochemical analysis of vimentin (a stromal cell marker), cytokeratin 
(an epithelial cell marker) and CD45 (leukocyte marker) of cells prepared and grown 
this way have shown that the epithelial and stromal cells are essentially pure and free 
of leukocyte contamination after 48 hours in culture (Tuckerman, et al., 2000).
Cells were counted using a haemocytometer by counting the number of cells in 5 of 
the large squares (outer four corners and the central square) which was multiplied by 
50, 000 to give the number cells per ml. Approximately 4xl05 cells in 5 ml of 
appropriate medium (cDMEM for epithelial cells and cDMEM/F-12 for stromal cells) 
was added to 12.5 cm2 flasks which were pre-coated with 500 pi of FBS to aid cell 
adhesion. Cells were incubated at 37°C and 5% C02 with medium changed every 48 
hours while growing. Cells were not passaged but underwent addition of CXCL12, 24 
hours prior to expected confluence (section 2.2.5). Figure 2.1 shows images of primary 
epithelial and stromal cells cultured using this method. A total of six samples were 
used for cell culture obtained throughout the menstrual cycle, three of known date 
(day 8, 25 and 29) and three of unknown date.
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A.
B.
Figure 2:1: images of cultured primary endometrial epithelial and stromal cells 
The figure shows confluent primary epithelial (A) and stromal (B) endometrial cells. No 
visible contamination is apparent in either culture model.
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2.2.5 Addition of CXCL12a/SDF-la to endometrial cell cultures
A recombinant polypeptide sequence representing amino acid residues 22-89 of 
human CXCL12a (NCBI sequence ID: 1352728) with an ED50 of 3-9 ng/ml for cultured T 
lymphocytes was obtained from R&D Systems, UK. 10 pg of lyophilised CXCL12 was 
reconstituted to a recommended concentration of 100 pg/ml by addition of 100 pi of 
sterile PBS to create a stock solution. This was separated into 10 pi aliquots designed 
for single use to minimise damage due to freeze/thawing. Aliquots were stored at - 
80°C.
For use in microarray analysis, Ishikawa cells were incubated 24 hours prior to 
expected confluence with 0 and 5 ng/ml of recombinant CXCL12. This concentration 
was chosen to be relatively low as the sensitivity of microarray analysis should detect 
any changes in any mRNA transcript expression. For real-time RT-PCR experiments 
Ishikawa and HEC-l-B cells were incubated with 0 ,10  and 100 ng/ml of CXCL12 for 24 
hours prior to expected confluence. Primary epithelial and stromal cell cultures also 
incubated with 0, 10 and 100 ng/ml of CXCL12 24 hours before reaching confluence. 
24 hours after addition of CXCL12, Ishikawa and HEC-l-B cells were removed from 
flasks by trypsinisation as described in sections 2.2.2 and 2.2.3. Primary epithelial and 
stromal cells were detached from the flask by addition of 1 ml of trypsin/EDTA solution 
followed by incubation at 37°C for 5 minutes followed by gentle tapping and use of a 
cell scraper if necessary to remove cells. The action of trypsin/EDTA was stopped by 
addition of 1 ml of cDMEM. Cells were pelleted by centrifugation at 300 x g for 5 
minutes. The supernatant was removed and discarded and cells were washed by 
addition of 10 ml of PBS. Centrifugation was repeated and the supernatant was 
discarded. Pellets were kept on ice until RNA was extracted.
2.3 RNA extraction
RNA was extracted from all cells cultures using the Genelute™ Mammalian Total RNA 
Miniprep Kit (Sigma-Aldrich, UK) which uses spin columns to extract RNA from cell 
cultures or tissue. RNA in human endometrial tissue biopsy samples was extracted 
using TRI REAGENT™ (Sigma-Aldrich, UK).
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2.3.1 Genelute™ Mammalian Total RNA Miniprep Kit
RNA extraction from Ishikawa and HEC-l-B cells and primary endometrial epithelial 
and stromal cells was carried out according to the manufacturer's protocol:
Cell lysis solution was prepared by addition of 10 pi of 2-Mercaptoethanol (2-ME) per 
ml of provided lysis solution. 500 pi of 2-ME/lysis solution was added to each cell 
pellet and was vortexed thoroughly to lyse the cells and inactivate RNases. The lysate 
was then added to the Genelute™ filtration column and receiving tube and centrifuged 
at 16,000 x g for 2 minutes, to remove cellular debris and to shear genomic DNA.
The filtration column was discarded and the filtered lysate was prepared for RNA 
binding by adding an equal volume (500 pi) of 70% ethanol solution. The 
lysate/ethanol solution was bound to a Genelute™ RNA binding column by a two-step 
addition of 500 pi of lysate/ethanol solution followed by centrifugation at 16,000 x g 
for 15 seconds. The flow-through was discarded and the binding insert containing the 
RNA was retained.
Bound RNA was washed by addition of 500 pi of wash solution 1 to the RNA binding 
column which was placed into a collection tube, followed by centrifugation at 16,000 x 
g for 15 seconds. The binding column was then placed into a fresh collection tube and 
500 pi of wash solution 2 was run through the column by further centrifugation at 
16,000 x g for 15 seconds. This was repeated with a third column wash which was 
again centrifuged for 2 minutes to dry the column. As the column must be free of any 
ethanol before eluting the RNA a further drying step was carried out by centrifugation 
at 16,000 x g for 1 minute.
RNA was eluted from the column by adding 50 pi of elution solution to the RNA 
binding column followed by centrifugation at 16,000 x g for 1 minute. The resulting 
purified RNA in the eluate was stored at -80°C.
2.3.2 Extraction of total RNA from human endometrial tissue samples 
using TRI REAGENT™
RNA was directly extracted from endometrial tissue using TRI REAGENT™ according to 
manufacturer's instructions (Sigma-Aldrich Technical Bulletin MB-205): Human
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endometrial tissue samples were collected into 1.5 ml of RNA later® tissue collection 
RNA stabilisation solution (Applied Biosystems, UK) which rapidly permeates tissue to 
preserve and protect samples from RNase degradation. Samples were stored at -80°C. 
When required, samples were thawed at room temperature and weighed to ascertain 
the amount of TRI REAGENT™ required to successfully extract the RNA. Samples were 
then finely chopped with surgical scissors and homogenised by hand in a plunging glass 
homogeniser with 1 ml of TRI-REAGENT™ added per 100 mg of endometrial tissue.
The homogenised tissue/TRI REAGENT™ mixture was placed into 1.5 ml micro­
centrifuge tubes and centrifuged at 12,000 x g for 10 minutes at 4°C to remove 
insoluble materials such as extracellular membranes, polysaccharides and high 
molecular weight DNA. The resulting supernatant was transferred to a fresh micro­
centrifuge tube and allowed to stand at room temperature for 5 minutes to ensure 
dissociation of nucleoprotein complexes. Addition of 0.2 ml of chloroform (Sigma- 
Aldrich, UK) per ml of TRI REAGENT™ to each sample was followed by vigorous shaking 
and each sample was left to stand for 15 minutes at room temperature. The mixture 
was centrifuged at 12,000 x g for 15 minutes at 4°C. This procedure resulted in the 
separation of each sample into three phases. A red organic phase containing protein, 
an inter phase containing DNA and the colourless upper phase that contained RNA.
To isolate and precipitate RNA, the upper aqueous phase was removed to a fresh 
micro-centrifuge tube to which, 0.5 ml of isopropanol (Fisher Scientific, UK) per ml of 
TRI REAGENT™ (first used in sample homogenisation) was added and thoroughly 
mixed. The sample was allowed to stand for 10 minutes at room temperature. 
Centrifugation at 12,000 x g for 10 minutes at 4°C led to the formation of an RNA pellet 
on the bottom of the tube. The pellet was washed by removing the supernatant and 
adding 1 ml of 75% ethanol per ml of TRI REAGENT™ followed by vortexing and 
centrifugation at 7,500 x g for 5 minutes at 4°C. The supernatant was removed and the 
pellet left to air dry ensuring it did not do so completely. 50 pi of nuclease free water 
(Sigma-Aldrich, UK) was added to the pellet which was re-suspended by repeated 
pipetting of the sample. Samples were stored until required at -80°C.
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2.4 Assessing RNA quantity and integrity
2.4.1 Quantification of RNA samples using NanoDrop ND-1000 UV-VIS 
Spectrophotometer
RNA quantity was accurately measured in using the NanoDrop ND-1000 UV-VIS 
Spectrophotometer in the RNA40 nucleic acid mode. The spectrophotometer was 
initialised using nuclease-free water and then blanked using the appropriate solution 
(nuclease-free water or elution solution from the Genelute™ Mammalian Total RNA 
Miniprep Kit). 1 pi of each RNA sample was used to obtain the RNA concentration. 
Generally, 500 ng aliquots of RNA in 10 pi of nuclease-free water were prepared and 
stored at -80°C for use in cDNA synthesis. Samples considered to have a low 
abundance of total RNA were adjusted to 250 ng.
2.4.2 Assessing RNA integrity using Experion™ LabChip microfluidic 
technology
Assessment of RNA integrity by automated electrophoresis was carried out using the 
Experion™ LabChip microfluidic technology in conjunction with the Experion™ RNA 
Standard Sensitivity Analysis Kit (Biorad, UK) and was carried out according to the 
manufacturer's instructions.
Cleaning of the electrodes on the electrophoresis station was carried out before each 
run by filling the provided cleaning chip with 800 pi of Experion™ electrode cleaning 
solution and placing in the instrument with the lid closed for 2 minutes, immersing the 
electrodes into the solution within the cleaning chip. A separate cleaning chip 
containing 800 pi of nuclease-free water was then placed in the instrument for 5 
minutes followed by replacement of the water and further electrode immersion for 1 
minute. The lid was then left open to allow evaporation of any remaining water from 
the electrodes.
Experion™ RNA Standard Sensitivity Analysis Kit reagents were removed from storage 
at 4°C and left at room temperature for 15 minutes to equilibrate while the provided 
RNA ladder was removed from storage at -80°C and placed on ice. Stocks of filtered 
gel were prepared by pipetting 600 pi of RNA gel into a provided spin filter tube 
followed by centrifugation for 10 minutes at 1,500 x g. The filter insert was discarded
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and the resulting filtered gel was viable for 4 weeks after this procedure when stored 
at 4°C.
65 pi of the filtered gel was pipetted into an RNase free micro-centrifuge tube and 1 pi 
of gel stain (foil wrapped to protect it from light damage) was added and briefly 
vortexed to obtain the appropriate ratio of gel to gel stain. This solution was prepared 
on the day of use.
2 pi of the RNA ladder and 2 pi of each RNA sample to be analysed (maximum 12 per 
chip) were placed into RNase free micro-centrifuge tubes. The ladder and RNA 
samples were denatured at 70°C in a heating block for 2 minutes to remove secondary 
RNA structures and cooled by immediately placing on ice for a minimum of 5 minutes.
An Experion™ RNA Standard Sensitivity Chip was removed from its packaging and 
placed on the platform of the instrument's priming station. 9 pi of the filtered gel 
solution was placed into the gel priming well labelled GS on the RNA chip. Care was 
taken to avoid bubble formation when applying reagents to the RNA chip wells and 
was fundamental to achieving successful analysis. The lid of the priming station was 
closed and the chip primed for 30 seconds at time setting 1 and pressure B. The chip 
was removed from the priming station and placed on a clean surface.
9 pi of filtered gel-stain solution was placed into the second GS well on the RNA chip. 
9 pi of the filtered gel was placed into the well labeled G. 5 pi of provided loading 
buffer was placed into each sample well (1 to 12) and the ladder well labeled L. 1 pi of 
denatured RNA ladder was pipetted into the well labeled L and a maximum of 12 
denatured RNA samples were removed from ice and placed into the sample wells. 1 pi 
of nuclease-free treated water was pipetted into any unused wells.
The loaded chip was clipped into the instrument's vortex station which operates to mix 
the reagents and samples for 60 seconds and automatically shuts down. The chip was 
removed from the vortex station and placed immediately into the instrument's 
electrophoresis station. Each run was performed using the RNA StdSens Eukaryotic 
protocol which was selected via the provided computer software.
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2.4.3 Assessing mRNA integrity from endometrial cell extracts
Successful and accurate real-time RT-PCR and microarray analysis depends upon good 
quality mRNA for reverse transcription to cDNA. To assess the integrity of mRNA 
obtained from Ishikawa, HEC-l-B, epithelial and stromal endometrial cells Experion™ 
LabChip microfluidic technology was used. Figure 2.2 shows an example of the results 
obtained from this automated electrophoresis procedure in which peaks at 18S and 
28S rRNA show the presence of intact RNA which has not been degraded by the 
extraction procedures. The results displayed in Figure 2.2 are for RNA extracted from 
primary endometrial epithelial and stromal cells but RNA extracted from all cell types 
were tested in this way before their use in real-time RT-PCR and microarray analysis 
and similar peaks for 18S and 28S rRNA were seen in all samples tested showing that 
all RNA was of good integrity.
Total RNA extracted from endometrial biopsy tissue generally showed poorer levels of 
RNA integrity when investigated by the same method (Figure 2.3). This was expected 
due to unavoidable degradation that occurs in obtaining the sample prior to its 
stabilisation in RNA later® solution. All tissue samples used for calculating the in-vivo 
expression of CXCL12 and CXCR4 were consistently and immediately placed into RNA 
later solution once removed from the volunteer to minimise this effect.
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Figure 2.2: Example of results obtained from analysis of RNA by Experion™
LabChip microfluidic technology in primary endometrial cells
A. Shows a digital gel produced after analysis of primary epithelial and stromal cell RNA
extracts. Lane 1 shows the RNA ladder which allows identification of the 18S and 28S
rRNA subunits in the experimental samples. Lanes 2-5 show RNA from epithelial cells
incubated with 0, 10 and 100 ng/ml of CXCL12, while lanes 5-7 show stromal cells
incubated in the same manner. B. Shows a plot of recorded fluorescence displayed as a
8 0
function of time for the RNA ladder used by Experion™ to identify the 18S and 28S 
rRNA subunits. C, D and E shows the results obtained for epithelial cells while F, G and 
H show stromal cells. The samples all show tight peaks for 18S and 28S rRNA and 
demonstrates that the extracted RNA is intact RNA and has not been subjected to 
degradation during the extraction process.
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Figure 2.3: Example of results obtained from analysis of RNA by Experion™ 
LabChip microfluidic technology in endometrial biopsies
A. Shows a digital gel produced after analysis of endometrial biopsy RNA extracts. Lane 
1 shows the RNA ladder which allows identification of the 18S and 28S rRNA subunits
in the experimental samples.
B. Shows a plot of recorded fluorescence displayed as a function of time for the RNA 
ladder used by Experion™ to identify the 18S and 28S rRNA subunits. C-H shows the 
results obtained from six endometrial biopsy RNA extracts.
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2.5 Real-time RT-PCR assay preparation and validation
2.5.1 Complementary DNA synthesis from RNA samples for use in real­
time RT-PCR
First strand complementary DNA (cDNA) synthesis was carried out using the High 
Capacity cDNA Reverse Transcription Kit (Applied Biosystems, UK).
10 pi aliquots of extracted total RNA previously adjusted (section 2.4.1) to 500 ng or 
250 ng in 0.2ml micro-centrifuge tubes were reversed transcribed to cDNA by addition 
of 10 pi of cDNA master mix which contained 2.0 pi 10X reverse transcriptase (RT) 
buffer, 0.8 pi 25X dNTP mix (100 mM), 2 pi 10X RT random primers, 1 pi MultiScribe™ 
Reverse Transcriptase and 4.2 pi of nuclease-free water per required reaction to a total 
volume of 20 pi. Mixing was carried out using repeated pipetting and brief 
centrifugation to drive down tube contents and remove air bubbles.
Reaction tubes were placed in a PCR thermocycler at 25°C for 10 minutes, 37°C for 120 
minutes and 80°C for 5 seconds respectively. Samples were held at 4°C until stored at 
-20°C.
Negative controls for the cDNA synthesis reaction were prepared in the same manner 
but with 1 pi of nuclease-free water instead the Multiscribe™ Reverse Transcriptase so 
no cDNA could be produced.
Master mixes were made by multiplying the amounts of each component in the cDNA 
reaction by the number of samples to be prepared. One additional reaction for both 
the experimental and control mixes was added to account for evaporation and 
pipetting error.
2.5.2 Custom primer design of oligonucleotide primers for use in real­
time RT-PCR
Oligonucleotide PCR Primers were synthesised by Invitrogen, UK. Housekeeping genes 
sequences were selected from established primers reported by Vandesompele et al. 
(2002) designed for use as reference transcripts to normalise real-time RT-PCR data 
(Table 2.1).
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Primers for chemokine ligand CXCL12 and receptor CXCR4 were designed after 
obtaining mRNA sequences from NCBI. The selected portion of the mRNA sequence 
was pasted into Primer3 software and sequences were generated. A G:C content of 
approximately 50% was considered acceptable for use (Table 2.2).
Sequences for primers to be used in real-time RT-PCR for IL6, IL8, MMP2 and MMP9 
were obtained from a report by Wang et ol. (2006), while sequences for primers for 
VEGFA was obtained from Thijssen et ol. (2004) (Table 2.3).
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symbol Number Product 
Size (base 
pairs)
Reverse sequence
ACTB NM_001101.2 Beta actin Cytoskeletal 
structura l prote in
CTGGAACGGTGAAGGTGACA 141
AAGGGACTTCCTGTAACAATGCA
B2M NM_004048.2 Beta-2-microglobulin Beta- 
chain of major 
histocompatibility complex 
class 1 molecules
TGCTGTCTCCATGTTTGATGTATCT 86
TCTCTGCTCCCCACCTCTAAGT
GAPDH NM_002046.2 Glyceraldehyde-3- 
phosphate dehydrogenase
Oxidoreductase in glycolysis 
and gluconeogenesis
TGCACCACCAACTGCTTAGC 125
GGCATGGACTGTGGTCATGAG
HPRT1 NM_000194.1 Hypoxanthine
phosphoribosyl-transferase 1
Purine synthesis in salvage 
pathway
TGACACTGGCAAAACAATGCA 98
GGTCC IT IICACCAGCAAGC1
RPL13A NM_012423.2 Ribosomal protein L13a
Structural component of the 
large 60S ribosomal subunit
CCTGGAGGAGAAGAGGAAAGAGA 126
TTGAGGACCTCTGTGTATTTGTCAA
SDHA NM_004168.1 Succinate dehydrogenase 
complex, subunit A Electron 
transporter in the TCA cycle 
and resp iratory chain
TGGGAACAAGAGGGCATCTG 86
CC ACC ACT G CAT C AAATT CAT G
UBC M26880.1 Ubiquitin C Protein 
degradation
ATTTGGGTCGCGGTTCTTG 90
TGCCTTGACATTCTCGATGGT
YWHAZ NM_003406.2 Tyrosine 3-
monooxygenase/tryptophan 
5-monooxygenase 
activation protein, zeta 
polypeptide Signal 
transduction by binding to 
phosphorylated serine 
residues on a variety of 
signalling molecules
ACI1I I  IGGTACATTGTGGCTTCA
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CCGCCAGGACAAACCAGTAT
Table 2.1: House-keeping genes analysed fo r stability in different cell types 
using real-time RT-PCR
Eight established housekeeping genes (Vandesomple et ai, 2002) were assessed for 
the ir stability across different endometrial cell types under different conditions. The 
above table lists the housekeeping genes assessed, the ir NCBI sequence ID, gene 
function, forward and reverse probe sequences and the expected amplicon product 
size.
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Chemokine/
chemokine
receptor
name
Accession
number
Forward sequence Product size 
(base pairs)
Reverse sequence
CXCR4 NM_001008540.1 CATTTTT CAG ATAT AAAAG ACT G AC 151
GGTCCTGCCTAGACACACATC
CXCL12 NMJL99168.2 TCAGCCTGAGCTACAGATGC 121
CTT IAGCIICGGGILAAIGC
Table 2.2: Custom designed primers used in real-time RT-PCR
Primer3 software (http://primer3.sourceforge.net/) was used to create oligonucleotide
real-time RT-PCR primers for chemokine ligand CXCL12 and receptor CXCR4. The table
shows their mRNA sequence ID from NCBI and the resulting forward and reverse
primer sequences created along with the expected product size for each transcript of
interest.
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Gene
name
Accession
number
Forward sequence Product size 
(Base pairs)
Reverse sequence
IL6 NM_000600 G ACAG CCACT CACCT CTT C A 211
TT C ACC AG GC AAGT CT CCT C
IL8 NM_000584 CTGCGCCAACACAGAAATTATTGTA 170
TTCACTG G C AT CTT CACGT ATT CTT
MMP2 NM_002801 TGCTGGAGACAAATTCTGGA 200
ACTT CACG CT CTT CAG ACTTT G G
MMP9 NM_004994 TGCCCGGACCAAGGATACAG 182
TCAGGGCGAGGACCATAGAG
VEGFA NM_001025366 AAGGAGGAGGGCAGAATCAT 100
CCAGGCCCTCGTCATTG
Table 2.3: Previously published real-time RT-PCR primers fo r five genes of 
interest
Established real-time RT-PCR primers were used to investigate mRNA expression for 
five transcripts of interest. Oligonucleotide probes for IL6, IL8, MMP2 and MMP9 first 
published by Wang et al. (2006) and VEGFA (Thijssen et ol., 2004) are shown along 
with their transcript ID obtained from NCBI, forward and reverse probe sequences and 
the expected amplicon size.
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2.5.3 Real-time RT-PCR primer preparation
A stock solution of concentration 100 pM was prepared from the lyophilised 
oligonucleotide primers by addition of nuclease-free water and thorough vortexing. 
Working solutions for each primer were prepared by adding 12.5 pi of stock primer 
solution to 87.5 pi of nuclease-free water to a total volume of 100 pi and 
concentration of 12.5 pM. 1 pi of forward and lp l of reverse primer solution was 
added to each 25 pi PCR reaction giving a final primer concentration of 0.5 pM.
2.5.4 Components of a SYBR® Green real-time RT-PCR reaction
Each individual real-time RT-PCR reaction consisted of 12.5 pi Absolute QPCR SYBR® 
Green Mix (ABgene, UK), which contains all the components necessary to perform real­
time RT-PCR except for oligonucleotide primers and cDNA. This includes a Thermo- 
Start™ DNA polymerase which requires activation by heating at 95°C for 15 minutes 
and prevents non-specific amplification during the reaction set-up, proprietary 
reaction buffer optimised to MgCI2 which was at a final concentration of 3 mM, dNTPs 
and SYBR® Green I dye which fluoresces upon binding double stranded DNA. The 
overall fluorescence increases proportionally to the concentration of double stranded 
DNA present. Inclusion of a fluorescein reference dye allowed normalisation of 
reactions in the PCR plate (referred to as the well plate factor) to account for the well 
position and inherent pipetting error.
Each reaction also contained 1 pi of both the forward and reverse of oligonucleotide 
primer for the gene of interest from its 12.5 pM working solution giving a final 
concentration of 0.5 pM per reaction (section 2.4.3). 4.5 pi of nuclease-free water and 
2 pi of cDNA from a reverse transcribed RNA sample were also added. The total 
reaction volume was 25 pi.
A negative control reaction was included which contained 2 pi of nuclease-free water 
in place of 2 pi of cDNA and a minus reverse transcriptase (-RT) reaction was included 
which contained 2 pi of -RT control in place of cDNA. Master mixes were made by 
multiplying the amount of each component required by the number of reactions 
required plus one to account for possible evaporation and pipetting error. The cDNA 
was individually pipetted into wells of an iCycler iQ™ 96-well PCR plate (Bio-Rad, UK)
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which was sealed using Microseal® B Adhesive Seals (Bio-Rad, UK) before placing into 
the Bio-Rad iCycler iQ™ Multicolour Real-Time Dectection System. All SYBR® Green 
real-time RT-PCR reactions were subjected to the same thermal protocol shown in 
Figure 2.4.
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Figure 2.4: Bio-Rad iCycler iQ™ Multicolour Real-Time Detection System 
thermocycler protocol
All SYBR® Green real-time RT-PCR was subjected to the thermal protocol shown above. 
Step 1 activated the Termo-Start™ DNA polymerase. Step 2 allowed amplification of 
the target of interest, while Step 3 consisted of 45, 10 second cycles starting at 50°C 
(initially for 30 seconds) w ith an increase of 1°C per cycle enabling melt curve data 
collection to distinguish the PCR product from possible non-specific DNA amplification.
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2.5.5 Assessing reference gene transcript stability
Reference gene transcript stability between Ishikawa and HEC-l-B cell lines was 
compared. Individual 25 pi SYBR Green real-time RT-PCR reactions (section 2.4.4) were 
prepared in duplicate for each gene of the 8 housekeeping genes (HK) to be compared 
(Table 2.1) in both cell types. A negative control reaction was performed for each gene 
in which no cDNA was added. The samples were assessed by performing real-time RT- 
PCR in the Bio-Rad icycler iQ™ according to the thermal protocol shown in Figure 2.4.
The resulting cycle threshold (Ct) values obtained for each HK gene for both cell types 
were log2 transformed and had their expression ratios calculated using the formula:
2 (control-sample)
The control used in this case was the lowest expressed sample (the highest Ct value) to 
ensure all ratios had a positive expression value. Ratios were imported into GeNorm 
software which calculated the most stable HK gene by stepwise removal of genes after 
analysis of pair-wise variation of all possible combinations to leave the two most stable 
genes with a stability value M  (Vandesomple et ol, 2002). The two HK genes 
determined to be the most stably expressed across cell types were used as reference 
transcripts for quantifying relative expression values of all genes of interest.
Figure 2.5 shows the melt curves that were obtained from initial real-time RT-PCR 
experiments investigating reference gene stability. B2M, GAPDH, HPRT1 and SDHA (A- 
D respectively) were left out of GeNorm analysis as they showed poorer product 
specificity in the samples tested. ACTB, RPL13A, UBC and YWHAZ (E-H respectively) 
were included in the GeNorm analysis and the software carried out stepwise removal 
of genes, after analysis of pair-wise variation of the reference transcripts to generate 
an M  value. An attributed M  value of <1.5 is considered acceptable for a transcript to 
be used as a reference transcript in real-time RT-PCR (Vandesompele et ol, 2002). UBC 
and YWHAZ were found to be the most stably expressed transcripts with an M  value of 
0.64 which coupled with their good real-time RT-PCR expression profiles and product 
specificity made then suitable for use as reliable reference transcripts to quantify gene 
expression.
92
11 mm m m m
Figure 2.5: M elt curves obtained for reference transcripts assessed fo r stability 
in ishikawa and HEC-l-B endometrial cells
The figure shows melt curves produced for A. B2M (beta-2-microglobulin), B. GAPDH 
(glyceraldehyde-3-phosphate dehydrogenase), C. HPRT (hypoxanthine phosphoribosyl- 
transferase 1), D. SDHA (succinate dehydrogenase complex, subunit A), E. ACTB (Beta 
actin), F. RPL13A (ribosomal protein L13a), G. UBC (ubiquitin C) and H. YWHAZ 
(tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein) in 
Ishikawa (blue) and HEC-l-B (red) endometrial cell lines.
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To further investigate the accuracy of the SYBR® Green real-time RT-PCR data that was 
generated, a retrospective study of the variations in the reference gene YWHAZ was 
carried out across all four endometrial cell types used as ideally the reference 
transcript should not vary significantly between them. Also, epithelial endometrial 
cells were used to investigate any potential effects of incubation of cells with CXCL12 
on YWHAZ expression. The use of a fixed concentration of RNA in each cDNA synthesis 
reaction allowed for a statistical comparison of Ct values generated for YWHAZ in all 
SYBR® Green real-time RT-PCR experiments.
Relative expression of YWHAZ was calculated in relation to the mean triplicate Ct value 
obtained for YWHAZ from one of the six epithelial cell mRNA samples to which no 
CXCL12 had been added. Using this value as a control, variations in YWHAZ expression 
were calculated using the formula:
Variation = 2-(sample-contro'>
A non-parametric ANOVA (Kruskal-Wallis test) coupled with a Dunn's multiple 
comparison test was used to identify any significant differences in YWHAZ expression 
between endometrial cell types and in response to incubation with CXCL12. As YWHAZ 
was used in each endometrial cell type to quantify expression levels of 1L6, IL8, MMP2, 
MMP9 and VEGFA and these experiments were carried out on up to six separate 
occasions, data for up to thirty, triplicate real-time RT-PCR reactions could be included. 
Figure 2.6, A. shows the results for epithelial endometrial cells incubated with 0, 10 
and 100 ng/ml of CXCL12. No significant difference in YWHAZ expression was found 
between any of the CXCL12 concentrations used (P=0.24, n=30), confirming that 
incubation with CXCL12 was unlikely to affect the expression of the reference 
transcript YWHAZ.
Figure 2.6, B. shows the results obtained for epithelial, stromal, Ishikawa and HEC-l-B 
endometrial cells. While there were no significant differences between the epithelial, 
stromal and Ishikawa endometrial cells, the HEC-l-B cells produced significantly more 
YWHAZ mRNA in comparison to the epithelial (P=0.0002) and stromal endometrial cell 
types (P=<0.01, n=12-30).
94
Figure 2.7 shows the results obtained when the same analysis was carried out for 
YWHAZ and UBC in mRNA extracted directly from endometrial biopsies throughout the 
menstrual cycle. No significant difference could be observed between any menstrual 
cycle phases for either reference transcript.
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Figure 2.6: Variation in reference transcript YWHAZ mRNA in endometrial cells 
A. Shows expression of YWHAZ mRNA in endometrial epithelial cells following 
incubation with or without CXCL12 for 24 hours. B. Shows expression of YWHAZ mRNA 
in epithelial, stromal, Ishikawa and HEC-l-B endometrial cells.
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Figure 2.7: Variation in reference transcripts UBC and YWHAZ mRNA in 
endometrial biopsies collected throughout the menstrual cycle
A. Shows expression of UBC through the menstrual cycle. Although variation was 
visible, there was no statistical difference in the expression levels between menstrual 
cycle phases.
B. Shows expression of YWHAZ through the menstrual cycle. Although variation was 
visible, there was no statistical difference in the expression levels between menstrual 
cycle phases.
9 7
2.5.6 Measuring primer efficiency
The efficiency of the primers used in the SYBR® Green real-time RT-PCR experiments 
were assessed to ensure they performed comparably and effectively. Six serial 
dilutions of cDNA from RNA extracted from primary epithelial cell cultures, which had 
been reversed transcribed according to section 2.4.1 were used to assess the efficiency 
of each primer. Serial dilutions were made by addition of appropriate volumes of 
nuclease-free water to cDNA (Table 2.4). 2 pi of each serially diluted cDNA sample was 
plated out in triplicate into an iCycler iQ™ 96-well PCR plate for all primer sets used. 
SYBR® Green real-time RT-PCR was carried out by addition of 23 pi of SYBR® Green RT- 
PCR master mix to each cDNA sample for each primer set to be assessed. PCR plates 
were placed into the Bio-Rad iCycler iQ™ instrument and the standard thermal 
protocol performed.
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Dilution Dilution
concentration
cDNA required (pi). Nuclease-free water required 
(Hi).
A Neat 10 0
B 1 in 5 2(A) 8
C 1 in 10 1(A) 9
D 1 in 100 1(C) 9
E 1 in 500 2(D) 8
F 1 in 1000 1(D) 9
G 1 in 10000 1(F) 9
Toble 2.4: Preparing serial dilutions of primary epithelial endometrial cDNA to 
calculate real-time RT-PCR primer efficiency
Serial dilutions of cDNA reverse transcribed from extracted primary epithelial 
endometrial RNA was carried out using the above method for all reference transcripts 
and transcripts of interest used in this study.
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The Ct values for each sample assessed were recorded and the primer efficiency of 
each oligonucleotide primer set was calculated by the method described by Pfaffl 
(2001):
Efficiency = i o (‘1/slope)
The slope was calculated by plotting cDNA concentration along the horizontal axis of a 
scatter graph versus determined Ct values for each concentration on the vertical axis in 
Microsoft Excel software. Primer efficiencies between 90-110% were considered 
acceptable for use.
The efficiencies of each of the primer sets used in SYBR® Green real-time RT-PCR were 
calculated, the efficiencies were: CXCL12 = 106%, IL6 =95%, IL8 =91%, MMP2 =89%, 
MMP9 =95%, VEGFA =90%, YWHAZ =92% and UBC =91%. The ideal range for real-time 
RT-PCR primer efficiency is between 90 and 110%. All the primer sets used fell within 
this range with the exception of MMP2 at 89% which was included as this 1% deviation 
was not expected to significantly alter the amplification of this transcript's cDNA. 
Figure 2.8 shows graphs of recorded Ct values as a function of cDNA concentration for 
all SYBR® Green primer sets used to calculate their primer efficiencies.
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Figure 2.8: Assessing efficiencies of primers used in SYBR® Green real-time RT- 
PCR
Efficiencies of all primers used in SYBR® Green Real-Time RT-PCR were calculated from 
the y value obtained from each serial dilution performed. R2 values are displayed on 
each chart. Primer efficiencies: CXCL12 = 106%, IL6 =95%, IL8 =91%, MMP2 =89%, 
MMP9 =95%, VEGFA =90%, YWHAZ =92% and UBC =91%.
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2.5.7 Identification of CXCR4 RT-PCR product by polyacrylamide gel 
electrophoresis
Initial SYBR® Green real-time RT-PCR experiments, which identified the presence of 
CXCR4 mRNA in cell lines used polyacrylamide gel electrophoresis to confirm the 
presence of a specific PCR product at the correct size. Following confirmation of this 
subsequent SYBR® Green real-time RT-PCR experiments used melt-curve analysis to 
confirm the presence of specific PCR products.
All reagents were obtained from Sigma-Aldrich, UK unless otherwise stated. 10X TBE 
buffer solution was prepared by adding 108 g of TRIS base, 55 g of boric acid and 40 ml 
of 0.5 M EDTA (pH 8.0) (Sigma-Aldrich, UK) and made up to 1 L with distilled water. 
The final pH was adjusted to 8.3 and the buffer stored at room temperature. 6% 
polyacrylamide gels were prepared by addition of 2 ml of 30% (w/v) 
acrylamide:bisacrylamide solution (19:1 ratio) to 6 ml of IX  TBE buffer. To initiate 
polymerisation, 150 pi of 10% (w/v) ammonium persulphate (APS) solution and 10 pi 
of TEMED were added immediately prior to pouring between gasket sealed pre­
prepared mini-gel casting plates. A plastic comb was placed into the gel to form 
loading wells. The polyacrylamide gels were allowed to set at room temperature.
5pl of each PCR product to be assessed was removed from the RT-PCR plate by pipette 
and mixed thoroughly with 1 pi of 6X stained loading buffer (Promega, UK) in micro­
centrifuge tubes. A 25 base-pair (bp) DNA ladder (Promega, UK) was prepared by 
adding 5 pi of ladder to 1 pi of 6X loading buffer and mixed by pipette.
The polyacrylamide gels were placed into an electrophoresis tank (Biorad, UK). The 
tank was filled with IX  TBE buffer and each 6 pi PCR product sample and the 25 bp 
DNA ladder was loaded into the wells. Electrophoresis was carried out at 100V for 
approximately 1 hour until the dye in the loading buffer had reached close to the 
bottom of gel ensuring appropriate separation of the DNA ladder and PCR products.
Gels were removed from their glass plates and placed into a plastic weighing boat
containing 20 ml of nuclease-free water. 10 pi of 10 mg/ml ethidium bromide solution
(Sigma-Aldrich, UK) was added and the gel was placed on an orbital shaker at low
speed for 10 minutes. To remove excess ethidium bromide, the gel stain was
discarded and the gel was de-stained for 10 minutes by addition of 20 ml of nuclease-
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free water. The gel was then removed from the weighing boat and viewed under a 
CCD camera fitted with a UV transilluminator and exposed until a clear image was 
obtained.
The analysis of CXCR4 in Ishikawa and HEC-l-B cells repeatedly showed the presence 
of a specific RT-PCR product for CXCR4 in both cell lines (Figure 2.9). Polyacrylamide 
gel electrophoresis of the PCR product showed clear bands at the expected size of 151 
base pairs (Figure 2.10). Negative controls showed no PCR product. The use of a 
polyacrlyamide gel to separate the DNA present in the completed PCR reaction, 
allowed discrete bands to be observed that can sometimes be seen due to primer 
dimer formation and would not be visible if agarose was used. The result shows that 
transcripts of CXCR4 mRNA were being expressed by the endometrial cell lines tested 
and therefore suggests that they were an appropriate model for studying the effects of 
CXCL12 in endometrial function.
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Figure 2.9: M elt curve analysis of CXCR4 real-time RT-PCR product in mRNA 
extracted from Ishikawa and HEC-l-B andenocarcinoma cell lines 
A clear peak at 80°C for CXCR4 can be observed in the figure for Ishikawa (red) and 
HEC-l-B (blue) cDNA. The negative control (black) showed no recorded fluorescence 
at any temperature confirming no DNA was present in the reaction.
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Figure 2.10: Polyacrylamide gel electrophoresis of CXCR4 RT-PCR product 
A single band at 151 base pairs was seen for mRNA extracted from Ishikawa and HEC- 
l-B cells. The negative control showed that no DNA and no PCR amplification occurred 
when cDNA was not added to the Real-Time RT-PCR reaction.
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2.5.8 Assessing the reproducibility and specificity of SYBR® real-time RT- 
PCR
Melt curve analysis was used to determine the specificity PCR products for IL6, IL8, 
MMP2, MMP9, VEGFA, CXCL12, YWHAZ and UBC produced using SYBR Green® real­
time PCR. Melt curves produced for these transcripts all showed product specific 
peaks indicating the presence of a single PCR product for each transcript studied (see 
Figures 2.11 and 2.12). The approximate melt temperatures (°C) for the transcripts 
studied were: 11.6=89, IL8=85, MMP2=90, MMP9=91, VEGFA=89, YWHAZ=84, UBC=84 
and CXCL12=87. All transcripts of interest were clearly distinguishable from their 
reference gene used to calculate their expression. Figure 2.11 shows melt curves 
obtained from an experiment measuring the expression of IL8 (blue) mRNA in primary 
epithelial endometrial cells. The IL8 and YWHAZ (reference transcript) (gold) exhibit 
the smallest difference in peak melt temperature of any transcripts included in the 
same SYBR® Green real-time RT-PCR assay. Despite their similarity, specific products 
for the transcripts are clearly visible.
Figure 2.13 shows the typical results generated for negative controls for both 
transcripts in which cDNA was replaced with water. YWHAZ (green) primers did not 
generate any detectable product and therefore shows a flat line. IL8 (black) primers 
generated non-specific PCR product which can occur due to primer dimerisation and a 
lack of suitable template. These non-specifc products can be detected by SYBR® Green 
but are clearly distinguishable from the specific PCR products and indicates the 
presence of no contamination in the samples. Melt curve peaks in negative or -RT 
control samples that could not be easily distinguished from the experimental samples 
indicated the presence of contaminating factors such as genomic DNA, present either 
from RNA which was not completely pure or introduced from the surroundings. If this 
was observed the resulting Ct values for the experimental samples could not be 
considered accurate and were discarded.
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Figure 2.11: Assessing SYBR Green real-time RT-PCR reproducibility and 
specificity
A-F shows the amplification graphs obtained for YWHAZ (orange), IL6 (black), IL8 (red), 
MMP2, (green), MMP9 (purple) and VEGFA (blue) for a number of samples of mRNA 
extracted from primary epithelial endometrial cells. The automatically applied cycle 
threshold line can be seen on these amplification plots in orange. G-L shows the 
associated melt curve produced for each real-time RT-PCR experiment.
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2.12: Assessing SYBR Green real-time RT-PCR reproducibility and specificity 
for CXCL12 and UBC using melt curve analysis
The figure shows examples of typical melt curves obtained for CXCL12 (A) and UBC (B) 
real-time RT-PCR products.
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Figure 2.13: Identification o f specific and non-specific real-time RT-PCR 
products using melt-curve analysis
Shows a melt-curve generated in a typical SYBR® Green real-time RT-PCR experiment. 
IL8 is shown in blue, YWHAZ in gold, IL8 negative control in black and YWHAZ negative 
control in green.
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2.6 Measuring expression of IL6, IL8, MMP2, MMP9, VEGFA and CXCL12 
using SYBR® Green real-time RT-PCR
Amounts of mRNA expression for: IL6, IL8, MMP2, MMP9 and VEGFA in Ishikawa, HEC- 
1-B, primary epithelial and stromal cell cultures were determined in the presence and 
absence of CXCL12 using SYBR® Green real-time RT-PCR. Experiments were repeated 
on three separate occasions for Ishikawa and HEC-l-B cells. Experiments on primary 
epithelial and stromal cell cultures were repeated six times using endometrial tissue 
obtained from different women. All cell types were incubated with 0, 10 and 100 
ng/ml of CXCL12 for 24 hours prior to reaching expected confluence according to 
section 2.2.5. RNA was extracted using the Genelute™ Mammalian Total RNA 
Miniprep Kit by the method described in 2.3.1. 500 ng of each RNA sample was 
reverse transcribed into cDNA according to 2.5.1. Expression levels of IL6, IL8, MMP2, 
MMP9 and VEGFA were quantified using YWFIAZ as the reference transcript.
The amount of CXCL12 expression was also determined in the presence and absence of 
CXCL12 in primary epithelial and stromal cells, which was repeated 3 times using 
endometrial tissue obtained from three different women. Cells were incubated with 0, 
10 and 100 ng/ml of CXCL12 for 24 hours according to the previously described 
methods and UBC was used as the reference transcript.
Individual 25 pi SYBR® Green real-time RT-PCR reactions were plated out in triplicate 
for each of the six genes and reference transcripts for RNA extracted from each cell 
type for each concentration of CXCL12. Negative controls and -RT controls were also 
included on each real-time RT-PCR plate. A typical plate set-up is shown in Figure 2.14.
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Figure 2.14: A typical plate set-up for a real-time RT-PCR experiment 
Each well contains cDNA prepared from mRNA extracted from one particular cell type 
after incubation with CXCL12 at 0, 10 and 100 ng/ml. Primers for the gene of interest 
were added to red wells, while primers for reference gene were added to the black 
wells. Negative controls for both the gene of interest and HK gene in which no cDNA 
was added to the reaction are shown in light and dark green. -RT controls (dark and 
light purple) for both the HK gene and gene of interest in which no reverse 
transcriptase was added to cDNA synthesis reactions are shown in purple. Unused 
wells are shown in grey.
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2.7 Measuring expression of CXCR4 in endometrial cell cultures using 
Taqman® real-time RT-PCR
Amounts of CXCR4 mRNA in epithelial and stromal primary cell cultures and Ishikawa 
and HEC-l-B cells incubated in the presence (10 and 100 ng/m) and absence of CXCL12 
were measured using Taqman® real-time RT-PCR. Experiments in epithelial and 
stromal cells were repeated on six different occasions, while those in HEC-l-B and 
Ishikawa cells were repeated three times.
For each sample, 500 ng of total RNA extract was reverse transcribed according to 
2.5.1. Taqman® assay probes for CXCR4 (assay: Hs00237052_ml) and YWHAZ (assay: 
Hs00237047_ml) along with Taqman® Fast Universal Master Mix were obtained from 
Applied Biosystems, UK. A ROX™ passive reference dye allowed normalisation of 
individual reactions on a MicroAmp® Fast Optical 96-well Reaction Plate (Applied 
Biosystems, UK), lp l of cDNA reverse transcribed from RNA extracted from a given cell 
type was added to wells in triplicate on the reaction plate for both CXCR4 and YWHAZ.
Two separate master mixes for CXCR4 and YWHAZ were prepared for the number of 
individual reactions required, plus one to account for potential pipetting error and 
sample evaporation. An individual reaction contained 5 pi of Taqman® Fast Universal 
Master Mix, 0.5 pi of either the CXCR4 or YWHAZ Taqman® assay probes and 3.5 pi of 
nuclease-free water. 9 pi of the appropriate master mix was pipetted into each 
reaction well of the reaction plate. The total volume of an individual reaction was 10 
pi. Negative controls containing nuclease-free water instead of cDNA and -RT controls 
were also prepared for each sample type. Plates were set up in a manner similar to 
that shown in Figure 2.14. Plates were sealed with MicroAmp™ Optical Adhesive Film 
(Applied Biosystems, UK) and placed in the Applied Biosystems StepOnePlus real-time 
PCR System and subjected to the thermal protocol shown in Figure 2.15. An overview 
of TaqMan® chemistry is shown in figure 2.16.
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Figure 2.15: Thermal protocol used for TaqMan® real-time RT-PCR 
The diagram shows the thermal protocol used for TaqMan® real-time RT-PCR gene 
expression analysis. After the initial holding step, target cDNA was amplified by 
application of 40 cycles at the stated temperatures and times. The Applied Biosystems 
StepOnePlus real-time PCR System collected data in the second step of the cycling 
stage to obtain Ct values.
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Figure 2.16: Overview of TaqMan® Gene Expression Assay chemistry
The diagram shows the unique steps involved in a TaqMan" Real-Time PCR reaction.
Adapted from Applied Biosystems TaqMan* Gene Expression Assay protocol
(www.appliedbiosystems.com).
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2.8 Measuring levels of CXCL12 and CXCR4 mRNA in endometrial 
biopsies obtained throughout the menstrual cycle
2.8.1 Taqman® real-time RT-PCR to investigate expression of CXCR4
RNA extracted from thirty one endometrial tissue samples obtained throughout the 
menstrual cycle using TR1 REAGENT™ as described in section 2.3.2 was reverse 
transcribed to cDNA according to the method described in section 2.5.1. CXCR4 
expression was quantified in each cDNA sample using the method described in section 
2.7 using YWHAZ as the reference transcript. The layout for a typical real-time RT-PCR 
plate is shown in Figure 2.17.
2.8.2 SYBR® Green real-time RT-PCR to investigate expression of CXCL12
RNA extracted from thirty one endometrial tissue samples obtained throughout the 
menstrual cycle using TRI REAGENT™ as described in section 2.3.2 was reverse 
transcribed to cDNA according to the method described in section 2.5.1. CXCL12 
expression was quantified in each cDNA sample using the method described in section 
2.5.4 using UBC as the reference transcript. A typical real-time RT-PCR plate set-up for 
these experiments is shown in Figure 2.17.
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Figure 2.17: Typical plate set-up fo r real-time RT-PCR experiments 
investigating the expression o f CXCR4 and CXCL12 throughout the menstrual 
cycle
cDNA from mRNA extracted from eight individual tissue samples can be analysed in 
triplicate on an individual plate. Wells occupying the gene of interest are shown in red. 
Wells occupying the reference gene are shown in black. Corresponding negative 
controls and -RT controls for both the gene of interest (dark green and dark purple) 
and the reference gene (light green and light purple) could also be accommodated. 
Unused wells are shown in grey.
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2.8.3 Calculating real-time RT-PCR gene transcript expression levels
Expression of CXCL12, CXCR4, IL6, IL8, MMP2, MMP9 and VEGFA mRNA in Ishikawa, 
HEC-l-B, primary epithelial and stromal endometrial cells were calculated using the 
2'(ACt) method relative to the reference transcript. Levels of CXCL2 and CXCR4 mRNA 
expression from endometrial samples obtained throughout the menstrual cycle were 
calculated in the same way.
The effects of CXCL12 on the expression of each gene of interest were calculated using 
the 2*(AACt) method relative to the reference transcript and further normalised relative 
to control samples to which no CXCL12 had been added (Livak and Schmittegen, 2001).
2.9 DNA Microarrays
DNA microarrays consist of a solid surface, usually a glass microscope slide onto which 
DNA molecules have been chemically bonded. The purpose of a DNA microarray is to 
detect the presence and quantity of labelled nucleic acids from a biological sample that 
bind to the DNA molecules on the array by Watson and Crick duplex formation (Stekel, 
2003). Developments in the production of microarray slides have a provided a means 
to quantify tens of thousands of genes in a single assay including low copy number 
gene transcripts and highly similar sequences including single nucleotide 
polymorphisms (SNPs) and RNA splice variants. Gene expression profiling is one of the 
most widespread uses of microarray analysis and has been applied to investigation of 
gene functions, classification of clinical samples, pathways analysis and drug evaluation 
(DeRisi etal., 1997; Schena eto i, 1995).
The volume of quantitative data produced by microarray analysis is both its major 
advantage and its most significant challenge and relies on the use of Bioinformatics 
which incorporates information technology, mathematics and statistical analysis to 
allow handling and subsequent interpretation of the data it produces (Bilban et al, 
2002 and Stekel, 2003).
2.9.1 Microarray production
The first DNA microarrays were made by amplifying DNA from a clone library using 
highly parallel PCR to create the reporter probes for the array. The probes are spotted
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onto a chemically modified glass surface using a robot after addition of an amine group 
to the 5' end of the reporter probe to allow attachment to chemical linkers on the 
glass surface (Stekel, 2003).
In 2001, Hughes et al. reported a method to produce DNA microarrays using 
oligonucleotide reporters synthesised in-situ directly onto the glass slide by using a 
modified inkjet printer in which the four colours used by the printer were replaced by 
the four bases of DNA (adenine, thymine, cytosine and guanine). Reporter probes 
were built up base by base by formation of a hydroxyl group from a protective group 
on the 5' end of the lengthening reporter probe. The 3' end of the next nucleotide was 
covalently bonded to the previous nucleotide following chemical deprotection (using 
acid or light). The function of the protective groups was to prevent the addition of an 
incorrect nucleotide to the reporter probe (Hughes et al, 2001 and Stekel 2003).
Perhaps the greatest advantage of this technology was that reporter probe synthesis 
was completely computer controlled allowing the user to define the sequences of the 
oligonucleotides at the time of synthesis with a computer file created from publically 
available sequence data published by GenBank and EMBL. This allowed the production 
of custom arrays to fit the needs required by any user and a simple point of reference 
for subsequent data interpretation. Also, inkjet arrays produced the highest quality 
features (a spot of reporter probes on the array for one specific gene) and allowed 
reproducible detection of single copy number genes and RNA splice variants. The most 
recent commercially available arrays have employed this method to produce 
numerous copies of the entire expressed human genome on a single microscope slide 
(Hughes et al, 2001 and Stekel, 2003).
2.9.1.1 Microarray probe design
Commercially or custom produced DNA microarrays must have oligonucleotide
reporter probes which are considered to be sensitive, specific and isothermal to
accurately measure the target genes in the mRNA extracted from a biological sample.
Microarray probes are usually between 20 and 60 oligonucleotides long. A sensitive
probe returns a strong signal when the complementary gene target is present in the
sample. Sensitivity is achieved by avoiding probes which have internal secondary
structure or that bind to adjacent identical probes within an array feature. Also, a
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sensitive probe must be able to access its complementary target sequence which 
potentially could be unavailable as a result of secondary structure present within that 
sequence.
A specific probe returns a weak signal when the target gene is absent from the sample 
by avoiding cross-hybridisation and non-specific binding as a result of Watson-Crick 
base pairing. Isothermal probes behave in a similar manner during the hybridisation of 
the target to the reporter probes. This means all probe-target duplexes on the array 
must have similar melting temperatures. Computer algorithms are employed to 
produce suitable probes for the microarray to filter out low complexity repeating 
sequences, predict potential cross-hybridisation to related genes, ensure comparable 
melting temperature of nucleic acid duplexes and eliminate probe secondary structure 
that may potentially self-hybridise (Stekel, 2003 and Sugimoto et al., 1995).
2.9.1.2 Microarray sample preparation and labeling for gene expression 
microarrays
The type of DNA microarray platform to be used determines the procedure for sample 
preparation and the labeling of mRNA extracted from the biological samples. The aim 
of performing a gene expression microarray experiment is to measure the differences 
in mRNA production between two or more biological samples. In all cases the first 
step is to perform RNA extraction from the tissues samples to be analysed. It is 
important that the RNA to be used is of good integrity to facilitate effective 
hybridisation and that it can be accurately quantified to ensure equal amounts of 
sample are used in the analysis. To measure the presence and quantities of the 
extracted mRNA present in the samples they must undergo a labeling step to allow 
detection by the microarray scanner once hybridisation to the array has taken place 
(Stekel, 2003).
For Affymetrix® microarray platforms the labeling step uses Biotin labeled cRNA. Both 
the control and experimental samples undergo labeling with biotin and are hybridised 
to separate identical microarray slides. Following slide scanning and data extraction, 
the ratios of labeled cRNA in each sample for each gene represented on the array are
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calculated to quantify differences in expression between the experimental and control 
samples.
The Agilent™ microarray platform uses a single array slide to which both the control 
and experimental samples are combined and simultaneously hybridised to the array. 
To discriminate between the two samples, RNA is reverse-transcribed to cDNA using 
reverse transcriptase and then employs a T7 RNA polymerase to produce cRNA. It is 
during this step of cRNA production that labeling takes place. In addition to the nucleic 
acids (NTPs) added to the cRNA reaction, a proportion of the CTPs added are 
covalently labeled with one of two fluorescent dyes. The two most commonly used 
fluorescent dyes are Cyanine 3 (Cy3) which is excited by a green laser at 550 nm and 
has an emission wavelength of 581 nm and Cyanine 5 (Cy5) which is excited by a red 
laser at 649 nm and has an emission wavelength of 670 nm. One dye is used to label 
cRNA from the control sample and the other to label cRNA from the experimental 
sample. Following cRNA synthesis, a proportion of the 'C's in the cRNA products have 
Cyanine fluorophores attached to them. Following microarray slide scanning and data 
extraction, the ratio of hybridisation of the Cy3 and Cy5 labeled cRNAs that have 
bound to the reporter probes within an array feature can be calculated. Figure 2.18 
summarises the sample preparation and labelling steps used to perform two-colour 
gene expression microarray analysis.
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Figure 2.18: Summary of the sample preparation and labeling steps required 
to perform two-colour gene expression microarray analysis 
This diagram shows the steps involved in performing Agilent™ two-colour gene 
expression microarray analysis (Adapted from the Agilent™ Two-Colour Microarray- 
Based Gene Expression Analysis Protocol Version 6.0, 2009. www.agilent.com).
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2.9.1.3 Microarray hybridisation
Hybridisation is the process by which the DNA reporter probes on the glass microarray 
slide form heteroduplexes with the labeled cRNA from the biological samples by 
Watson-Crick base-pairing. Hybridisation is affected by a number of conditions 
including temperature, humidity, salt concentrations and formamide concentration. 
Manual hybridisation uses a hybridisation chamber. A glass cover slide with a fixed 
gasket has the hybridisation solution containing the combined and labeled cRNA 
samples injected onto its surface. The array slide is placed onto the cover slide and 
sealed within the chamber. The chamber is placed into a rotating hybridisation oven 
which maintains the correct temperature for hybridisation to take place and mixes the 
sample to distribute it evenly over the microarray surface. Hybridisations are typically 
performed between 45 and 65°C for a period between 12 to 24 hours (Agilent™ Two- 
Colour Microarray-Based Gene Expression Analysis Protocol, Version 6.0, 2009 and 
Stekel, 2003).
2.9.1.4 Microarray washing
There are two reasons to perform microarray washing after hybridisation has taken 
place. The first is to remove excess hybridisation solution from the array ensuring only 
specifically bound labeled cRNA remains on the microarray surface. The second is to 
increase the accuracy of the analysis by reducing cross-hybridisation. This can be 
achieved using a high temperature or low-salt wash to ensure only cRNA 
complementary to the reporter probe features remains bound to the array (Stekel, 
2003).
2.9.1.5 Microarray image acquisition
The final laboratory step of performing two-colour microarray expression analysis is to 
produce an image of the hybridised array. The microarray slide is placed in a scanner 
which contains two lasers which can read the surface of the array by exciting the 
Cyanine labeled cRNAs causing fluorescence which is recorded by a photon multiplier 
tube (PMT) to produce a digital image. As the lasers shift across the array a pixilated 
digital image is produced. The intensity of each pixel produced represents the 
intensity of fluorescence at that point of the array from the labeled cRNA that has
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hybridised to the reporter probes within each microarray feature. Whole genome 
arrays require a pixel resolution of 5 pm. Each laser scans the slide separately and the 
scanner produces two monochrome images representing the fluorescence produced 
by the Cy3 and Cy5 dyes bound to the cRNA. These images are combined to produce a 
red-green false colour image. The intensity of each pixel on the array is stored as a 16- 
bit number which is used to calculate the intensity of Cy3 and Cy5 fluorescence on 
each feature of the microarray (Agilent™ Two-Colour Microarray-Based Gene 
Expression Analysis Protocol, Version 6.0 and Stekel, 2003). Figure 2.19 summarises 
how a microarray scanner acquires an image.
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Figure 2.19: Summary o f how a microarray scanner works 
A microarray scanner uses two lasers that excite Cyanine dyes present in the 
heteroduplexes on the array at their appropriate wavelengths (Cy3 at 550 nm and Cy5 
at 649 nm). This causes emission of light for Cy3 at 581 nm and Cy5 at 670 nm which is 
focussed through an objective lens and beam splitter onto a detector lens which 
focuses the fluorescence through a pinhole to be recorded by a photon mu ltip lier tube 
(PMT) converting florescence into a digital signal. The whole slide is scanned either by 
movement of the slide or the optics within the scanner (adapted from Stekel, 2003).
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2.9.2 Two-colour microarray-based gene expression analysis 
experiments
All Reagents were obtained from Agilent™ Technologies, UK unless otherwise stated. 
Agilent™ Ge45 4x44k whole genome arrays were used. The Agilent™ Two-Colour 
Microarray-Based Gene Expression Analysis Protocol (Version 5.5) was followed. 
Experiments were carried out at Oxford Gene Technologies, UK.
2.9.2.1 Microarray sample preparation
Ishikawa cell lines were incubated with 0 and 5 ng/ml of CXCL12 according to the 
methods stated in section 2.2.5. Each experiment was repeated four times.
2.9.2.2 Preparation of positive control RNA Spike Mixes A and B
Stock solutions of RNA spike mix A for cyanine 3 and spike B mix for cyanine 5 were 
mixed thoroughly on a vortex mixer and briefly centrifuged to drive contents to the 
bottom of the tube. A 1:20 dilution of both stock solutions was carried out in 1.5 ml 
tubes labeled A and B. 38pl of provided dilution buffer was added to each tube. 2 pi of 
each concentrated spike mix was added to their respective tubes (A and B), were 
mixed well and spun in a micro-centrifuge.
A further 1:40 dilution of each spike was carried out by adding 2 pi of each 1:20 diluted 
spike solution to 78 pi of dilution buffer in a fresh tube.
2.9.2.3 Preparing the labeling reaction
5000ng of RNA extracted from cells incubated with (experimental) and without 
(control) CXCL12 were added to labeled micro-centrifuge tubes. 2 pi of 1:40 diluted 
spike mix A was added to each of the four experimental RNA tubes and 2 pi of spike B 
was added to each of the four controls. 1.2 pi of T7 Promoter Primer from the 
Agilent™ Low RNA Input Linear Amplification Kit was added to all eight sample tubes. 
0.3 pi of water was added to bring the volume of all tubes to 11.5 pi. The T7 primer 
and RNA template was denatured by incubating the samples at 65°C in a heating block 
for 10 minutes. The samples were placed on ice.
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A cDNA master mix was prepared by adding the components listed in Table 2.5 in 
order. The 5X first strand buffer was heated at 80°C for 3 minutes to adequately re­
suspend the buffer components. 8.5 pi of cDNA master mix was added to each RNA 
sample tube and gently mixed by repeat pipetting. The samples were then incubated 
at 40°C for 2 hours. This was followed by further incubation at 65°C for 15 minutes 
and storage on ice.
An RNA transcription master mix was prepared by adding the components listed in 
Table 2.6 in order. The transcription master mix requires addition of Cyanine 3-CTP or 
Cyanine 5-CTP fluorescent label. Experimental samples were labeled with Cyanine 3- 
CTP and control samples with Cyanine 5-CTP. 60 pi of transcription master mix was 
pipette into each sample tube and mixed gently. The samples were incubated for 2 
hours at 40°C.
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Component Volume (pi) per reaction Volume (pi) per 9 
reactions
5X First Strand Buffer 4 36
0.1 M DTT 2 18
lOmM dNTP mix 1 9
MMLV-RT 1 9
RNaseOut 0.5 4.5
Total Volume 8.5 76.5
Table 2.5: Components of the cDNA synthesis reaction performed using the 
Agilent™ Low RNA Input Linear Amplification Kit
The supplied kit reagents were prepared as shown above to perform reverse 
transcription of RNA to cDNA.
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Component Volume (pi) per reaction Volume (pi) per 5 
reactions
Nuclease-free water 15.3 76.5
4X Transcription Buffer 20 100
0.1 M DTT 6 30
NTP mix 8 40
50% PEG 6.4 32
RNaseOut 0.5 2.5
Inorganic pyrophosphatase 0.6 3
T7 RNA Polymerase 0.8 4
Cyanine 3-CTP or Cyanine 5-CTP 2.4 12
Total Volume 60 300
Table 2.6: Components of the cDNA synthesis reaction performed using the 
Agilent Low RNA Input Linear Amplification Kit
The supplied kit reagents were prepared as shown above to perform synthesis of cRNA 
from cDNA and to allow labeling of cRNA with the appropriate Cyanine 3 or Cyanine 5 
fluorescent dyes.
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2.9.2.4 Purifying the labeled/amplified RNA samples
RNeasy spin columns (Qiagen, UK) were used to purify the amplified cRNA samples. 20 
pi of nuclease free water was added to each cRNA sample to make a final volume of 
100 pi per sample. 350 pi of provided RLT buffer was added to each sample and mixed 
by pipetting. 250 pi of ethanol was added to each sample tube and mixed by pipetting. 
The resulting 700 pi samples were then transferred to individual RNeasy mini-columns 
which were placed into 2 ml collection tubes. The tubes were centrifuged in a mini­
centrifuge at 16, 000 x g and 4°C for 30 seconds.
Each cRNA bound column was transferred to a new collection tube and 500 pi of 
ethanol-containing RPE buffer was added to each column. Samples were centrifuged 
again for 30 seconds at 16, 000 x g and 4°C. The resulting flow through was discarded 
from the collection tubes and the tubes reused to perform a repeated second wash 
using 500 pi of RPE buffer and centrifugation for 30 seconds. Cleaned cRNA samples 
were eluted from the columns by transferring columns to fresh collection tubes and 
adding 30pl of nuclease free water directly to the column membrane. After 60 
seconds the samples were centrifuged for 30 seconds at 16,000 x g and 4°C. The 
resulting cRNA sample flow-through from each column was stored on ice.
2.9.2.5 Quantifying the purified cRNA samples
Samples were quantified using the NanoDrop ND-1000 UV-VIS Spectrophotometer 
described in section 2.3.1. After starting the NanoDrop software and selecting the 
microarray measurement tab, the instrument was initialised by adding 1 pi of 
nuclease-free water to the sample loading area and clicking OK. RNA-40 was selected 
as the sample type using the drop down menu. After blanking the instrument with 
nuclease-free water, each sample was measured for labeled cyanine 3-CTP (Cy3) or 
cyanine 5-CTP (Cy5) dye concentration (pmol/pl), RNA absorbance ratio and cRNA 
concentration.
The yield and specific activity of each reaction was determined by:
[concentration of cRNA in ng/pl) X 30 pi (elution volume ofcRNA sample)
/  1000 = pg of cRNA
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{Concentration ofCy3 or Cy5 in pmol/pl) /  (concentration ofcRNA in ng/pf) X 1000
= pmol of Cy3 or Cy5 per pg of cRNA
After ensuring a yield of greater than 825 ng and a specific activity of greater than 8.0 
pmol for each Cy 3 or Cy5 cRNA sample, the samples were prepared for hybridisation.
2.9.2.6 Hybridisation of samples to Agilent™ Ge45 4x44k whole genome 
arrays
10X blocking agent was prepared by adding 500 pi of nuclease-free water to 
lyophilised 10X blocking agent provided with the Agilent™ Gene Expression 
Hybridisation Kit. To ensure the pellet completely entered solution, the solution was 
mixed gently and heated at 37°C for 5 minutes. This was followed by brief 
centrifugation.
The fragmentation mix was prepared by combining 825 ng of each Cyanine labeled 
cRNA sample from each corresponding experimental and control sample to create 4 
tubes containing combined experimental and control RNA samples n 1 to 4. 11 pi of 
10X blocking agent was added to each of the 4 tubes and made up to a volume of 52.8 
pi using nuclease-free water. Finally, 2.2 pi of 25X fragmentation buffer was added to 
each sample mixed gently with a vortex mixer and incubated at 60°C for exactly 30 
minutes to facilitate the fragmentation of the cRNA.
The fragmentation of cRNA was stopped by adding an equal volume (55 pi) of 2X GE 
hybridisation buffer HI-RPM to each combined cRNA sample. Mixing was carried out 
gently using repeat pipetting avoiding bubble formation, which may lead to poor 
hybridisation to the array surface. To further aid bubble reduction, samples were 
centrifuged at 16,000 x g for 1 minute in a micro-centrifuge.
A gasket slide was placed face up into an assembled SureHyb microarray hybridisation 
chamber and the total 500 pi of each sample (n 1-4) was dispensed into 4 separately 
sealed gasket chambers in a drag and dispense manner with care to avoid bubble 
formation. A Ge45 4x44k array slide was placed with its active side down onto the 
gasket slide containing the samples. The array was sealed to the gasket slide by closing 
and tightening the hybridisation chamber. After ensuring there were no stationary
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bubbles, the hybridisation chamber containing the sandwiched array was placed into a 
rotating hybridisation oven (Agilent™, UK) at 10 rpm for 15 hours.
2.9.2.7 Microarray wash
Array slides were washed in Gene Expression wash buffers 1 and 2 provided with the 
kit. Gene expression wash buffer 2 was warmed overnight at 37°C prior to the day of 
use. Clean (washed five times with sterile distilled water) and designated slide 
chambers were used for holding the washing buffers. Slide dish 1 was completely 
filled with room gene expression wash buffer 1 at room temperature. The 
hybridisation chamber containing the hybridised array was removed from the 
hybridisation oven. The chamber was disassembled and the gasket/array sandwich 
removed. The sandwiched slides were separated under submersion in slide dish 1 
containing wash buffer 1. The array was carefully removed to a slide tray and placed in 
previously prepared wash buffer 1 contained in slide dish 2. This wash buffer in slide 
dish two was stirred for 1 minute using a magnetic stirrer and the slide tray containing 
the hybridised array was transferred to a third slide dish containing wash buffer 2 at 
37°C. The wash buffer was stirred on a magnetic stirring plate for 1 minute. The slide 
tray was slowly removed from wash buffer 2 to minimise droplet formation on the 
slide surface. The slide was immediately placed in an Agilent™ Technologies Scanner 
G2505B to minimise impact of environmental oxidants on signal intensity.
2.9.2.8 Microarray scanning and feature extraction
Microarray slide scanning was carried out using an Agilent Technologies Scanner 
G2505B in conjunction with Agilent™ Feature Extraction Software (v9.5). A photon 
multiplier tube (PMT) gain of 10 at a resolution of 5 microns was used to scan the 
microarray slide and obtain an image. Figure 2.20 shows the design of the Agilent™ 
Ge45 4x44k slide. Once an image was obtained the appropriate feature extraction grid 
for the array design (Agilent™ Grid 014850_D) was imported into the feature 
extraction software to facilitate spot finding and data extraction. The appropriate 
feature extraction protocol (GE2-v5_95) for the Ge45 4x44k microarray slide design 
was used to obtain, normalise and statistically analyse the image. Table 2.7 
summarises the feature extraction protocol used.
131
- J , * *| l3T , «H3*
t t t t  i i t i
Cr Q0 — 0
1, 84
st ) ^  lea
< > < -. 3 » - ( J54 P —' f  ?S5
f 85 V -STY 1*
) <W>1 IjC *.
f- ! - ^ © V v v ^  H
^ ( 1 *  )W (  137 —
T T1 1  TTIT
Feature Row, and Column numbering in DNABacX, BaroodeLeft orientation for the Agilent 4 X 45,220 feature 
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Figure 2.20; Design of the Agilent™ Ge45 4x44K microarray slide 
The diagram above shows the layout of the human whole genome expression array 
slide. Each array slide contains probes (features) for the entire expressed human 
genome as well as positive control probes which bind the RNA spike-ins, negative 
control probes and dark corner probes. The positive and negative control probes are 
used to normalise the array data while multiple copies of features for some genes are 
distributed across the array to aid spatial distribution normalisation. Full probe 
information for the GE45x44K slide is published for reference at www.agient.com 
(image: www.agilent .com).
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Protocol Step Parameter Default Setting Value iv 9 5)
Place Grid Array Format For arty format automatically
determined or selected by you the 
software uses the default 
Placement Method listed below.
Automatically Determine 
[Recognized formats: Single 
Density f 1 lk_ 22k). 25k Oouhle 
Density |44k). 95k. 185k |5 and 10 
u). 244k (5 and 10 u) and Third 
Party]
Placement Method The parameters and values for
placing the gnd differ depending on 
the format but you can’ t  see the 
differences because the values are 
hrdden.
Allow Some D istorter
Find Spots Spot Format Depending on the format selected 
by the software or by you. the 
default settings for this step 
change See the rows below for the 
default values for finding spats
Automatically Determine 
[Recognized formats: same as 
those listed above]
Use the Nomina! Diameter from the 
Grid Template
Spot Deviation Limit
Calculation of Spot Statistics 
Method
Cookie Percentage
Exclusion Zone Percentage
True (All Formats!
1 50 iAII Formats!
Use Cookie lAli Formats!
0 550 (Single Density 25k|
0 561 Double Density. 96k.) 
Q 700085k 244k)
1 200 {AH Formats)
Auto Estimate the Local Radius True lAH except 185.244j 
False . ‘ 95- 2441c)
LocalBGRadtus 
P;xel Outlier Reaction Method
RejectlQRFeat
ReiectlQRBG
Statistical Method for Spot Values from Pixels
100 -when False for 185k 244k:
Inter Quartile Region 
(Automatically Determine and All 
Formats)
1 42 (All Formats)
1 42 (Ail Formats)
Use Me an/Standard Deviation 
I Automatically Determine a->d All 
Formats)
Flag Outliers Compute Population Outliers True
Minimum Population 10
IQRatto 142
Backgr ound IQRatio 1.42
Use thest for Small Populations? True
Compute *Jon Uniform Outliers True
Scanner The values for the parameters
change depending on the scanner 
used for the image See below for 
differences
Automatically Determine
Agilent scanner
Automatically Compute 01 Polynomial Terms True
Feature -  |kC V r2 004
Red Poissonian Noise Term 
Multiplier
20
Red Signal Constant Term 1 
Multiplier
Green Poissonian Noise Term 
Multiplier
20
1 3 3
Protocol Stop PidmwOr Dolouh Sorting V*iu» ! v # 5)
Sown Sign*: Constant fe rn  t
Mui&ptwr
8 ac* ground -  |\CV»' 2 0 §8060
Red* Po tsorrc-an H o n #  Tr-T> 3
Mute piter
Red Bidigtauntl C on*to" fe rn  I
Mufepitw
Green Pa»sseni«ri No- at Terr- 3
Mu!1: pite.1
Gtetri Background Comunt rer- I
Mutepimf
Table 2.7: GE2-v5_95 feature extraction protocol
The table summarises the settings used to feature extract microarray data from the 
Ge45 4x44K array using the appropriate 014850_D feature extraction grid with the 
Agilent™ Feature Extraction Software (v9.5) (source: Agilent™ Feature Extraction 
Software v9.5 Reference Guide).
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2.9.2.9 Microarray data normalisation and statistical analysis
The Agilent™ Feature Extraction Software produced text files for each of the four array 
repeats. Each file contained the data acquired for each of the 45, 220 features within 
each experimental repeat. The data files included the raw signal data obtained for 
each feature on the array and data for the normalisation procedures carried out which 
used predefined complex algorithms employed by the Agilent™ Feature Extraction 
Software. These normalisation steps adjust the raw data to take into account 
systematic errors. This is followed by background fluorescence subtraction and then 
uses a LOWESS non-linear regression algorithm to correct for dye and laser bias. These 
procedures results in the production of processed signal data for each microarray 
feature, which is used to calculate the logi0 ratio between the Cy3 and Cy5 signals 
showing the observed changes in gene expression between the control and 
experimental samples. Microarray features which fall outside the software defined 
parameters necessary to produce accurately normalised data are highlighted using a 
flagging system. The Agilent™ Feature Extraction Software then attributes statistical 
significance to the normalised data by applying an algorithm based on a two-sided t 
test to produce P values for each microarray feature.
The text files produced were imported into Microsoft Excel to organise, search and 
check data validity to find genes of interest which showed statistically significant 
differential expression of mRNA in cells incubated with and without CXCL12.
135
Chapter 3 
Expression of CXCL12 and CXCR4 mRNA in 
human endometrium
3.1 Hypothesis
Human endometrium shows differential expression of CXCL12 and CXCR4 mRNA 
throughout the menstrual cycle and between endometrial cell types.
3.1.1 Expression of CXCL12 in human endometrium
Little is currently known about the expression of CXCL12 in human endometrial cells 
though its expression has been identified in monkey and bovine endometrium (Ace 
and Okulicz, 2004 and Mansouri-Attia et al., 2009). Expression of CXCL12 throughout 
the menstrual cycle of non-pregnant human endometrium has not previously been 
demonstrated, though CXCL12 has previously been detected by immunohistochemistry 
during the proliferative phase of the menstrual cycle (Kitaya et al., 2004). Expression 
of CXCL12 in human decidual cells has also been previously demonstrated and CXCL12 
has also shown to be expressed by human placenta and invading trophoblast (Hanna et 
al., 2003).
3.1.2 Expression of CXCR4 in human endometrium
Expression of CXCR4 mRNA throughout the human menstrual cycle has previously 
been investigated by Dominguez et al. (2003) who identified a trend of decreasing 
expression of CXCR4 mRNA during the proliferative phase of the cycle and a significant 
increase in expression during the mid secretory phase when implantation occurs. 
CXCR4 is also expressed by human trophoblast and placenta (Hanna et al., 2003). 
CD56+ uNK cells express CXCR4 and have been shown to respond via chemotaxis to 
trophoblast supernatant containing CXCL12 and also recombinant CXCL12 (Wu et al., 
2005).
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3.1.3 The function of CXCL12 and CXCR4 in human endometrium
The available evidence suggests an important role for the chemokine ligand CXCL12 
and its receptor CXCR4 in human female reproductive function, which may involve the 
trafficking of uNK cells to decidualising endometrium and sites of trophoblast invasion 
during the initiation of placentation (Hanna et al., 2003; Wu et al., 2005 and Zhou et 
al., 2008). Furthermore, the significant increase observed in CXCR4 mRNA expression 
by endometrial tissue during the mid secretory phase of the menstrual cycle implicates 
a role for CXCL12 and CXCR4 in the initial stages of implantation (Dominguez et al., 
2003). This is further supported by an in vitro model of apposition which showed 
increased levels of CXCR4 immunohistochemical staining in endometrial cells in the 
presence of blastocyst, which was found to express CXCL12 protein but not its receptor 
CXCR4 (Valles and Dominguez, 2006). Unpublished data from our laboratory has 
shown expression of CXCL12 at the protein level throughout the menstrual cycle and 
has found to be predominantly located to the glandular and luminal epithelium (Figure 
3.1).
There remains a lack in knowledge regarding the expression and function of CXCL12 
and CXCR4 throughout the human non-pregnant menstrual cycle and within specific 
endometrial cell types. No study to date has investigated fully the expression of 
CXCL12 throughout the human menstrual cycle. The distribution of CXCL12 and CXCR4 
between different endometrial cell types also remains unknown. The differential 
expression of CXCL12 and CXCR4 throughout the menstrual cycle and between 
different endometrial cells types could provide further evidence of how the chemokine 
ligand and receptor carry out their functions in endometrium. The current evidence 
potentially indicates roles for CXCL12 and CXCR4 in uNK cell recruitment and cross-talk 
between the endometrial surface and the blastocyst during the implantation window. 
However, chemokine ligand and receptors, including CXCL12 and CXCR4 have the 
potential to carry out a wide range of cellular functions such as contributing to cell 
proliferation and differentiation (Busillo and Benovic, 2006). These additional 
potential functions may be of particular relevance in endometrium, which undergoes 
dynamic cycles of growth and differentiation during the menstrual cycle.
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Figure 3.1: Detection of CXCL12 in human endometrium using
immunohistochemistry (Unpublished laboratory data courtesy of Mariam  El- 
Sheiki)
Detection of CXCL12 in the human endometrium, CXCL12 staining appears to be 
predom inantly confined to the luminal and glandular epithelium.
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3.1.4 Aims
To test our hypothesis, that CXCL12 and CXCR4 mRNA may be differentially expressed 
at key stages of the menstrual cycle in the human endometrium, we aim to quantify 
levels of CXCL12 and CXCR4 mRNA in endometrial biopsies obtained throughout the 
menstrual cycle. This would allow identification of potentially important differences at 
key stages of the menstrual cycle, which may be of functional importance.
To test our hypothesis that different endometrial cell types may potentially express 
different levels of CXCL12 and CXCR4 between specific endometrial cell types, we aim 
to quantify expression levels of CXCL12 and CXCR4 in primary cultures of epithelial and 
stromal endometrial cells.
It was also our aim to quantify expression levels of CXCL12 and CXCR4 in the Ishikawa 
and HEC-l-B cell lines to allow their suitability to act as a model in comparison to their 
epithelial counterparts to be assessed.
To achieve our aims, real-time RT-PCR will be used to accurately measure mRNA 
expression levels of CXCL12 and CXCR4 in tissue obtained from healthy volunteers 
throughout the menstrual cycle from which, either levels of CXCL12 and CXCR4 were 
directly quantified or the tissue was used to prepare pure epithelial and stromal cell 
cultures.
3.2 Methods
Endometrial biopsies were obtained from normal fertile women [n=31) at different 
times in the menstrual cycle attending the Jessop Hospital for Women in Sheffield. All 
samples were obtained with informed consent as described in section 2.1.
RNA was extracted from the samples and quantified as described in sections 2.3.2 and 
2.4.1. Expression of CXCL12 mRNA was quantified using SYBR® Green real-time RT-PCR 
and using UBC as the reference transcript as described in section 2.8.2. Levels of 
CXCR4 mRNA expression were quantified using TaqMan® real-time RT-PCR and using 
YWHAZ as the reference transcript as described in section 2.8.1. Different types of 
real-time RT-PCR assays were used with different reference transcripts as they
139
provided the most accurate means available for quantifying each individual mRNA 
transcript.
The biopsies were dated according to the day of the last menstrual period followed by 
confirmation of sample date by histological staging and divided into early proliferative 
(days 1-9), late proliferative (days 10-14), early secretory (days 15-18), mid secretory 
(days 19-23) and late secretory (days 24-28) phases of the cycle. Grouping samples 
into these menstrual phases allowed direct comparision of results to studies such as 
that by Dominguez et a i, (2003). A Kruskall-Wallis test was used to determine 
statistical differences in expression of CXCL12 and CXCR4 mRNA at different times in 
the cycle.
Primary epithelial and stromal endometrial cells were prepared according to section 
2.2.4 and grown to near confluence. Primary cultures used for investigating CXCR4 
expression were prepared from six different women and CXCL12 expression was 
investigated from cultures prepared from three different women. Experiments in cell 
lines were repeated on three separate occasions. Following RNA extraction and 
reverse transcription (according to sections 2.3.1 and 2.5.1) levels of CXCL12 mRNA 
were quantified using SYBR® Green Real-Time RT-PCR using reference transcript 
YWHAZ. Levels of CXCR4 mRNA were quantified using Taqman® real-time RT-PCR with 
reference transcript YWHAZ. Mean expression levels were calculated using the 2‘(ACt) 
method. A Mann-Whitney U test was used to assess levels of statistical significance.
3.3 Results
3.3.1 Expression of CXCL12 mRNA in endometrium obtained throughout 
the menstrual cycle
CXCL12 mRNA was detected in 28 out of the 31 mRNA samples obtained (Figure 3.2). 
The observed values ranged from 0.0037 to 0.15 relative to the UBC reference gene 
(expression = 1). There appeared to be no differential expression in biopsies obtained 
at different times in the cycle.
The lack of a change during the cycle was confirmed by analysis of samples grouped 
according to the phases of the menstrual cycle (Figure 3.3). Mean expression values 
for CXCL12 mRNA were 0.0086 in endometrium from the early proliferative, 0.022
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during the late proliferative, 0.037 during the early secretory, 0.023 during the mid 
secretory and 0.04 during the late secretory phases of the cycle.
3.3.2 Expression of CXCR4 mRNA in endometrium obtained throughout 
the menstrual cycle
CXCR4 was detected in 30 of the 31 mRNA samples extracted from endometrial tissue, 
(Figure 3.4). The observed values ranged from 0.16 to 12.01 relative to YWHAZ 
(expressions). Median expression values for CXCR4 were 10.07 during the early 
proliferative, 2.58 during the late proliferative, 1.75 during the early secretory, 3.82 
during the mid secretory and 1.83 during the late secretory phases. From the 
individual biopsy data there appeared to be an increase in CXCR4 expression in 
endometrium obtained during the early proliferative phase of the cycle.
Application of a Kruskall-Wallis test to all groups representing phases of the menstrual 
cycle failed to show any significant difference between the data. However, significant 
differences between CXCR4 mRNA expression was observed when the early 
proliferative phase was compared individually with the other phases of the menstrual 
cycle using a Mann-Whitney U test. The expression level of CXCR4 mRNA was found to 
be significantly higher in endometrium obtained during the early proliferative phase of 
the menstrual cycle compared to the late proliferative (p=0.035), early secretory 
(p=0.022) and late secretory (p=0.026) phases. Expression of CXCR4 in endometrium 
from the early proliferative phase was not significantly different to endometrium 
obtained in the mid secretory phase of the cycle (p=0.067) (Figure 3.5).
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Figure 3.2 Relative expression of CXCL12 mRNA in individual biopsies obtained 
throughout the menstrual cycle
0.20-1
0.15-
+->u<
(N 0. 10-
0.05-
0.00
V
Figure 3.3 Relative expression of CXCL12 mRNA in endometrium obtained 
during the phases of the menstrual cycle
The points shown are from each individual volunteer samples plus the median. EP = 
early proliferative (days 1-9) (n=5), LP = late proliferative (days 10-14) (n=5), ES = early 
secretory (days 15-18) (n=7), MS = mid secretory (days 19-23) (n= 4), LS = late 
secretory (days 24-28) (n=7).
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Figure 3.4 Relative expression of CXCR4 mRNA in individual biopsies obtained 
throughout the menstrual cycle
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Figure 3.5 Relative expression of CXCR4 mRNA in endometrium obtained 
during the phases of the menstrual cycle
The points shown are from each individual volunteer samples plus the median. EP = 
early proliferative (days 1-9) (n=6), LP = late proliferative (days 10-14) (n=7), ES = early 
secretory (days 15-18) (n=7), MS = mid secretory (days 19-23) (n= 4) LS = late secretory 
(days 24-28) (n=6). * Significantly different to early proliferative phase at P<0.05.
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3.3.3 Expression of CXCL12 mRNA in endometrial cell cultures
Both primary epithelial and stromal endometrial cells expressed CXCL12 in vitro, but 
levels were low compared to the reference transcript Epithelial cell expression of 
CXCL12 was lower than stromal cell expression but these results were not significantly 
different from each other (Figure 3.6). Experiments attempting to measure expression 
of CXCL12 in Ishikawa cell lines (n=3) could not conclusively identify any level of 
expression that could be considered different to non-specific amplification observed in 
negative controls experiments (data not shown). Therefore, measurement of CXCL12 
mRNA expression in cell lines was not continued.
3.3.4 Expression of CXCR4 mRNA in endometrial cell cultures
CXCR4 was expressed by all cell types. CXCR4 mRNA expression was lowest in HEC-l-B 
cells, while median CXCR4 expression in Ishikawa cells was considerably higher. 
Primary epithelial endometrial had the highest levels of CXCR4 mRNA expression, 
which was higher than the reference transcript (expression = 1). Levels of epithelial 
CXCR4 mRNA expression was more than twice that seen in stromal cells but expression 
levels were not significantly different from each other (P=0.056). Expression of CXCR4 
in Ishikawa cells Ishikawa cells was comparable levels of CXCR4 expression to their 
primary epithelial counterparts, while expression in HEC-l-B cells was considerably 
lower than primary epithelial cells (Figure 3.7).
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Figure 3.6: Relative expression of CXCL12 mRNA in primary endometrial cells 
Median relative expression values: Epithelial = S .^ a n d  Stromal = 0.014. n=3 for 
epithelial and stromal cells.
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Figure 3.7: Relative expression of CXCR4 mRNA in primary endometrial cells 
Median relative expression values: Epithelial = 0.95 and Stromal = 0.28. n=6 for
epithelial and stromal cells.
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Figure 3.8: Relative expression of CXCR4 mRNA in Ishikawa and HEC-l-B cell 
lines
Median relative expression values: Ishikawa = 0.63, HEC-l-B =0.05. n=3 for Ishikawa 
and HEC-l-B cells.
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3.4 Discussion
It was our hypothesis that CXCL12 and CXCR4 may be differentially expressed in human 
endometrium both throughout the menstrual cycle and between different endometrial 
cell types present within the tissue. Identification of differential expression of CXCL12 
and CXCR4 throughout the menstrual cycle or between cell types within the 
endometrial tissue provides the basis of a possible mechanism by which CXCL12 and 
CXCR4 carries out their endometrial functions.
3.4.1 Expression of CXCL12 mRNA throughout the menstrual cycle
Few studies have investigated the expression of CXCL12 and CXCR4 in human 
endometrium through the human menstrual cycle. One immunohistochemical study 
of CXCL12 expression in the human endometrium detected the presence of CXCL12 
during the proliferative phase of the menstrual cycle but did not detect CXCL12 during 
other phases (Kitaya et al., 2004). A further study which investigated expression of 
CXCL12 and other chemokines in human endometrium through the menstrual cycle 
using gene arrays could not detect the presence CXCL12 mRNA during any phase of the 
menstrual cycle (Jones et al., 2004). In contrast this current study did show the 
expression of CXCL12 mRNA in the endometrium throughout the non-pregnant 
menstrual cycle which was comparatively low compared to the reference gene UBC. 
The levels of its expression did not appear to vary during the phases of the menstrual 
cycle. This suggests that the steroid hormones do not affect the expression of CXCL12 
as levels increase through the proliferative and secretory phases of the menstrual 
cycle. In contrast to this observation, a recent study has demonstrated that addition of 
estradiol to human endometrial stromal cell lines increased expression of CXCL12 in a 
time and dose-dependent manner, which could be blocked by addition of an estradiol 
antagonist (Tsutsumi et al., 2011).
3.4.2 Expression of CXCR4 mRNA throughout the menstrual cycle
A study by Dominguez et al. (2003) investigated the expression of CXCR4 mRNA 
through the phases of the menstrual cycle using SYBR® Green real-time RT-PCR. The 
study showed an apparent decrease in expression levels of CXCR4 mRNA through the 
proliferative phase of the menstrual cycle which was in agreement with this study.
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However, this study found the levels of CXCR4 mRNA to be significantly higher in the 
early proliferative phase of the menstrual cycle in comparison to the late proliferative, 
early and late secretory phases. Dominguez et al. (2003) showed levels of CXCR4 to 
peak significantly during the mid secretory phase in comparison to all other phases. 
The results displayed in Figure 3.5 show a slight increase in the levels of CXCR4 mRNA 
expression in the mid secretory endometrium in comparison to the early and late 
secretory phases, this difference was not found to be significantly higher than the ES 
and LS phases. It is possible that the presence of a blastocyst could cause an increase 
in MS CXCR4 levels.
Both our study and that of Dominguez et al. (2003) showed a decrease in CXCR4 levels 
through the menstrual cycle suggesting regulation by the steroid hormones. Ruiz et al. 
(2010) recently showed both estradiol and progesterone caused down-regulation of 
CXCR4 at the mRNA level in endometrial epithelial cell lines adding further support to 
this idea. Little is known about how and if steroid hormones regulate the expression of 
CXCR4 in the endometrium, though the recent evidence suggests it is likely to occur.
While both studies investigated CXCR4 expression in human endometrium from 
normal fertile patients using real-time RT-PCR, this study used a TaqMan probe to 
identify CXCR4 mRNA, while Dominguez et al. (2003) used SYBR® Green chemistry. 
The main difference between the current study and that of Dominguez et al. (2003) is 
that their study used tissues from 15 subjects while our group size was considerably 
larger.
3.4.3 Expression of CXCL12 and CXCR4 in endometrial cell cultures
The expression levels of CXLC12 transcripts were low in both primary epithelial and
stromal cells in comparison to the reference transcript which was also observed in the
results obtained from intact tissue from throughout the menstrual cycle. It was
surprising that stromal cells exhibited higher CXCL12 mRNA levels in comparison to
epithelial cells as unpublished data from our laboratory showed protein expression of
CXCL12 to be highest in the glandular and luminal epithelium. However, this result is
in agreement with that of Ruiz et al. (2010) and Tsutsumi et al. (2011) which found
endometrial stromal cell lines to express higher levels of CXCL12 in comparison to
epithelial derived cell lines. The study by Tsutsumi et al. (2011) also confirmed our
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observation that Ishikawa cell lines do not produce CXCL12 but are CXCR4 positive. 
Interestingly, addition of CXCL12 to Ishikawa cells induced proliferation leading to the 
suggestion that a function of stromal CXCL12 in the endometrium is to control 
epithelial cell growth.
3.4.4 Potential functions of CXCL12 and CXCR4 in endometrium
It is possible that CXCL12 expression in the endometrium functions to recruit 
leukocytes. The apparently increased expression of CXCL12 in endometrial stromal 
cells in comparison to epithelial cells supports this idea, as secretion of the chemokine 
ligand would occur close to blood vessels through which leukocytes such as uNK cells 
could infiltrate, expression CXCL12 in the epithelial glands is more likely to be secreted 
into intraluminal spaces on the innermost surface of the uterus to which the blastocyst 
attaches during implantation. CXCL12 could potentially have an alternate role at this 
interface. Although recruitment of leukocytes such as uNK cells to the endometrium 
by CXCL12 seems possible (Hanna et al., 2003; Wu et al., 2005), our study could not 
identify any differential expression of CXCL12 during the non-pregnant menstrual 
cycle. uNK cells appear in greatest numbers in the endometrium during the mid- 
secretory phase, if CXCL12 secretion was responsible for this it would be expected that 
an increase in CXCL12 mRNA production would have been observed close to this time.
Other studies such as that by Tsutsumi et al. (2011) have suggested that stromal 
CXCL12 may serve as a growth factor for epithelial cell proliferation thus accounting for 
increased CXCL12 levels. Conversely, Diagram 3.1 shows immunohistochemical 
localisation of CXCL12 to the endometrial epithelium and not stoma but it is possible 
that CXCL12 is receptor bound to epithelial cells following secretion from the stroma. 
It is also possible that post-translational regulation may affect the amount of CXCL12 
protein actually produced as increased levels of CXCL12 in endometrial stroma in 
comparison to epithelial cells has so far only been observed at the mRNA level.
CXCR4 has been shown to be maximally expressed in human endometrium during the
MS phase of the menstrual cycle and presence of CXCL12 positive blastocyst has been
shown to increase CXCR4 expression in endometrial cell culture models (Dominguez et
al., 2003). This suggests a role in mediating the cross-talk between the blastocyst and
endometrium during the initial stages of implantation. Our Larger study found
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maximal expression of CXCR4 during the early proliferative phase of the menstrual 
cycle when the endometrium begins to rapidly grow. Combined with evidence that 
CXCL12 can cause proliferation of epithelial endometrial cell lines (Tsutsumi et al., 
2011) it is possible that a major role for this chemokine and receptor is in the paracrine 
control of endometrial proliferation. This does not rule out a potential role in 
mediating the early stages of implantation as a slight increase in MS CXCR4 levels was 
observed by our study.
CXCL12 and CXCR4 are also known to be involved with the control of angiogenesis, 
stem cell migration and cell differentiation (Busillo and Benovic, 2006). All these 
processes are of great potential importance to the endomtrium. The maximal 
expression of CXCR4 during the early proliferative phase and the unchanging presence 
of CXCL12 throughout the menstrual cycle could also be consistent with these 
functions also.
3.4.5 Limitations
Direct measurement of CXCL12 and CXCR4 from biopsies obtained from human 
volunteers using real-time RT-PCR allows ex vivo quantification of chemokine and 
receptor levels which is useful for observing any potential changes throughout the 
menstrual cycle. The technique is most limited by its inability to distinguish in which 
cell types the factors are expressed. Endometrium consists of not only epithelial and 
stromal cells but also vascular cells and leukocytes which may contribute to the levels 
of mRNA expression observed. To overcome this to some degree, levels of CXCL12 and 
CXCR4 were quantified in primary epithelial and stromal cultures but this in itself does 
not fully account for all potential expression of CXCL12 and CXCR4 in the endomtrium.
Levels of variability of CXCL12 and CXCR4 between individual biopsy samples appeared
high. As each sample was from a different human volunteer it is likely that natural
variations between individuals could produce this effect. This is supported by use of
reference genes that were shown not to significantly vary between the phases of the
menstrual cycle into which our data was grouped (Figure ???). This highlights the
importance of using as many samples a possible to obtain robust averages for each
menstrual cycle phase, increasing the likelihood of significant differences between the
phases being observed if present. Degradation of mRNA during collection of the
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sample and its storage along with reverse transcription may also potentially account 
for some sample variability, although attempts to minimise this were made and 
samples were treated consistently.
The primary cell cultures were prepared from biopsies taken throughout the cycle. As 
CXCR4 was shown to be differentially expressed throughout the menstrual cycle it is 
possible that this may affect the levels of CXCR4 produced by the individual cultures. 
However as the samples were taken throughout that cycle, median values were likely 
to be a good representation of the amount of CXCL12 and CXCR4 present in terms of 
investigating the distribution between epithelial and stromal cells. Furthermore, the 
process of removing a sample and preparing it for cell culture is highly invasive, 
degrading extracellular matrix and potentially causing trauma to cells which become 
isolated from their normal environment and endocrine control. Therefore it is 
inherent in primary cell culture experiments such as these that expression levels of 
many factors may be different to the true in vivo levels and in particular relation to the 
endometrium, individual cultures may exhibit levels of CXCL12 and CXCR4 which do 
not directly relate to the stage of the menstrual cycle from which they are taken.
The cell culture conditions themselves may also affect the expression levels primary 
cultured cells. FCS was used to aid cell adhesion and supplement growth but contains 
many factors which could potentially interact with the cells in culture and alter gene 
expression. This culture model did not use steroid hormones which would normally be 
present to some degree in endometrial cell environments. Overcoming some of these 
limitations would potentially improve the accuracy of the experiments and reduce 
some of variability present in the data shown.
3.4.6 Summary
It was our hypothesis that CXCL12 and CXCR4 mRNA is differentially expressed during
the non-pregnant menstrual cycle and may differ between endometrial cell types.
Both CXCL12 and CXCR4 mRNA was found to be expressed throughout the menstrual
cycle but only CXCR4 mRNA was found to be differentially expressed, exhibiting
maximal levels during the early proliferative phase of the menstrual cycle. Stromal
endometrial cells expressed higher levels of CXCL12 than epithelial cells in culture,
while CXCR4 was higher in epithelial cells compared to the stromal. While CXCL12 may
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potentially recruit uNK cells to endometrium and epithelial CXCR4 expression may 
contribute to controlling implantation on the maternal side, our findings along with 
recent studies by Ruiz et al. (2010) and Tsutsumi et al. (2011) suggests stromally 
secreted CXCL12 could act as a growth factor for endometrial epithelial cells during the 
early stages of the menstrual cycle and may potentially also contribute to local 
angiogenesis, cell differentiation and stem cell migration.
Finally, Ishikawa cells were found to express high levels of CXCR4 but CXCL12 could not 
be detected. This was also recently confirmed by Tsutsumi et al. (2011). Therefore 
this cell line could be a particularly good endometrial model for studying the effects of 
exogenously added CXCL12 on an endometrial cell line.
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Chapter 4
Effects of CXCL12 on the expression of IL6, IL8, 
MMP2, MMP9 and VEGFA mRNA in cultured 
endometrial cells._________________________
4.1 Hypothesis
CXCL12 regulates expression of IL6, IL8, MMP2, MMP9 and VEGFA in endometrial cell 
types.
4.2 Effects of CXCL12 on IL6, IL8, MMP2, MMP9 and VEGFA in non- 
endometrial cell types
Effects of CXCL12 on endometrial cell function have not been reported. However, 
many studies have shown the ability of this chemokine ligand to up-regulate the 
expression of IL6, IL8, MMP2, MMP9 and VEGF in various other human cells.
CXCL12 has been shown to up-regulate IL6 production in human primary cultured 
microglia (Lu et al., 2009), basal cell carcinoma cell lines (Chu et al., 2008) and oral 
cancer cells (Tang etal., 2008). Both IL6 and IL8 (CXCL8) production has been shown to 
be increased by CXCL12 in PC3 prostate cancer cell lines (Wang et al., 2005) and 
fibroblast-like synoviocytes from patients with rheumatoid arthritis (Nanki et al., 
2001). IL8 production has been shown to be increased by CXCL12 in human retinal 
pigment epithelial cells (Crane et al., 2000), mast cells (Lin et al., 2000) and T cell acute 
lymphoblastic leukemia cells (Scupoli et al., 2008).
CXCL12 has been shown to increase production of MMP2 and MMP9 protein in PC3
prostate cancer cell lines (Singh et al., 2004). CXCL12 has been shown to increase
MMP9 expression in U87 malignant glioma cells (Kenig et al., 2010), adult neural
proginator cells (Barkho et al., 2008), lung cancer cell lines (Tang et al., 2008), Hela
cells (Brule et al., 2006), head and neck squamous carcinoma cells (Samara et al.,
2004), cultured chondrocytes (Kanbe et al., 2004), primary human monocytes (Klier et
al., 2001) and megakaryocytes (Lane et al., 2000). Both MMP2 and MMP9 have been
shown to be increased at the mRNA level by CXCL12 in human ovarian cancer cells
(Yuecheng and Xiaoyan, 2007). VEGF has been shown to be up-regulated by CXCL12 in
malignant glioma cells (Yang etal., 2005), human arterial endothelial cells (Neuhaus et
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al., 2003), lymphohaematopoietic cells (Kijowski et al., 2001) and microvascular 
endothelial cells (Mirshahi etal., 2000).
Expression of IL6, IL8, MMP2, MMP9 and VEGFA mRNA was measured in four 
endometrial cell types: primary epithelial cells, primary stromal cells and the Ishikawa 
and HEC-l-B adenocarcinoma cell lines. This chapter investigates the expression of 
these factors in the endometrium; in particular their cellular distribution between 
endometrial epithelial and stromal cells. It also considers the appropriateness of using 
HEC-l-B and Ishikawa cell lines as a model to study these factors in relation to 
endometrial function. This is explored further in chapter 7, which investigates the 
effect of CXCL12 on the production of these factors in each cell type.
The precise functions of the chemokine ligand CXCL12 and its receptor CXCR4 in the 
endometrium, remains unknown. In other tissues CXCL12 has been shown to up- 
regulate IL6, IL8, MMP2, MMP9 and VEGF in various human cell types. This chapter 
reviews the evidence for the ability of CXCL12 to up-regulate these important 
endometrial factors in non-endometrial cell types and investigates the effects of 
CXCL12 on the mRNA levels of IL6, IL8, MMP2, MMP9 and VEGFA in HEC-l-B and 
Ishikawa cell lines and primary cell cultures of endometrial epithelial and stromal cells.
4.3 Aims
To investigate our hypothesis that CXCL12 may regulate the expression of IL6, IL8, 
MMP2, MMP9 and VEGFA in endometrial cells, it is our aim to measure changes in the 
mRNA expression levels of these factors in endometrial cell cultures in response 
incubation with recombinant CXCL12. To achieve this, real-time RT-PCR will be used to 
accurately measure the amounts of mRNA present in primary cell cultures and cell 
lines both in the presence and absence of CXCL12.
4.4 Methods
To assess basal mRNA expression, Ishikawa, HEC-l-B cells and primary cultures of 
epithelial and stromal cells were prepared as described in sections 2.2.2, 2.2.3 and
2.2.4 respectively. RNA was extracted from the cells (section 2.3.1) and levels of IL6, 
IL8, MMP2, MMP9 and VEGFA mRNA were quantified using SYBR® Green real-time RT- 
PCR (as described in sections 2.5 and 2.6). Expression levels of the gene transcripts of
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interest were quantified using the 2'ACt method relative to reference gene YWHAZ as 
described in section 2.8.3. RNA was extracted from endometrial epithelial and stromal 
cells prepared from endometrial biopsies, obtained throughout the menstrual cycle 
and prepared from 6 different women. Experiments using HEC-l-B and Ishikawa cells 
were carried out on 3 separate occasions. The Kruskal-Wallis and Mann-Whitney U 
test was used to determine any statistical differences in mRNA levels between cell 
types.
To assess the effects of CXCL12 on IL6, IL8, MMP2, MMP9 and VEGFA in endometrial 
cell cultures, Ishikawa, HEC-l-B cells, primary endometrial epithelial and stromal cells 
were prepared and grown as described in sections 2.1.3, 2.1.4 and 2.1.5 respectively. 
All endometrial cell types were incubated with 0, 10 and 100 ng/ml of recombinant 
CXCL12 for 24 hours prior to expected confluence as described in section 2.16. 
Following RNA extraction and reverse transcription (sections 2.2.1 and 2.4.1), SYBR® 
Green real-time RT-PCR was carried out to quantify the expression levels of IL6, IL8, 
MMP2, MMP9 and VEGFA relative to reference transcript YWHAZ (described in section 
2.4). Incubation with CXCL12 was repeated 3 times in HEC-l-B and Ishikawa cells and 
with epithelial and stromal cells prepared from tissue obtained from 6 different 
women. The effects of CXCL12 on the expression levels of CXCR4 and CXCL12 mRNA 
were also assessed. To investigate potential effects of CXCL12 on the mRNA production 
of CXCR4, the effects of CXCL12 on CXCR4 mRNA expression levels was quantified in all 
four endometrial cell types using Taqman® real-time RT-PCR and reference transcript 
YWHAZ. To assess any effects of CXCL12 on CXCL12 mRNA production, the effects of 
CXCL12 treatment on CXCL12 mRNA production was assessed in primary epithelial and 
stromal cells to using SYBR® Green real-time RT-PCR and UBC as a reference transcript. 
This experiment was repeated 3 times. Resulting Ct values were quantified relative to 
the relevant reference transcript and compared to levels in mRNA extracted from cells 
incubated without CXCL12 to give relative expression values using the 2*(AACt) method. 
Mean expression values for levels of mRNA for IL6, IL8, MMP2, MMP9, VEGFA, CXCR4 
and CXCL12 were calculated and differences in expression between control cells and 
cells incubated with 10 or 100 ng/ml of CXCL2 was assessed using a Kruskal-Wallis test.
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4.5 Results: basal expression of IL6, IL8, MMP2, MMP9 and VEGFA in 
endometrial cell cultures
4.5.1 IL6
IL6 mRNA expression was highest in primary epithelial cells, while expression in the 
stromal cells was less than half that of the epithelial cells. There was no statistical 
difference in levels of IL6 mRNA expressed in the two cell types. Expression of IL6 
mRNA in the endometrial adenocarcinoma cell lines was found to be considerably 
lower than their primary epithelial counterparts with Ishikawa cells showing higher 
levels of IL6 expression in comparison to the HEC-l-B cells which were found to 
express significantly less IL6 mRNA in comparison to primary epithelial cells using a 
Kruskal-Wallis test (Figure 4.1).
4.5.2 IL8
IL8 mRNA expression in primary endometrial epithelial cells was found to be 
approximately equal to that of reference transcript YWHAZ. Expression of IL8 mRNA in 
the primary stromal cells was significantly lower than mRNA expression in primary 
epithelial cells when the two cell types were directly compared with a Mann-Whitney 
U test (P=0.002). Expression of IL8 mRNA in Ishikawa and HEC-l-B cell lines was found 
to be several orders of magnitude lower than their primary epithelial cell counterparts 
and was significantly lower than epithelial cells when all groups were compared using 
Kruskal-Wallis test (Figure 4.2).
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Figure 4.1: Relative expression of basal IL6 mRNA in cultured endometrial cells 
Median relative expression values: Ishikawa = 1.39'05, HEC-l-B = 1.18'05, Epithelial = 
8.52'03and Stromal = 4.34-03. n=6 for epithelial and stromal cells, n=3 for Ishikawa and 
HEC-l-B cells.
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Figure 4.2: Relative expression of basal IL8 mRNA in cultured endometrial cells 
Median relative expression values: Ishikawa = 1.32'06, HEC-l-B = 5.73"04, Epithelial = 
0.99 and Stromal = 0.017. n=6 for epithelial and stromal cells, n=3 for Ishikawa and 
HEC-l-B cells. ** Significantly different from stromal cells when compared directly to 
epithelial cells using a Mann-Whitney U test (P <0.01).
4.5.3 MMP2
Endometrial stromal cells were shown to express the highest levels of MMP2 mRNA, 
which was found to be approximately twice that of reference transcript YWHAZ. 
Expression of MMP2 mRNA in primary epithelial cells was approximately equivalent to 
that of the reference transcript YWHAZ. Despite stromal levels of MMP2 mRNA 
appearing to be twice that of epithelial cells, levels of expression in each cell type were 
not significantly different from each other (P >0.05) when directly compared to each 
other using a Mann-Whitney U test. Levels of MMP2 mRNA expression in the Ishikawa 
and HEC-l-B cell lines were several orders of magnitude lower than their primary 
epithelial counterparts and found to be significantly lower than stromal cells when all 
groups were compared using a Kruskal-Wallis test (Figure 4.3).
4.5.4 MMP9
Primary endometrial epithelial cells expressed the highest levels of MMP9 mRNA and 
levels were found to be significantly higher than those in stromal cells (P=0.026) when 
both groups were compared directly to each other using a Mann-Whitney U test. Both 
Ishikawa and HEC-l-B cell lines expressed levels of MMP9 mRNA several orders of 
magnitude lower than their primary epithelial counterparts. Ishikawa cells were found 
to express significantly lower MMP9 mRNA than epithelial cells when all groups were 
compared using a Kruskal-Wallis test. Levels of expression of MMP9 by HEC-l-B 
cultures showed considerable variation in the three different experiments (Figure 4.4).
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Figure 4.3: Relative expression of basal M M P2 mRNA in cultured endometrial 
cells
Median relative expression values: Ishikawa = 4.73'05, HEC-l-B = 2.06"05, Epithelial = 
0.55 and Stromal = 1.81. n=6 for epithelial and stromal cells, n=3 for Ishikawa and 
HEC-l-B cells.
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Figure 4.4: Relative expression of basal M M P9 mRNA in cultured endometrial 
cells
Median relative expression values: Ishikawa = 1.59'06, HEC-l-B = 2.09'06, Epithelial = 
0.027 and Stromal = 0.009. n=6 for epithelial and stromal cells, n=3 for Ishikawa and 
HEC-l-B cells. * Significantly different from stromal cells when compared directly to 
epithelial cells using a Mann-Whitney U test (P <0.05).
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4.5.5 VEGFA
Primary endometrial stromal cells were found to express significantly higher levels of 
VEGFA mRNA when directly compared to primary epithelial cells using a Mann- 
Whitney U test (P=0.004). In contrast to other factors VEGFA was expressed by HEC-1- 
B and Ishikawa cells in amounts comparable to their primary cell counterparts. 
Expression of VEGFA in Ishikawa cells was greater than in HEC-l-B cells (Figure 4.5).
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Figure 4.5: Relative expression of basal VEGFA mRNA in cultured endometrial 
cells
Median relative expression values: Ishikawa = 0.22, HEC-l-B = 0.10, Epithelial = 0.09 
and Stromal = 0.29. n=6 for epithelial and stromal cells, n=3 for Ishikawa and HEC-l-B 
cells. * Significantly from epithelial cells when compared directly to stromal cells using 
a Mann-Whitney U test (P <0.05).
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4.6 Results: effects of CXCL12 on expression levels of CXCR4 and CXCL12 
mRNA in endometrial cell cultures
4.6.1 CXCR4
CXCL12 appeared to cause a dose-dependent decrease in CXCR4 mRNA expression in 
Ishikawa cells. However, levels of CXCR4 mRNA in cells incubated with CXCL12 at 10 
and 100 ng/ml were not significantly different from those to which no CXCL12 was 
added. CXCL12 at 10 and 100 ng/ml appeared to have no effect on CXCR4 expression 
in HEC-l-B, epithelial and stromal endometrial cells (Figure 4.6 and 4.7).
4.6.2 CXCL12
Exogenously added CXCL12 had no effect on CXCL12 mRNA expression in primary 
epithelial and stromal cells (Figure 4.8). The effects of exogenous CXCL12 on CXCL12 
mRNA expression in Ishikawa and HEC-l-B cells was not investigated as no basal 
CXCL12 mRNA expression could be identified in Ishikawa cell lines.
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Figure 4.6: Effects of CXCL12 on CXCR4 mRNA expression in primary 
endometrial cells
Relative expression of CXCR4 in endometrial (A) epithelial cells (Medians: 0 ng/ml =
1.00, 10 ng = 0.96, 100 ng/ml = 0.85) and (B) stromal cells (Medians: 0 ng/m l = 1.00, 10 
ng/ml = 0.90,100 ng/ml = 0.85). n=6 for epithelial and stromal cells.
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Figure 4.7: Effects of CXCL12 on CXCR4 mRNA expression in endometrial cell 
lines
Relative expression of CXCR4 in endometrial (A) Ishikawa cells (Medians: 0 ng/ml =
1.00, 10 ng = 0.77,100 ng/ml = 0.09) and (B) HEC-l-B cells (Medians: 0 ng/m l = 1.00,10 
ng/ml = 0.84,100 ng/ml = 0.89). n=3 for Ishikawa and HEC-l-B cells.
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Figure 4.8: Effects of CXCL12 on CXCL12 mRNA expression in primary 
endometrial cells
Relative expression of CXCL12 in endometrial (A) epithelial cells (Medians: 0 ng/ml =
1.00, 10 ng = 1.07, 100 ng/ml = 1.05) and (B) stromal cells (Medians: 0 ng/m l = 1.00, 10 
ng/ml = 0.70, 100 ng/ml = 0.95). n=3 for epithelial and stromal cells.
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4.7 Results: Effect of CXCL12 on expression levels of IL6, IL8, MMP2, 
MMP9 and VEGFA mRNA in endometrial cell cultures
4.7.1 IL6
CXCL12 appeared to cause a dose-dependent increase in IL6 mRNA expression in 
primary epithelial cells. However, levels of IL6 mRNA in cells incubated with either 
concentration of CXCL12 were not significantly different to cells in which no CXCL12 
was added. CXCL12 at 10 and 100 ng/ml appeared to have no effect on IL6 expression 
in Ishikawa, HEC-l-B and stromal endometrial cell types (Figure 4.9 and 4.10).
4.7.2 IL8 (CXCL8)
CXCL12 at 10 or 100 ng/ml did not significantly alter the expression of IL8 mRNA in the 
Ishikawa and HEC-l-B endometrial cell lines or in primary epithelial and stromal 
endometrial cell types (Figure 4.11 and 4.12).
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Figure 4.9: Effects of CXCL12 on IL6 mRNA expression in primary endometrial 
cells
Relative expression of IL6 in endometrial (A) epithelial cells (Medians: 0 ng/m l = 1.00, 
10 ng = 1.16, 100 ng/ml = 1.43) and (B) stromal cells (Medians: 0 ng/m l = 1.00, 10 
ng/ml = 0.85,100 ng/ml = 0.99). n=6 for epithelial and stromal cells.
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Figure 4.10: Effects of CXCL12 on IL6 mRNA expression in endometrial cell lines 
Relative expression of IL6 in (A) Ishikawa cells (Medians: 0 ng/ml = 1.00, 10 ng = 1.53, 
100 ng/ml = 0.97) and (B) HEC-l-B cells (Medians: 0 ng/ml = 1.00, 10 ng/ml = 0.93, 100 
ng/ml = 0.85). n=3 for Ishikawa and HEC-l-B cells.
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Figure 4.11: Effects of CXCL12 on IL8 mRNA expression in primary endometrial 
cells
Relative expression of IL8 in endometrial (A) epithelial cells (Medians: 0 ng/m l = 1.00, 
10 ng = 0.67, 100 ng/ml = 1.18) and (B) stromal cells (Medians: 0 ng/m l = 1.00, 10 
ng/ml = 1.15,100 ng/ml = 0.99). n=6 for epithelial and stromal cells.
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Figure 4.12: Effects of CXCL12 on IL8 mRNA expression in endometrial cell lines 
Relative expression of IL8 in (A) Ishikawa cells (Medians: 0 ng/ml = 1.00, 10 ng = 0.39, 
100 ng/ml = 0.60) and (B) HEC-l-B cells (Medians: 0 ng/m l = 1.00, 10 ng/ml = 0.71, 100 
ng/ml = 1.66). n=3 for Ishikawa and HEC-l-B cells.
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4.7.3 MMP2
CXCL12 at 10 or 100 ng/ml did not significantly alter the expression of MMP2 mRNA in 
the Ishikawa and HEC-l-B endometrial cell lines or in primary epithelial and stromal 
endometrial cell types (Figure 4.13 and 4.14).
4.7.4 MMP9
CXCL12 appeared to cause a dose-dependent increase in MMP9 mRNA expression in 
primary epithelial cells and a dose-dependent decrease in MMP9 mRNA expression in 
Ishikawa cells. However, levels of MMP9 mRNA in either epithelial or stromal cells 
incubated with either concentration of CXCL12 were not significantly different to cells 
in which no CXCL12 was added. CXCL12 at 10 and 100 ng/ml appeared to have no 
effect on MMP9 expression in HEC-l-B or primary stromal endometrial cell types 
(Figure 4.15 and 4.16).
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Figure 4.13: Effects of CXCL12 on M M P2 mRNA expression in primary 
endometrial cells
Relative expression of MMP2 in endometrial (A) epithelial cells (Medians: 0 ng/ml =
1.00, 10 ng = 1.38, 100 ng/ml = 1.27) and (B) stromal cells (Medians: 0 ng/m l = 1.00, 10 
ng/ml = 1.10,100 ng/ml = 0.92). n=6 for epithelial and stromal cells.
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Figure 4.14: Effects of CXCL12 on M M P2 mRNA expression in endometrial cell 
lines
Relative expression of MMP2 in (A) Ishikawa cells (Medians: 0 ng/ml = 1.00, 10 ng = 
0.95, 100 ng/ml = 0.70) and (B) HEC-l-B cells (Medians: 0 ng/ml = 1.00, 10 ng/ml = 
1.45, 100 ng/ml = 0.5). n=3 for Ishikawa and HEC-l-B cells.
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Figure 4,15: Effects of CXCL12 on M M P9 mRNA expression in primary 
endometrial cells
Relative expression of MMP2 in endometrial (A) epithelial cells (Medians: 0 ng/m l =
1.00, 10 ng = 1.34,100 ng/ml = 1.56) and (B) stromal cells (Medians: 0 ng/m l = 1.00, 10 
ng/ml = 1.04,100 ng/ml = 0.89). n=6 for epithelial and stromal cells.
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Figure 4.16: Effects of CXCL12 on M M P9 mRNA expression in endometrial cell 
lines
Relative expression of MMP9 in (A) Ishikawa cells (Medians: 0 ng/ml = 1.00, 10 ng = 
0.68, 100 ng/ml = 0.0.44) and (B) HEC-l-B cells (Medians: 0 ng/ml = 1.00, 10 ng/ml = 
0.39,100 ng/ml = 0.64). n=3 for Ishikawa and HEC-l-B cells.
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4.7.5 VEGFA
CXCL12 appeared to cause small dose-dependent increases in VEGFA mRNA in 
Ishikawa and HEC-l-B cell types. However, levels of VEGFA mRNA in cells incubated 
with either concentration of CXCL12 were not significantly different to cells in which no 
CXCL12 was added. CXCL12 at 10 and 100 ng/ml appeared to have no effect on VEGFA 
mRNA expression in primary epithelial or stromal cell types (Figure 4.17 and 4.18).
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Figure 4.17: Effects of CXCL12 on VEGFA mRNA expression in primary 
endometrial cells
Relative expression of VEGFA in endometrial (A) epithelial cells (Medians: 0 ng/ml =
1.00, 10 ng = 1.04, 100 ng/ml = 1.07) and (B) stromal cells (Medians: 0 ng/m l = 1.00, 10 
ng/ml = 0.85,100 ng/ml = 0.94). n=6 for epithelial and stromal cells.
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Figure 4.18: Effects of CXCL12 on VEGFA mRNA expression in endometrial cell 
lines
Relative expression of VEGFA in (A) Ishikawa cells (Medians: 0 ng/ml = 1.00, 10 ng = 
0.91, 100 ng/ml = 1.12) and (B) HEC-l-B cells (Medians: 0 ng/ml = 1.00, 10 ng/ml = 
0.91,100 ng/ml = 0.81). n=3 for Ishikawa and HEC-l-B cells.
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4.8 Discussion
4.8.1 Basal expression of IL6, IL8, MMP2, MMP9 and VEGFA in 
endometrial cell cultures
Real-time RT-PCR was used to identify and quantify IL6, IL8, MMP2, MMP9 and VEGFA 
mRNA expression in four endometrial cell types. Specific PCR products for each of 
these gene transcripts, was observed in primary epithelial and stromal cells and also in 
the Ishikawa and HEC-l-B adenocarcinoma cell lines. Differential expression of the 
transcripts of interest was seen in the cell types studied.
The most striking difference between the endometrial cell types was the apparent low 
expression of the majority of the transcripts in the cell lines in comparison to their 
primary epithelial cell counterparts. The expression of IL6, IL8, MMP2 and MMP9 was 
many orders of magnitude lower in the cell lines. While cell lines provide a useful and 
practical in vitro tool for the study of endometrial cells, the results obtained here 
clearly suggest that the Ishikawa and HEC-l-B cell lines express different levels of 
Important endometrial factors compared to primary endometrial epithelial cells. 
Levels of VEGFA mRNA were more comparable to the primary epithelial cells, though 
this high expression could potentially be due to their cancerous nature rather than 
representing normal endometrial function. It was surprising that MMP2 and MMP9 
production was lower in the adenocarcinoma cell lines than primary cells. Cancer cells 
are usually more invasive than normal cells and part of this invasiveness is due to the 
production of MMPs.
The expression of IL6 mRNA was found to be higher in the epithelial cells than the 
stromal cells though this difference was not significant. Greater expression of IL6 
mRNA in endometrial epithelial cells compared to stromal cells is in agreement with 
previous studies of IL6 expression in the endometrium (Laird et a!., 1993; Tabibzadeh 
et oi., 1995 and Vandermolen and Gu, 1996). The expression of IL8 was significantly 
higher in the endometrial epithelial cells than in the stromal cells and expression of IL8 
mRNA in both cell types was considerably higher than IL6. This result is in agreement 
with previous studies that have investigated the distribution of IL8 in the 
endometrium, which have shown expression of IL8 to be highest in the endometrial 
epithelium (Arid et oi., 1998b and Garcia-Valesco and Arid, 1999). Expression of IL8 in
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the endometrial epithelium confirms the importance of IL8 at the endometrial surface 
and may well relate to its proposed functions in leukocyte recruitment during the 
menstrual cycle.
MMP2 mRNA was the most abundant transcript of those studied in both epithelial and 
stromal cells. The apparently higher expression of MMP2 in the stromal cells 
compared to epithelial cells is consistent with previously reported studies and with its 
proposed functions in the control of menstruation and may relate to the invasion of 
trophoblast through the endometrial stroma during implantation (Salamonsen and 
Woolley; 1996).
In contrast to MMP2, MMP9 mRNA expression was significantly higher in the epithelial 
cells rather than the stromal cells but was lower in both cells types compared to 
MMP2. The increased expression of MMP9 mRNA in epithelial cells is in agreement 
with immunolocalisation studies which have found MMP9 expression to be located 
within the luminal and glandular epithelium (Jeziorska et al., 1996). These results 
suggest potentially differing functions of MMP2 and 9 within the endometrium; 
though it is likely as previous studies have suggested; that these and other MMPs act 
in a concerted manner in the endometrium to achieve their functions (Salamonsen; 
1999 and Salamonsen and Woolley 1999).
Angiogenesis of spiral arteries occurs during every menstrual cycle and is important in 
endometrial function and VEGF is involved in the control of angiogenesis. This study 
found VEGFA mRNA expression to be significantly higher in endometrial stromal cells 
in comparison to epithelial cells. VEGFA mRNA was expressed in substantial quantities 
in both endometrial epithelial and stromal cells; which is in agreement with 
Punyadeera et al (2006). This suggests that both endometrial stromal and epithelial 
cells may play direct roles in the production of VEGFA and thus in the control of 
angiogenesis in the endometrium.
Overall the results have shown considerable differences in the expression of 
endometrial factors in HEC-l-B and Ishikawa cells lines and primary endometrial 
epithelial and stromal cells. The results suggest that care should be taken in 
extrapolating the results seen in cell lines to the in vivo situation.
182
4.8.2 Effect of CXCL12 on expression of IL6, IL8, MMP2, MMP9 and 
VEGFA mRNA in endometrial cell cultures
This study investigated the effects of CXCL12 on the expression of mRNA for IL6, IL8, 
MMP2, MMP9 and VEGFA in endometrial Ishikawa, HEC-l-B, primary epithelial and 
stromal cells in vitro. In contrast to studies in non-endometrial cells, CXCL12 did not 
significantly alter any of the transcripts even at high concentrations (100 ng/ml). 
When a relatively low concentration (5 ng/ml) of the recombinant CXCL12 chemokine 
was used with the same methodology for the same incubation time (24 hr) in the 
Ishikawa cell line, in genome wide microarray experiments, statistically significant and 
reproducible alterations in gene transcript expression was observed (see chapter 5). 
This strongly suggests that the recombinant CXCL12 used was functional. This raises 
the possibility that CXCL12 does not regulate the expression of these genes in the 
endometrium.
CXCR4 dependent signal transduction has been shown to occur through the 
MAPK/ERK1/2 and PI3K/Akt pathways leading to the activation of the nuclear-factor 
kappa B (NFKB) transcription factors (Chinni et ai., 2006; Huang et al., 2009 and Tang et 
a!., 2008). The activation of NFKB via the MAPK/ERK1/2 and PI3K/Akt signal 
transduction pathways has been shown to cause the up-regulation of IL6 (He et ai., 
2008 and Tagashira etol., 2009)), IL8 (Chen et ai., 2008), MMP2 (Chang et al., 2007 and 
Zhang et ai., 2010), MMP9 (Van Themsche et al., 2007 and Zhang et al., 2010) and 
VEGF (Kazi and Koos, 2007) in endometrial cell types. While this suggests that CXCL12 
and CXCR4 could potentially cause the up-regulation of the factors studied through 
these signal pathways in the endometrium, this effect was not observed. This suggests 
that CXCL12/CXCR4 signaling may occur through alternative pathways in endometrial 
epithelial and stromal cells.
CXCL12 and CXCR4 are known to affect a wide range of cellular activity in the human. 
It is implicated in leukocyte recruitment, haematopoiesis, angiogenesis, cellular 
differentiation and apoptosis (Busillo and Benovic, 2006). All these functions are of 
particular importance in the endometrium. If CXCL12 and CXCR4 are involved in any or 
all of these functions in the endometrium it is likely that precise control of both the 
ligand and the receptor is required to carry out such diverse functions. CXCL12 is
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known to be able to oligomerise, interact with glycosaminoglycans in aiding gradient 
formation and produce differing cellular effects in a concentration dependent manner 
(Majika et al., 2000 and Wysoczynski et al., 2005). These factors may affect 
downstream responses upon receptor binding and effect function. The receptor 
CXCR4 can undergo both transcriptional and translational control which may affect its 
functional responses. Receptor glycosylation, homodimerisation, heterodimerisation, 
extracellular tyrosine sulfation and internal phosphorylation patterns of the CXCR4 
receptor may all contribute to functional heterogeneity (Babcock et al., 2003; 
Basmaciogullari et al., 2006; Chabot et al., 2000; Farzan et al., 2002 and Issafras et al., 
2002). Understanding these complex interactions within the endometrium may be 
essential to reveal endometrial function of the chemokine and its receptor.
4.8.3 Limitations
These experiments are subject to the same inherent potential sources of error and 
variation as the cell culture real-time RT-PCR experiments discussed in 3.4.5. Of 
particular importance is the potential effects of progesterone withdrawal on the cells 
in culture to which no steroid hormones was added. A known effect of this is the 
upregulation of MMP expression in endometrial cells (Lockwood et al., 1998). Our 
study did identify high levels of MMP2 in the primary epithelial cells in comparison to 
other factors measured but levels of MMP9 in primary cells was comparable to other 
factors and cell lines expressed low levels of MMP mRNA in comparison to primary 
cells even though all cells were exposed to the same culture conditions.
This study could not identify any effects of CXCL12 on the regulation of IL6, IL8, MMP2, 
MMP9 and VEGFA. It is possible that the inherent variation in real-time RT-PCR and 
cell culture models used contributed to this by masking clear statistically significant 
effects of CXCL12 on the factors measured. However, no cell cultures exhibited 
dramatic changes in mRNA levels in response to CXCL12 (e.g. ± 5 fold change) in any 
case. Investigating receptor activation of CXCR4 using an antagonist or downstream 
pathways activated by CXCR4 may have provided more information on what is 
precisely occurring in the cultures models. It is possible that the factors investigated 
are critically regulated at the protein level and thus changes in mRNA levels become
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less significant to overall cell function. With more time, all these aspects could be 
investigated.
A further limitation of this study is the separation and isolation of the endometrial 
epithelial and stromal cells from one another. Studies such as that by Albrecht et al. 
(2003) have shown the potential importance of the cross-talk that may occur between 
these cell types in which are important in controlling their function and that of the 
endometrium. Co-culture models of these cell types coupled with in vitro steroid 
hormone treatment may more accurately replicate the function of each cell type in 
vivo. However, the cell culture models used in this study does allow measurement of 
the potential molecular effects of a single endometrial factor on individual cell types, 
which is useful for determining the molecular effects of the chemokine ligand CXCL12 
and its receptor CXCR4.
4.8.4 Summary
The hypothesis could not be confirmed. Despite evidence that IL6, IL8, MMP2, MMP9 
and VEGFA are regulated by CXCL12 in non-endometrial cell types, this may not be the 
case in endometrial cells. This may be due to the activation of different signaling 
pathways following activation of CXCR4 by CXCL12 in endometrial cell types.
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Chapter 5 
Gene expression microarray analysis
5.1 Hypothesis
CXCL12 may regulate the gene expression of factors that remain unknown in 
endometrial cells.
5.2 Aims
So far, this study has investigated the effects of CXCL12 on factors which are known 
outside of the endometrium to be upregulated by CXCL12 using a targeted search of 
the literature. As CXCL12 and CXCR4 may carry out various activities in the 
endometrium beyond that of leukocyte chemotaxis and other established functions, a 
global approach will be used to identify any gene expression potentially caused by 
CXCL12 within the genome of Ishikawa cell lines. The advantage of using this cell type 
is that the cell line expresses high levels of CXCR4 and no CXCL12 (Tsutsumi et al., 
2011) allowing the effects of adding known concentrations of CXCL12 to be quantified. 
This will be achieved using two-colour gene expression microarray analysis of the 
entire known expressed human genome.
5.3 Methods
Ishikawa cells were incubated with and without CXCL12 at 5 ng/ml for 24 hours. mRNA 
was extracted from the cells and its integrity checked as described in section 2.4. The 
mRNA extracted from the cells incuabted without CXCL12 (control) were labeled with 
Cy5 while that from the cells incubated with CXCL12 was labeled with Cy3. The 
hybridisation of the mRNA to the microarray and subsequent analysis of the data 
provided was carried out as described in section 2.9. The mRNA extracted from 
Ishikawa cells incubated with CXCL12 on four different occasions was analysed in this 
way.
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5.4 Microarray results
For each individual whole human genome block on the Agilent™ Ge45 4x44K 
microarray (n=4), data was extracted for each feature according to the protocol to 
produce individual spreadsheets containing raw data, normalisation factors, statistical 
analysis and the log ratio (baseio) of the processed signal from the Cy3 and Cy5 
channels. The log ratio of the processed signals gives the fold change of gene 
expression for each feature on the array and indicates the effects of exogenous 
CXCL12 (5 ng/ml for 24 hours) on Ishikawa cells. It is calculated as follows:
Log Ratio= Logio(Cy3 processed signal/ Cy5 processed signal)
5.4.1 Microarray quality control reports
Agilent™ Quality control (QC) reports were generated for each microarray block. 
These reports show the feature extraction protocol used to generate array data, the 
normalisation factors applied and the number of differentially expressed features on 
the array as well as their spatial distribution. Figure 5.1 shows an example of spot 
finding by the feature extraction software which is included in the Agilent™ QC reports 
demonstrating successful spot finding by the feature extraction software. Positive 
control probes for the Agilent™ spike-ins allow the user to confirm the success of the 
experiment and that feature extraction software has successfully found the features 
on the array. The distinct probe pattern on each corner of each array ensures the 
correct orientation of the slide. Spot finding was successful in all cases and exhibited 
the correct pattern in the correct orientation.
Figure 5.2 shows MA plots of each array block, which plots the log ratio of a microarray 
feature (M) on the Y axis and the average log processed signal intensity (A) on the X 
axis. This allows visualisation of differentially expressed features on the arrays for 
each experimental repeat and the spread of the normalised data. As expected, the 
number of up-regulated and down-regulated features detected by this method was 
only a small proportion of the total on the array. Figure 5.3 shows the spatial 
distribution of differentially expressed features on each array block representing each 
experimental repeat. There was a greater number of up-regulated features compared 
to down regulated.
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Figure 5.1: Spot finding o f m icroarray features
The Agilent™ feature extraction process produces quality control reports for each 
microarray (n=4). The above example is from block 1 of 4 on the array slide.
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Figure 5.2: MA plots of processed feature extracted microarray data
T MAgilent QC reports produce MA plots as a convenient way to view processed data. A 
MA p lot was generated for each array repeat (repeat 1 at the top and 4 at the bottom).
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Significantly up-regulated features are highlighted in green, significantly down- 
regulated features are highlighted in red. Features which show no differential 
expression are shown in yellow, while features used to normalise the data are blue.
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Figure 5.3: Spatial distribution o f differentially expressed microarray features  
The Agilent™ QC reports produce diagrams of the spatial distribution of significantly 
up- and down-regulated features on each array repeat in all four array repeats.
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5.4.2 Comparing microarray data from experimental repeats
Each feature on each array is subject to potential inherent error from RNA labeling 
bias, poor or cross-hybridisation, high background signal and compromised spot 
finding by feature extraction software. This results in application of high normalisation 
factors leading to the generation of log ratios which are biologically inaccurate. 
Boolean flags in the data spreadsheets highlight features where this is likely to have 
occurred allowing the user to ignore them from further analysis. Also, features where 
experimental error has had an effect will show high P values, which in the most 
extreme cases are = 1 indicating that no confidence can be applied to log ratio value.
To ensure accurate and manageable data was generated when comparing 
experimental repeats a number of steps were taken. For each experimental repeat, 
genes which showed <5-fold change in expression were ignored. If a feature on any 
block showed a fold change greater than this it was compared to its corresponding 
repeats on the other three arrays. If a >5-fold change was not seen in any of the other 
experimental repeats it was excluded from further analysis. If a >5-fold change for any 
feature was seen on 2 or more arrays, all four corresponding features were directly 
compared to assess the quality of the data generated in all cases and to investigate 
significance. To eliminate the chance of false positives occurring in the data a stringent 
P value of lxlO ’06 or less was used to attribute a significant result as the number of 
features expected to give a false-positive result on an 44K array when using this P 
value was 0.04% giving a high level of stringency to the data included.
Tables 5.1 and 5.2 list the gene transcripts that were up-regulated >5-fold and
occurred on two or more of the experimental repeats with the required stringent P
values necessary to ensure significance. The tables also includes log ratios and P
values for counterparts in experiments where no significant change was seen that 
confirm that in each case, these features were likely to have been affected by inherent 
experimental errors and not conflicting biological data.
Table 5.1 includes known genes and cDNA clones with full Coding Sequence (CDS) 
information. 37 known genes or cDNA clones with fully identified Coding Sequences 
(CDS) were shown to be significantly >5-fold up-regulated in 2 or more experimental 
repeats from separate cell cultures {n=4). In no cases were genes significantly up-
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regulated in all experimental repeats and was up-regulated in 3 out of 4 repeats in 3 
cases (U50277, SNX15 and PSCD4). However, in all 37 cases, features which did not 
show a log ratio of >0.5 did not exhibit a significant result and in many cases a P value 
of 1.00 was attributed indicating that there was no confidence in the value of the log 
ratio. This indicates that feature was subject to inherent experimental errors and was 
therefore attributed a Log Ratio of 0 by the feature extraction software. In most of the 
remaining cases, features had high error values and the P values generated were many 
orders of magnitude away from the required lxlO -06 value required to minimise 
possible false positive results also indicating that the feature was likely to be affected 
by inherent errors in probe hybridisation or high background signal. In exceptional 
cases where P values were closer to the accepted value, the log ratio was in good 
general agreement with the significant values in corresponding experimental repeats. 
The gene ETS1 on chromosome 11 is a good example of these principles as block 1 has 
a Log Ratio of 0.00 and a P value of 1.00 indicating a feature subjected to poor 
hybridisation or high background fluorescence. Block 2 has a significant log ratio of 
0.78 indicating a 7.8 fold increase (P= 5xl0‘n ), block 3 has a significant log ratio of 0.80 
indicating an 8.0 fold increase (P= 8xlO'10). While block 4 does not quite exhibit the 
highly stringent P required to confirm significance (3xl0"°5), it is still unlikely to be a 
false-positive result and is in good general agreement with the log ratios of the two 
significant results. There are no exceptions to these principles in any of the genes 
identified.
Table 5.2 includes cDNA clones with partial CDS information and completely unknown 
genes. 14 genes with cDNA clone partial CDS sequences or that are completely 
unknown were shown to be significantly >5-fold up-regulated in 2 or more 
experimental repeats from separate cell culture treatments [n=4). In no cases were 
genes significantly up-regulated in all experimental repeats and were up-regulated in 3 
out of 4 repeats in 2 cases (THC2385437 and A_32_P147500). There are no conflicting 
results between repeats using the principles described for Table 8.1 in any case.
When this procedure was carried out for down-regulated genes, no genes were found 
to be significantly down-regulated by 5-fold or below in two or more repeats so further 
analysis concentrated on the up-regulated genes identified.
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Chromosome Gene Name Systematic Name Log ratio Log ratio 
error
P Value
1 ADORA3 NM_020683 0.00 0.82 1.00
1.20 0.16 3x10 14
1.48 0.21 lx lO 12
0.97 0.25 lx lO '04
1 CR600872 CR600872 0.73 0.10 lx lO '13
-0.11 0.08 0.17
0.78 0.09 0.38
0.68 0.12 2x10 11
2 FU38377 NMJL52698 -0.008 0.44 0.99
0.65 0.11 1x10 09
0.67 0.12 1x10 08
0.69 0.17 lx lO 05
2 ARHGEF4 NM_015320 0.98 0.15 1x10 10
-0.03 0.22 0.90
0.16 0.22 0.49
0.65 0.14 5x10 06
2 ENST00000244221 ENST00000244221 0.28 0.32 0.38
0.67 0.11 lx lO 09
-0.2 0.35 0.56
0.61 0.14 6xlO'06
3 DOC1 NMJL82909 0.00 0.81 1.00
1.54 0.27 9x10 09
1.28 0.22 8x10 09
0.00 0.65 1.00
3 GHRL NM_016362 0.00 0.51 1.00
0.73 0.11 4x lO n
0.65 0.11 7x l0 ‘°9
0.66 0.15 lx lO '05
3 LRRC2 NM_024512 0.70 0.31 0.02
0.68 0.11 lx lO 10
-0.31 0.29 0.27
0.60 0.13 lx lO '06
3 CACNA2D3 NM_018398 0.00 0.81 1.00
1.28 0.18 4x10 13
1.56 0.24 3x10 11
1.01 0.25 3x10 05
4 MGC27016 NM_144979 1.32 0.29 7xlO’06
1.46 0.21 1x10 12
0.00 0.82 1.00
0.25 0.64 0.69
4 AF130075 AF130075 0.00 0.81 1.00
1.49 0.18 1x10 16
1.49 0.25 1x10 09
0.85 0.65 4 x l0 ‘°3
6 OFCC1 AF520801 1.56 0.18 lx lO 18
0.00 0.84 1.00
0.82 0.62 0.19
1.42 0.19 1x10 14
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Chromosome Gene Name Systematic Name Log ratio Log ratio 
error
P Value
7 U50277 U50277 0.00 0.81 1.00
1.59 0.23 4x10 12
1.43 0.26 4 x l0 08
1.13 0.22 lx lO '07
7 DPP6 NM_130797 0.00 0.81 1.00
1.31 0.17 lx lO '14
1.34 0.29 2x10 06
1.02 0.24 2x l0 '05
8 TRHR NM_003301 0.00 0.81 1.00
1.02 0.21 lx lO 06
1.38 0.24 7x10 09
0.00 0.65 1.00
8 AF426412 AF426412 0.00 0.81 1.00
1.23 0.22 3x10 08
1.49 0.25 1x10 09
0.00 0.65 1.00
8 LY6K NM_017527 1.46 0.17 2x l0 '17
0.00 0.84 1.00
0.53 0.77 0.49
1.29 0.20 4x10 11
8 DEFA6 NM_001926 0.00 0.81 1.00
0.82 0.14 1x10 08
1.10 0.20 5 x l0 °8
0.00 0.65 1.00
10 COL13A1 NM 005203 1.08 0.13 2 x l0 16
-0.44 0.27 0.10
-0.05 0.25 0.8
0.94 0.13 2 x l0 13
10 KCNMA1 NM_002247 0.38 0.17 0.02
0.62 0.09 8x10 11
0.12 0.13 0.37
0.78 0.12 3xlO"10
10 SH2D4B NM_207372 0.84 0.56 0.13
1.33 0.12 lx lO 12
0.00 0.83 1.00
1.13 0.22 4x10 07
11 ETS1 NM_005238 0.00 0.55 1.00
0.78 0.12 5x10 11
0.80 0.13 8x10 10
0.90 0.22 3x10 05
11 FAM111A NM_022074 0.38 0.22 0.09
0.63 0.10 lx lO 10
-0.23 0.23 0.32
0.86 0.13 9x lO n
11 SNX15 NM_147777 -0.06 0.42 0.90
0.73 0.11 1x10 11
0.83 0.11 1x10 13
0.71 0.15 5xlO'06
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Chromosome Gene Name Systematic Name Log Ratio Log Ratio 
Error
P value
11 SLC02B1 NM_007256 1.64 0.23 6x1013
0.70 0.78 0.37
0.68 0.75 0.36
1.07 0.23 5 x l0 °6
13 TNAP AF463496 0.00 0.81 1.00
1.11 0.20 2x l0 ‘°8
0.94 0.19 9x l0 ‘°7
0.75 0.34 0.03
13 AF305819 AF305819 1.64 0.23 lx lO '12
0.00 0.84 1.00
0.72 0.72 0.32
1.12 0.22 3x l0 ‘°7
15 MAP1A NM_002373 0.59 0.26 0.02
0.83 0.12 1x10 12
-0.19 0.37 0.62
1.20 0.17 7x10 13
17 KRTAP3-3 NM_033185 1.43 0.20 3 x l0 13
-0.11 0.39 0.79
0.00 0.74 1.00
1.09 0.23 lx lO '06
17 AF090926 AF090926 0.00 0.77 1.00
1.14 0.15 1x10 13
0.75 0.13 5xlO'09
0.98 0.25 9x l0 ‘°5
17 PITPNM3 NM_031220 0.00 0.81 1.00
1.41 0.20 3 x l0 13
0.00 0.83 1.00
1.08 0.23 3xl0 ‘°6
17 KIF19 NM_153209 0.00 0.81 1.00
0.98 0.21 1x10 06
1.31 0.29 6x10 06
0.00 0.65 1.00
17 CV390614 CV390614 0.00 0.81 1.00
1.52 0.20 1x10 14
1.58 0.23 8 x l0 '12
0.00 0.65 1.00
19 EBI3 NM_005755 0.00 0.81 1.00
1.14 0.16 4x10 13
1.61 0.23 4x10 12
0.00 0.65 1.00
20 BIRC7 NM_022161 0.00 0.81 1.00
1.21 0.20 7x10 10
1.21 0.20 3X1009
0.00 0.65 1.00
21 BX414807 BX414807 1.19 0.15 2x l0 ‘15
0.49 0.15 0.001
0.26 0.27 0.34
1.02 0.15 2x10 12
1 9 6
Chromosome Gene Name Systematic Name Log ratio Log ratio 
error
P Value
22 PSCD4 NM_012285 1.54 0.20 5 x l0 15
1.13 0.15 lx lO '14
0.00 0.83 1.00
1.39 0.19 lx lO 13
Table 5.1: Known genes up-regulated by addition of CXCL12 (5 ng/ml for 
24 hours) in the Ishikawa cell line
The genes are ordered in the table by chromosome location followed by the gene 
name and systematic name. The four log ratio values, error and P values for each gene 
listed are ordered by the array block number (1-4). The log ratio shows the fold 
change of the experimental sample versus the control and is in baseio, meaning genes 
with a log ratio of 0.5 have a 5 fold increase (light green) and genes with a Log Ratio of 
1.0 have a 10 fold increase (dark green). Significant values are highlighted in yellow.
1 9 7
chromosome Gene name Systematic name Log ratio Log ratio 
Error
P value
1 AB015616 AB015616 0.00 0.81 1.00
1.52 0.27 2xlO'08
1.45 0.26 1x10 08
0.00 0.65 1.00
1 A_23_P136392 A_23_P136392 0.71 0.11 2x lO n
-0.06 0.09 0.52
0.10 0.10 0.32
0.56 0.11 lx lO 07
2 AK055428 AK055428 0.00 0.81 1.00
1.42 0.21 2xlO-11
1.54 0.24 6x l0"n
0.00 0.65 1.00
3 THC2272949 THC2272949 1.22 0.14 2 x l0 17
0.04 0.26 0.87
0.82 0.14 lx lO 09
1.08 0.15 1x10 12
4 THC2385437 THC2385437 0.00 0.82 1.00
1.35 0.16 lx lO 16
1.44 0.17 lx lO '17
1.16 0.21 4x l0 '°8
5 ENST00000381528 ENST00000381528 0.00 0.78 1.00
0.70 0.14 6xlO"07
0.93 0.19 5xlO'07
1.36 0.18 0.46
5 AK025252 AK025252 0.00 0.81 1.00
1.75 0.22 6x10 15
1.51 0.24 4x lO'10
0.00 0.65 1.00
6 A_24_P648813 A_24_P648813 0.00 0.81 1.00
1.41 0.30 3x10 06
1.53 0.24 1x10 10
0.00 0.65 1.00
7 A_32_P147500 A_32_P147500 0.00 0.81 1.00
1.11 0.13 1x10 17
1.20 0.23 9x10 08
1.18 0.21 1x10 08
7 THC2350949 THC2350949 1.36 0.16 1x10 17
-0.18 0.36 0.61
0.64 0.24 6x10 03
1.25 0.16 2x10 15
11 THC2349421 THC2349421 1.33 0.16 2x10 17
0.000 0.74 1.00
0.77 0.25 lx lO 03
1.33 0.18 4x10 13
12 A_24_P943657 A_24_P943657 0.86 0.55 0.12
1.33 0.18 2x10 13
0.00 0.83 1.00
1.23 0.20 lx lO 09
1 9 8
Error
14 A_32_P63630 A_32_P63630 0.00 0.81 1.00
1.50 0.28 6x10 08
1.39 0.27 3x10 07
0.00 0.65 1.00
17 THC2315277 THC2315277 0.00 0.50 1.00
0.82 0.11 8 x l0 14
0.58 0.14 5xl0 '05
0.86 0.15 4X10'09
Table 5.2: Unknown genes up-regulated by addition of CXCL12 (5 ng/m l 
for 24 hours) in the Ishikawa cell line
The genes are ordered in the table by chromosome location followed by the gene 
name and systematic name. The four log ratio, error and P values for each gene listed 
are ordered by the array block number (1-4). The log ratio shows the fold change of 
the treated sample versus the control and is in baseio, meaning genes with a log ratio 
of 0.5 have a 5 fold increase (light green) and genes with a Log Ratio of 1.0 have a 10 
fold increase (dark green). Significant values are highlighted in yellow.
1 9 9
5.5 Attributing gene function to up-regulated genes
Internet based searches using the EntrezGene and Swiss-Prot databases (via: 
www.genecards.org) were carried out to try and attribute functions to known gene 
transcripts that were shown to be up-regulated by addition of CXCL12 to Ishikawa cells 
and to identify the cellular location of the proteins they encode. EntrezGene uses 
RefSeq genomes while Swiss-Prot database is provided by the Swiss Institute of 
Bioinformatics. Table 5.3 summarises the information obtained. Genes for which 
there was no significant functional information available were ignored. The database 
search revealed that CXCL12 may up-regulate G-protein coupled receptors and 
peripheral membrane proteins; a secreted chemokine, hormones and a defensin; 
calcium and potassium dependent ion channels, anti-apoptotic protein or cell cycle 
regulators, protein sorting regulators, secondary messengers and a transcription 
factor. The localisation of the products of these genes in the cell is summarised in 
Figure 5.4. It shows that the products of identified genes were a) transmembrane 
proteins which span the cell membrane (receptors (blue), ion channels (red) and 
structural proteins brown), b) membrane associated signalling proteins (purple), c) 
cytoplasmic proteins (blue), d) proteins that shuttle between the cytoplasm and the 
nucleus (yellow) and secreted proteins (green).
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Gene name, (accession number), 
description and cellular location
Mean fold- 
change and 
(standard 
deviation)
Possible function
AD0RA3 (NM_020683) Homo 
sapiens adenosine A3 receptor, 
transcript variant 1. G-protein 
coupled multipass cell membrane 
protein.
13.40 (1.98) Protein belongs to a family of adenosine 
receptors involved in a variety of intracellular 
signalling pathways, may mediate cell 
proliferation and cell death (EntrezGene). 
Possible role in reproduction (Swiss-Prot).
ARHGEF4 (NM_015320) Homo 
sapiens Rho guanine nucleotide 
exchange factor (GEF) 4, 
transcript variant 1. 
Cytoplasmic/peripheral 
membrane protein.
8.15 (2.33) Acts as a GEF for RhoA and RAC1 GTPases. May 
bind APC. The APC-ARGEF4 may be involved in 
cell migration as well as in E-cadherin mediated 
cell-cell adhesion (EntrezGene).
DOC1/CDK2AP1 (NM_182909) 
Homo sapiens downregulated in 
ovarian cancer 1. Specific CDK2- 
associated protein in the cytosol.
14.10 (1.84) Thought to negatively regulate CDK2 by 
sequestering monomeric CDK2 and targeting for 
proteolysis. Also found to interact with DNA 
polymerase alpha and suggests a role in DNA 
replication during the S phase of the cell cycle 
(EntrezGene).
GHRL (NM_016362) Homo 
sapiens ghrelin/obestatin 
preprohormone. Secreted.
6.90 (0.57) Generates ghrelin and obestatin. Ghrelin is the 
ligand for growth hormone secretagogue 
receptor type 1 (GHSR) which induces release of 
growth hormone from the pituitary. May play a 
role in appetite stimulation, induce adiposity and 
stimulate gastric acid secretion. Obestatin may be 
the ligand for GPR39, may reduce appetite 
(EntrezGene).
CACNA2D3 (NM_018398). Homo 
sapiens calcium channel, voltage- 
dependent, alpha 2/delta 3 
subunit. Cell membrane.
14.20 (1.98) A member of the alpha-2/delta subunit, a protein 
in the voltage-dependent calcium channel 
complex which mediates the influx of calcium 
ions into cells.
DPP6 (NMJL30797) Homo 
sapiens dipeptidyl-peptidase 6, 
transcript variant 1. Single-pass 
cell membrane protein.
13.25 (0.21) A single pass type II membrane protein which is a 
member of serine protease family. Has no 
detectable protease activity due to the absence 
of a conserved serine residue normally found in 
the catalytic domain of serine proteases 
(EntrezGene). May modulate cell surface 
expression and activity of the potassium channel 
KCND2 (Swiss-Prot).
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TRHR (NM_003301) Homo 
sapiens thyrotropin-releasing 
hormone receptor. G-protein 
coupled receptor. Cell membrane 
protein.
12.00 (2.55) Activates the inositol phospholipid-calcium- 
protein kinase C transduction pathway upon the 
binding thyrotropin-releasing hormone (TRH) 
which is a neuropeptide synthesised in the 
hypothalamus (EntrezGene).
LY6K (NM_017527) Homo sapiens 
lymphocyte antigen 6 complex, 
locus K. Secreted from the 
cytoplasm and cell membrane.
13.75 (1.20) May play a role in cell growth (Swiss-Prot).
DEFA6 (NM_001926) Homo 
sapiens defensin, alpha 6. 
Secreted.
9.60 (1.98) Defensins are microbicidal and cytotoxic peptides 
thought to be involved in host defense. They are 
abundant in granules of the neutrophils and the 
epithelia of mucosal surfaces (EntrezGene).
COL13A1 (NM_005203) Homo 
sapiens collagen, type XIII, alpha 
1, transcript variant 1. Single-pass 
type II cell membrane protein.
10.10 (0.99) The alpha chain of one of the nonfibrillar 
collagens (EntrezGene). Involved in cell-matrix 
and cell-cell adhesion interactions and binds 
heparin (Swiss-Prot).
KCNMA1 (NM_002247) Homo 
sapiens potassium large 
conductance calcium-activated 
channel, subfamily M, alpha 
member 1, transcript variant 2. 
Cell membrane protein.
7.00 (1.13) Potassium channel activated by both membrane 
depolarisation or increase inn cytosolic calcium 
that mediates export of potassium, thought to 
have numerous functions such as smooth muscle 
control and innate immunity (Swiss-Prot).
ETS1 (NM_005238) Homo sapiens 
v-ets erythroblastosis virus E26 
oncogene homolog 1. Transcption 
factor. Nucleus.
7.90 (0.14) Regulates numerous genes and are involved in 
stem cell development, cell senescence and 
death, and tumorigenesis. The conserved ETS 
domain within these proteins is a winged helix- 
turn-helix. DNA-binding domain that recognizes 
the core consensus DNA sequence GGAA/T of 
target genes (EntrezGene).
SNX15 (NM_147777) Homo 
sapiens sorting nexin 15 (SNX15), 
transcript variant B. Cytosol.
7.57 (0.64) Structural protein involved in the filamentous 
cross-bridging between microtubules and other 
skeletal elements (Swiss-Prot).
MAP1A 9 (NM_002373) Homo 
sapiens microtubule-associated 
protein 1A. Structural protein.
10.15 (2.62) Catalyzes the transfer of phosphatidylinositol and 
phosphatidycholine between membranes (in 
vitro). Binds calcium ions (SwissProt).
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PITPNM3 (NM_031220) Homo 
sapiens PITPNM fam ily member 3. 
Peripheral cell membrane 
protein.
12.45 (2.33) Cytokine with pro- and anti-inflammatory 
processes that can regulate T-helper 
development, suppress T-cell proliferation, 
stimulate cytotoxic T cell activity, drives rapid 
clonal expansion of naive CD4 T-cells. it binds to 
the cytokine receptor WSX-1/TCCR. Has 
antiangiogenic properties by activating 
antiangiogenic chemokines (Swiss-Prot).
EBI3 (NM_005755) Homo sapiens 
Epstein-Barr virus induced gene 3. 
Secreted.
13.75 (3.32) Binds caspases (EntrezGene) and supresses 
apoptosis by activation of MAPK8/JNK1 (Swiss- 
Prot).
BIRC7 (NM_022161) Homo 
sapiens baculoviral IAP repeat- 
containing 7. Nucleus and 
cytoplasm.
12.10 (0.00) May play a role in apoptosis, expression is 
modulated by cytokines in natural killer cells 
(Swiss-Prot).
PDCD4 (NM_013385) Homo 
sapiens pleckstrin homology, Sec7 
and coiled-coil domains 4.
Nucleus and cytoplasm.
13.53 (2.07) Protein is localised to the nucleus in proliferating 
cells, expression of the gene is modulated by 
cytokines in natural killer and T cells, may play a 
role in apoptosis but the specific role is not yet 
determined (EntrezGene).
Table 5.3: Known functions of up-regulated genes
Table of up-regulated genes for which proposed functions and cellular locations of the 
proteins they encode were found using the EntrezGene and Swiss-Prot databases (via 
www.genecards.org). The mean fold changes n number is 2 with the exception of 
SNX15 where n=3.
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Figure 5 A: Representation of cellular location of up-regulated genes with 
known function
Diagram show ing the  p robab le ce llu la r loca tion o f >5 fo ld  up -regu la ted  gene p roducts  in Ishikawa ce lls 
fo llow ing  ad d ition  o f CXCL12. P rote ins o f fu n c t io n a lly  s im ila r type  o r  ce llu la r loca t ion are a ttr ib u te d  th e  
same co lours.
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5.6 Discussion
The aim of performing genome-wide expression profiling in response to the addition of 
CXCL12 to Ishikawa cells was to identify previously unknown effects of CXCL12 and 
relate these effects to the possible role of CXCL12/CXCR4 in endometrial function. By 
using highly stringent P values to remove false-positives and comparing experimental 
repeats to assess potentially inaccurate results, both known and unknown gene 
transcripts were found to be significantly up-regulated following addition of CXCL12 for 
at a concentration of 5 ng/ml for 24 hours.
The study identified a total of 51 genes transcripts that were shown to be up-regulated 
greater than 5 fold in two or more experimental repeats, of which 14 were unknown 
genes transcripts. There were 37 known genes transcripts identified to be up- 
regulated by CXCL12 for which further functional information could be potentially 
identified. Using the stated criteria, CXCL12 was not found to down-regulate the 
expression of any transcripts in the Ishikawa cell line. Ideally the change in expression 
of these genes in the presence of CXCL12 should have been confirmed by real-time RT- 
PCR with specific primers for these genes, but time did not allow these experiments to 
take place.
A review of the literature has suggested that the known transcripts found to be up- 
regulated by addition of CXC12 and assigned a general function, several are of 
potential importance to female reproductive function and endometrial function.
5.6.1 Ghrelin
Ghrelin is a multifunctional hormone with both paracrine and autocrine capacities, 
that is known to be involved in the control of growth and metabolism. It acts via the 
growth hormone secretagogue receptor (GHSR) to stimulate growth hormone (GH) 
from the pituitary gland. Both the ligand and receptor are present in the pituitary and 
hypothalamus. It is also found in high levels in the stomach and many peripheral 
tissues including the uterus (Kojima et al., 2001 and Tawadros et al., 2007). Expression 
of ghrelin and its receptor has been demonstrated in the human endometrium, with 
both ghrelin and GHSR expression highest in the secretory phase of the cycle and 
lowest during menses. Ghrelin appears to be confined to the glandular epithelium and
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stromal cells it has been suggested that it may be important in the process of 
decidualisation (Tawadros et al., 2007). The potential importance of ghrelin in the 
process of decidualisation is further supported by its increase in decidualised 
endometrium in comparison to non-pregnant endometrium (Tanaka et al., 2003). In 
mice, ghrelin has been shown to be present in the endometrium and in the embryo at 
both the morula and more advanced embryonic developmental stages. In vitro 
addition of ghrelin was found to inhibit embryo development, an effect which was 
abolished following addition of a GHSR antagonist. Ghrelin is thought to act as a 
modulator of feeding behavior and metabolism in the central nervous system and 
increased levels of ghrelin were identified in the uterine fluid of fasting mice in 
comparison to those with free access to food (Kawamura et al., 2003). Although the 
distribution of ghrelin might suggest an important role in pregnancy, a recent study 
which investigated ghrelin levels in early failed and successful pregnancies following 
IVF treatment found it to be of no prognostic value (Vidal et al., 2008). No studies to 
date have reported the ability of CXCL12 to up-regulate ghrelin in any cell type, but 
confirmatory studies are needed before conclusions can be made.
5.6.2 Adenosine A3 receptor
There is no existing available evidence that the adenosine A3 receptor (ADORA3) is 
expressed in the endometrium or that CXCL12 can modulate its expression, but 
ADORA3 expression has been identified in trophoblast and shown to be upregulated in 
preeclampsia. Increased expression of ADORA3 has been shown in both normal and 
preeclamptic villous explants in low oxygen conditions. Addition of an ADORA3 agonist 
in preeclamptic villous explants was found to increase MMP2 and 9 in a dose- 
dependent manner in low oxygen conditions (Kim etal., 2008a). This microarray study 
has identified the presence of ADORA3 mRNA in an endometrial epithelial cell line and 
demonstrated increased expression in response to CXCL12. As trophoblast expresses 
both CXCL12 and ADORA3, it is possible that CXCL12 could influence ADORA3 in this 
tissue as well as the endometrium. The ability of ADORA3 to influence MMP 
expression is of potential interest because of the importance of MMPs in controlling 
trophoblast invasion into the receptive endometrium.
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5.6.3 Cyclin-dependent kinase 2-associated protein 1
The tumour suppressor gene, cyclin-dependent kinase 2-associated protein 1 
(CDK2AP1) is an inhibitor of cyclin-dependent kinase 2 (CDK2) and therefore prevents 
the Gl/S transition of the cell cycle. Disruption of this gene in mice leads to embryonic 
lethality and suggests a role for CDK2AP1 in the early stages of embryogenesis (Kim et 
al., 2008b). In the human, CDK2AP1 has been detected in the endometrium where it is 
largely found in the epithelium and known to be induced by the presence of 
progesterone (Cheon and Kim, 2010). Endometrial tissue goes through a series of cell 
proliferations during the menstrual cycle and CDK2AP1 may play a role in this process.
5.6.4 EB!3/interleukin 27
IL27 is a heterodimeric cytokine that is formed by the association of the cytokine 
subunit p28 with EBI3 which is a glycosylated protein related to the p40 subunit of 
IL12. Its expression has been shown in first trimester placenta and in 
syncytiotrophoblast and extravillous trophoblast. It has been shown to have the ability 
to act on CD4+ T cells, NK cells, macrophages and endothelial cells. It is proposed to 
function to regulate local immune responses and angiogenesis during human 
pregnancy (Coulomb-L'Hermine et al., 2007 and Devergne et al., 2001). IL27 is thought 
to be an important regulator of the T helper cell responses and in a mouse model of 
asthma has been shown to be involved in attenuating the Th2response (Fujita et al.,
2009). CXCL12 through IL27 may therefore have a role in cytokine balance which is 
thought to be important in pregnancy outcome (Laird eta!., 2003).
5.6.5 Signaling and transcription factors
This microarray study identified two factors which are known to be involved in the 
control of downstream CXCL12/CXCR4 signaling. The mRNA for the transcription 
factor E26 transformation-specific 1 (Etsl) was found to be upregulated by CXCL12 in 
the Ishikawa cell line. The Ets family members contain a highly conserved region of 85 
amino acids which is termed the Ets domain which binds purine rich core sequences 
(GGAA/T) in promoter and enhancer regions of target genes. Known Ets target genes 
include cytokines such as granulocyte-macrophage-colony-stimulating factor (GM- 
CSF), interleukin 12 (IL12) and IL1; apoptosis related genes and many matrix
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metalloproteinases (MMPs). Experiments in mice initially suggested the Ets genes were 
limited to controlling tissues undergoing morphogenesis and tissue remodeling but 
more widespread expression has since been identified (Kilpatrick et al., 1999).
In the human endometrium, it has been suggested that Etsl expression plays a critical 
role in the control of decidualisation where it has been shown that inhibition of Etsl 
caused down-regulation of mRNAfor specific decidualisation markers such as prolactin 
and insulin growth factor binding protein 1 (IGFBP-1) (Kessler et al., 2006). Etsl and 2 
has been identified in endometrial glandular and luminal epithelium and expression 
has been shown to be low during menses and higher during the late secretory phase of 
the menstrual cycle at the time of decidualisation (Kilpatrick et al., 1999). The mRNA 
for Etsl has also been identified in the endothelial cells of villous and extravillous 
trophoblast where the expression has been linked to the control of angiogenesis 
(Luton et al., 1997) which is one of the known functional effects of Ets outside of the 
endometrium (Lelievre et al., 2001). There is evidence in the developing spinal cord 
that CXCL12/CXCR4 causes rapid activation of extracellular signal-related kinase 1/2 
(ERK 1/2) and Etsl, which is a substrate for ERK phosphorylation. This demonstrates 
the possibility of CXCR4/ERK/Etsl linked signaling though this has not been 
demonstrated in other tissues (Luo et al., 2005). Alternative phosphorylation on one 
of two potential sites on Etsl has been shown to cause activation or inhibition of the 
transcription factor suggesting one potential means of creating differential regulation 
of gene expression of MMPs and VEGFs (Dittmer etal., 2003).
Programmed cell death factor 4 (PDCD4) mRNA was also shown to be up-regulated in 
response to addition of CXCL12 to Ishikawa lines. A study in leukaemic B cells 
identified PDCD4 as a previously unknown chemokine signaling target where CXCL12 
was shown to cause PDCD4 phosphorylation and subsequent inhibition of the 
transcription factor AP-1 which is a target of the Akt signal pathway (Hayre et al.,
2010). This effect remains unstudied in other cell types and combined with the 
upregulation of PDCD4 mRNA in Ishikawa cells may represent potential CXCL12/CXCR4 
signaling routes in the endometrium.
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5.6.6 Other factors
There is currently limited evidence for the potential involvement of other factors 
identified as responding to CXCL12 in terms of potential reproductive and endometrial 
function. However, expression of calcium-activated potassium channel KCNMA1 has 
been shown in the segments of the myometrium where it is postulated to play an 
important role in uterine contractility during pregnancy in humans (Gao et al., 2009). 
There is no evidence currently available of a role defensin alpha 6 (DEFA6) in the 
endometrium but it is an antimicrobial peptide which is linked to human host defense 
(Koslowski et al., 2010). It is conceivable that endometrial epithelium may secrete this 
protein for this reason. Microtubule associated protein 1A (MAP1A) has been shown 
to play a role in promoting cell adhesion in vitro in cell lines by controlling integrin 
activity (Gupta et al., 2006). This could therefore be an important factor in the control 
of integrin mediated attachment of the blastocyst to the luminal epithelium during the 
process of implantation.
5.6.7 Limitations
A limitation of this microarray study is the use of Ishikawa adenocarcinoma cell lines to 
study the effects of CXCL12, which may not accurately represent the in vivo function of 
epithelial cells in the endometrium. We initially chose this cell line rather than primary 
cells because of the ease of carrying out these complex experiments. The intention 
was to repeat the work on primary cells. However the amount of time needed to 
analyse the data was much greater than anticipated and time did not permit the 
repeat of the experiment. The Ishikawa cell line expressed CXCR4 comparable to that 
in cultured primary epithelial cells and does not express CXCL12, making it useful for 
this analysis (Tsutsumi et al., 2011). However levels of IL6, IL8, MMP2 and MMP9 
expression were lower (see Chapter 4). The up-regulated genes identified in this study 
can in several cases be related to normal endometrial function where the information 
is available. Validation of the effects identified at both the mRNA and protein level in 
primary endometrial cells and endometrial biopsies are needed to confirm the results, 
but if confirmed this would suggest a role for CXCL12 in endometrial function.
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5.6.8 Summary
CXCL12 was shown to affect the mRNA expression of numerous genes in the 
endometrium. The effects have not previously been identified in the endometrium. 
Further work is needed to confirm the observations but the study generates several 
testable hypotheses (Table 5.4) relating to the potential functions of CXCL12 in the 
endometrium and its regulatory effects
In summary this microarray study has identified both known gene transcripts and 
unknown gene transcripts that respond to CXCL12 in Ishikawa cells, which in several 
cases can be related to current understanding of normal endometrial function. The 
study revealed information on the potential signal pathways through which these 
effects may occur and also identified possible previously unknown effects of the 
CXCL12 and its receptor CXCR4 to activate the transcription of a number of factors that 
has not previously been demonstrated in any tissue type.
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CXCL12 source and 
CXCR4 location
Hypothesis Potential investigative 
techniques
Stromal/ epithelial 
CXCL12 binding 
epithelial CXCR4
CXCL12 promotes endometrial cell 
proliferation potentially via lymphocyte 
antigen 6 complex during the early 
proliferative phase of the menstrual 
cycle.
Primary cell culture, real-time 
RT-PCR
immunohistochemistry/ELISA, 
cell proliferation study.
Stromal/blastocyst 
CXCL12, epithelial 
CXCR4
CXCL12 regulates production of 
ghrelin/obestatin in endometrium 
during early proliferative and/or mid 
secretory endometrium.
Primary cell culture, real-time 
RT-PCR, 
immunohistochemistry/ELISA.
Stromal/blastocyst 
CXCL12, epithelial 
CXCR4
CXCL12 induces production of defensin 
alpha six as part of the non specific 
immune response during early 
proliferative and/or mid secretory 
endometrium.
Primary cell culture, real-time 
RT-PCR, 
immunohistochemistry/ELISA.
Stromal/blastocyst
CXCL12,
epithelial/stromal
CXCR4
CXCL12 alters endometrial gene 
expression via the ETS1 transcription 
factor.
Cell culture, signal pathway 
analysis.
Stromal/blastosyst
CXCL12,
epithelial/stromal
CXCR4
CXCL12 regulates calcium and potassium 
channel activity in endometrial cells.
Cell culture, real-time RT-PCR, 
immunohistochemistry.
Table 5.4: Summary of some of the hypotheses generated from microarray 
experiments
The table summarises potential hypotheses for the functions of CXCL12 in the 
endometrium generated by the microarray experiments.
2 1 1
Chapter 6 
General Discussion
6.1 Introduction
The function of the endometrium is to accept the implanting embryo and to give rise 
to the maternal side of the placenta, which supports the developing embryo and fetus 
during pregnancy. Abnormalities in endometrial function result in reproductive failure 
which manifests itself as infertility and recurrent miscarriage. Therefore an increased 
understanding of endometrial function is important and in the long term might provide 
alternative treatments to women who suffer these conditions.
Although the endometrium is under the control of the steroid hormones progesterone 
and oestradiol, many local factors are important in bringing about the effects of these 
hormones in the endometrium. CXCL12 and its receptor CXC4 has been implicated in 
the control of trophoblast cell growth and function. However little is known about its 
expression and action in the endometrium. The aim of this study was therefore to 
investigate the potential role of CXCL12 and CXCR4 in human endometrium.
This study adopted two main approaches to investigate further the function of the 
chemokine ligand CXCL12 and its receptor CXCR4 in the human endometrium. The 
first was a targeted approach which examined the in vivo expression of CXCL12 and 
CXCR4 through the menstrual cycle coupled with an investigation into the in vitro 
effects of CXCL12 on IL6, IL8, MMP2, MMP9 and VEGFA in human endometrial cells in 
culture. These factors had previously been established as of importance to 
endometrial function and CXCL12 had been shown to affect their expression in non- 
endometrial tissues but had not been previously investigated in the endometrium 
itself. CXCR7 was not studied because at the time the work was carried out, it was not 
a known receptor for CXCL12 and signaling still remains controversial (Mahabaleshwa 
et al., 2008). The precise functions of CXCL12 and CXCR4 remain unknown in the 
endometrium and evidence in many different tissues suggests a wider role for 
chemokines and their receptors beyond the chemotatic recruitment of leukocytes to 
sites of inflammation. To investigate this, the effects of in vitro addition of CXCL12 to 
endometrial cells and genome-wide microarray expression analysis was used to
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identify differential expression of gene transcripts in response to CXCL12 to further 
establish its potential effects in the endometrium.
6.2 Techniques used
This study focused on the measurement of mRNA levels in endometrial tissues and cell 
types to gain further information on the role of CXCL12 and CXCR4 in the endometrium 
but complementary protein studies were also carried out in our laboratory (Laird etaL,
2011). Measurement of mRNA levels in a cell allows the rapid analysis of transcript 
expression from just one gene right through to the entire genome of an organism 
giving mRNA based assays an enormous range of flexibility and power to reveal 
valuable new information on the physiological processes that occur within cells. The 
expression levels of mRNA in a cell do not necessarily relate to levels of protein 
produced due to regulatory processes at the translational level and a complete 
understanding of how cells function requires investigation of the processes that 
control the transcription of a gene through to its activity as functional proteins 
structures and must take into account the regulatory processes in between. This 
requires both mRNA and protein based molecular biology techniques to achieve this.
This study used real-time RT-PCR and gene expression microarray analysis to 
investigate the expression of CXCL12 and CXCR4 in the endometrium and the potential 
effects of CXCL12 on endometrial function. The techniques can accurately and 
reproducibly measure mRNA levels, but due to their complexity several steps must be 
taken to maintain their validity. This included the use of high quality RNA where 
possible, which was accurately quantified and of great importance to the success and 
validity of Real-Time RT-PCR and microarray experiments. Reference genes were used 
to quantify transcript levels using Real-Time PCR and stringent attempts were made to 
ensure the stability of the reference transcript between samples. Retrospective 
analysis found that HEC-l-B cells consistently expressed higher levels of YWHAZ 
compared to the other cell types used. Therefore, a more rigorous initial study of 
reference genes could have been useful.
The study of the endometrium in vivo in humans is limited because of the difficulty in
obtaining human tissue, or manipulating the tissue in vivo and therefore various
methods of indirect study are used to help understand its function. The use of cell
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culture systems is one approach that may provide important information into the 
control of endometrial cells. Two types of endometrial cell cultures were used: an 
established primary cell culture system where endometrial epithelial and stromal cells 
are separated from endometrial tissue and plated at a high density to establish 
confluency within 5 days (Cork et al., 2002; Laird et al., 1993 and Tuckerman et al., 
2000) and endometrial cell lines. The advantage of using cell lines is their ready 
availability; in contrast primary cell culture requires recruitment of suitable volunteers 
and ethical committee approval. However, this study showed that the Ishikawa and 
HEC-l-B cell lines did not show comparable mRNA expression profiles of important 
factors, such as cytokines and chemokines, MMPs and growth factors in comparison to 
their primary epithelial cell counterparts exhibiting very low expression of several of 
these factors. These results show that considerable care should be taken in relating 
the findings in cell lines directly to the functions of the endometrium.
6.3 Expression of CXCL12 and CXCR4 in the endometrium
Available information on the expression of CXCL12 and CXCR4 in the endometrium is 
limited. No previous studies have identified the presence of CXCL12 throughout the 
menstrual cycle in non-pregnant human endometrium, although its presence in 
monkey and bovine endometrium has been reported (Ace and Okuliez, 2004 and 
Mansouri-Attica et al., 2009). This study identified the presence of CXCL12 mRNA in 
human endometrium throughout the menstrual cycle that was low in comparison to 
the reference gene used and did not significantly alter during any phases of the cycle.
CXCR4 mRNA was also shown to be expressed in human endometrium throughout the 
menstrual cycle. The expression levels were found to be significantly higher in the 
early proliferative phase of the cycle in comparison to all other phases except the mid 
secretory. There was an apparent increase in CXCR4 levels during the mid secretory 
phase of the cycle in comparison to the early and late secretory phases but this was 
not found to be significantly different to other phases of the cycle. The expression of 
CXCR4 mRNA through the normal menstrual cycle has previously been studied by 
Dominguez et al. (2003). The study identified an apparent decrease in CXCR4 mRNA 
expression through the proliferative phase of the cycle that was in general agreement 
with our findings, though the decrease was of a lower magnitude. Dominguez et al.
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(2003) showed a significant increase in the levels of CXCR4 mRNA during the mid 
secretory phase of the cycle when the endometrium becomes receptive to the 
blastocyst. While the present study did show an apparent small increase in the levels 
of CXCR4 mRNA at this time, the difference was not found to be significant and 
expression levels were considerably lower than those of the early proliferative phase. 
The present study used twice the number of samples to obtain the data which could 
contribute to the differences observed between the studies. However, a decrease in 
the levels of CXCR4 mRNA through the proliferative phase of the menstrual cycle and 
an increase in CXCR4 during the mid secretory phase appear to be common factors 
between both of the studies.
As the ex vivo approach of quantifying the levels of CXCL12 and CXCR4 mRNA levels in 
the endometrium did not discriminate between the different cell types present within 
the samples obtained, primary cell cultures of endometrial epithelial and stromal cells 
were used to investigate the distribution of CXCL12 and CXCR4 between these cell 
types. The results showed that CXCL12 mRNA was found in both cell types studied at 
low levels in comparison to the reference gene used and there was no significant 
difference in the expression of the chemokine mRNA between the cell types. Levels of 
CXCR4 mRNA were found to be approximately equivalent to the reference gene used 
and while epithelial cell levels of CXCR4 mRNA appeared to be approximately twice 
that of the stromal cells, the levels of expression were shown not to be significantly 
different from one another. These findings suggest that endometrial epithelial and 
stromal cells are likely to be major sources of CXCL12 and CXCR4 in the endometrium 
and that this may relate to their endometrial functions. However CXCR4 is expressed 
by leucocytes and in particular NK cells, which are also present in the endometrium. 
Therefore immunohostochemical studies, which can identify the cell type from which 
expression originates, need to be carried out to show more conclusively precisely 
which cells express both CXCL12 and CXCR4.
6.4 Expression of IL6, IL8, MMP2, MMP9 and VEGFA by endometrial cells 
in vitro
The presence of mRNA transcripts for IL6, IL8, MMP2, MMP9 and VEGFA were 
identified in the Ishikawa, HEC-l-B, primary epithelial and stromal cell cultures used in
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this study. Comparison of the levels of these transcripts between primary epithelial 
and stromal endometrial cells identified significant differences in their expression 
which may relate to their endometrial function. IL8 expression was found to be 
significantly higher in the endometrial epithelial cells. This result is in agreement with 
other studies which have shown endometrial expression of IL8 (CXCL8) to be highest in 
the epithelium of the endometrium and further demonstrates its potential role in the 
recruitment of leukocytes to the endometrium through the menstrual cycle (Arid et 
al., 1998b and Garcia-Valesco and Arid, 1999). MMP9 mRNA expression was found to 
be significantly higher in the epithelial cells which is in agreement with studies such as 
that by Jeziorska et al. (1996), which showed expression of MMP9 at the protein level 
to be present in the luminal and glandular epithelium of the endometrium. VEGFA 
mRNA expression was also found to be significantly higher in the epithelial cells which 
is in agreement with studies such as that by Punyadeera et al. (2006). While the 
identification of differential expression of these factors between endometrial epithelial 
and stromal cells can be demonstrated, attributing function to them purely on the 
basis of their abundance is probably over-simplistic in terms of what functions they 
may play in the endometrium. All these factors will bring about their effects via 
specific cell surface receptors and therefore the distribution of their receptors is of 
equal importance when considering the function of these molecules in the human 
endometrium.
6.5 Effect of CXCL12 on the expression of IL6, IL8, MMP2, MMP9 and 
VEGFA
The overall aim of this study was to identify the functions of CXCL12 and its receptor 
CXCR4 in the endometrium and once mRNA expression of both the chemokine and its 
receptor throughout the menstrual cycle was established, likely targets for its effects 
had to be identified. While the microarray study employed a genome-wide approach 
to providing more information on the function of CXCL12 and CXCR4 in the 
endometrium, this part of the study used a targeted approach using the available 
current information to directly target factors that may be affected.
This study could not identify any significant alterations in the mRNA expression of IL6, 
IL8, MMP2, MMP9 or VEGFA in response to addition of 10 and 100 ng/ml of
216
recombinant CXCL12 for 24 hours in any of the cell culture types used. These 
transcripts were chosen for investigation because they are all factors which are 
established as being of importance to the control of endometrial function, have been 
shown in several non-endometrial cell types to respond to CXCL12 and have not 
previously been investigated in the endometrium in this respect.
The results suggested that CXCL12 might increaselL6 and MMP9 mRNA in primary 
epithelial cell cultures, but differences between control cells and cells incubated with 
CXCL12 were not significant. It is possible that CXCL12 does not play a role in the 
regulating the expression of IL6, IL8, MMP2, MMP9 and VEGFA in endometrial cells. 
Our studies have shown that the receptor for CXCL12 (CXCR4) is expressed by all cell 
types; therefore lack of expression of the receptor is unlikely to be a reason for a lack 
of response to CXCL12. However it is possible that binding of CXCL12 to its receptor 
may activate different signaling pathways to those operating in other cell types leading 
to the regulation of different genes in the endometrium.
6.6 Microarray analysis
The microarray study identified 51 gene transcripts that were greater than 5-fold 
upregulated in response to CXCL12 treatment at 5 ng/ml for 24 hours in two or more 
experimental repeats. In the remaining experimental repeats, it could be 
demonstrated that the features representing a transcript were compromised by 
factors such as poor hybridization, feature saturation or high background meaning P 
values could not be accurately generated and were attributed a value of P=1.00 by the 
feature extraction software. There were no cases of a transcript showing a conflicting 
and significant result and highly stringent P values were used to attribute significance 
to remove the possibility of a false-positive result occurring.
While the targeted Real-Time RT-PCR experiments could not identify any effects of 
CXCL12 on the targets chosen, the microarray experiment showed that addition 
CXCL12 to Ishikawa cell lines did significantly alter mRNA expression strongly 
suggesting the cell culture systems were functional.
The microarray analysis was carried out in Ishikawa cell lines, which this study itself 
demonstrates do not necessarily represent the likely in vivo situation due to their
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cancerous nature. However, Ishikawa cells did show similar levels of CXCR4 expression 
to their primary epithelial cell counterparts. The use of cell lines gives the advantages 
of an easily accessible and reproducible source of high quality RNA which is essential 
for successful and accurate microarray analysis. In this case where the effects of 
CXCL12 alone are investigated, it provides a useful tool for revealing entirely new 
information about transcripts that can be potentially affected by CXCL12.
Of the 51 gene transcripts identified in this study found to respond to CXCL12,14 were 
unknown transcripts and 37 were known transcripts to which potential functions could 
be attributed. However, before drawing definite conclusions the data needs to be 
verified both by using real-time RT-PCR for individual transcripts and confirming effects 
at the protein level by western blotting. While many of these transcripts remain 
unstudied in the endometrium and in most cases have not been previously shown to 
be affected by CXCL12 in any cell type, the accuracy of the data generated is supported 
by the identification of factors such as ghrelin, cyclin-dependent kinase 2-associated 
protein 1 (CDK2AP1), EBI3/IL27 and Etsl, which are known to be expressed in the 
endometrium and are implicated in playing important roles in its function. Further to 
this, programmed cell death factor 4 (PDCD4) was shown to be upregulated by CXCL12 
and has recently been identified as playing a role in the control of CXCR4-dependent 
cell signaling (Hayre et al., 2010).
6.7 Signaling pathways
The currently available evidence strongly suggests that CXCL12 can elicit 
multifunctional effects through its receptor CXCR4 (Busillo and Benovic, 2007). While 
CXCL12 has been shown to increase the expression of IL6, IL8, MMP2, MMP9 and 
VEGFA in non-endometrial cell types (see Chapter 4), this effect apparently does not 
occur in the endometrial cell types used in this study. Furthermore, genome wide 
analysis of transcripts in the Ishikawa cell line demonstrated the increase of numerous 
factors previously unknown to be affected by addition of CXCL12 in any cell type.
The likely explanation of how CXCL12 can exert these varying effects is by activating
different intracellular signal transduction pathways in different cell types. CXCR4 has
been shown to have the capacity to activate both the MAPK/ERK1/2 and PI3K/Akt
signal pathways both of which can cause activation of nuclear-factor kappa B (NFKB)
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and cause transcription of NFKB responsive genes (Chinni et al., 2006; Huang et al., 
2009 and Tang et al., 2008). CXCL12 binding of CXCR4 has also been shown to activate 
the transcription factors Etsl (Bu et al., 2005; Grund et al., 2005; Jinnin et al., 2005 and 
Liu et al., 2006), which was shown to be up-regulated by CXCL12 in our microarray 
study. The transcription factor API can also respond to CXCR4-dependent 
MAPK/ERK1/2 signaling (Liu et al., 2006), an effect that has recently been shown to be 
blocked by PDCD4 (O'Hayre et al., 2010), which was another of the transcripts shown 
to be increased by addition of CXCL12 to the Ishikawa cell line in the microarray study 
(Figure 6.1).
The activation of NFKB via the MAPK/ERK1/2 and PI3K/Akt signal transduction 
pathways has been shown to cause the up-regulation of IL6 (He et al., 2008 and 
Tagashira et al., 2009)), IL8 (Chen et al., 2008), MMP2 (Chang et al., 2007 and Zhang et 
al., 2010), MMP9 (Van Themsche et al., 2007 and Zhang et al., 2010) and VEGF (Kazi 
and Koos, 2007) in endometrial cell types. However, addition of CXCL12 did not cause 
up-regulation of the mRNA for these factors in the endometrial cell types investigated 
in this study, despite this effect being shown in other cell types. In the case of MMP9 
(Chinni et al., 2006) and VEGF (Liang et al., 2007) the effect of CXCL12 has been shown 
to occur specifically through the PI3/Akt pathway.
It is possible that CXCL12/CXCR4 may act through additional signal transduction 
pathways to cause its cellular effects. For example the Etsl transcription factor was 
found to be up-regulated in Ishikawa cell line in response to CXCL12. This factor has 
been shown to be of importance to endometrial function especially with respect to 
process of decidualisation (Kessler et al., 2006). Etsl may represent a means of 
alternate signaling through ERK1/2 and may provide an explanation to why CXCL12 did 
not affect the expression of IL6, IL8, MMP2, MMP9 and VEGFA. Furthermore, 
CXCL12/CXCR4 has recently been shown to cause signaling via the transcription factor 
API. This effect has been shown to be blocked by phosphorylation of PDCD4 (O'Hayre 
et al., 2010), which was also up-regulated in response to CXCL12 in the microarray 
experiment and further highlights the multiple possibilities of CXCL12/CXCR4 signal 
transduction. Activation of different pathways may depend on the many factors 
including the oligomerisation state of CXCL12 and its potential interactions with 
giycosaminoglycans; glycosylation of CXCR4's external structure (Majka et al., 2000
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and Wysoczynski et al., 2005); tyrosine sulfation of CXCR4's external structure (Farzan 
et al., 2002); homo- and hetero-dimerisation of CXCR4 (Babcock et al., 2003; 
Basmaciogullari et al., 2006 and Issafras et al., 2002) and phosphorylation patterns of 
CXCR4/s internal receptor structure (Krupnick et al., 1998).
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Figure 6.1: Schematic representation of the potentially important
CXCL12/CXCR4 dependent signal transduction pathways in endometrial cells. 
Compiled from Bu et al., 2006; Chinni et al., 2006; Huang et al., 2009; Jinnin et al., 
2005; Liu et al., 2006 and O'Hayre et al., 2010.
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6.8 Proposed functions of CXCL12 and CXCR4 in the endometrium
The precise functions of CXCL12 and CXCR4 remains unknown but it seems clear that 
their roles in the human are likely to be multifunctional (Bussilo and Benovic, 2007). 
Previous studies of CXCR4 in the endometrium focused on the implantation window 
when the endometrium becomes receptive to the blastocyst suggesting possible roles 
in the regulation of cross-talk between the endometrium and blastocyst during 
apposition and subsequent invasion of the trophoblast (Dominguez et al., 2003). The 
potential of CXCL12 to recruit uNK cells to the endometrium and decidua during 
pregnancy has also been considered (Wu et al., 2005).
This study showed that CXCR4 is most highly expressed during the early proliferative 
phase of the menstrual cycle and while increased levels of CXCR4 could be observed at 
the time of endometrial receptivity, the expression levels of CXCR4 at this time was 
significantly lower than during the early proliferative phase. This suggests that while 
CXCR4 expression could be of importance in the process of implantation, it is likely to 
have important endometrial functions during the early proliferative phase of the 
menstrual cycle. During the proliferative phase of the cycle the endometrium is lost 
during menses and then undergoes a phase of rapid growth and differentiation phase 
as endometrial thickness increases. Therefore it is reasonable to suggest that CXCR4 
may play a role in the processes that occur at this time in both endometrial epithelial 
and stromal cells, which could include regulation of angiogenesis, cell proliferation and 
differentiation. A recent study shows the potential for CXCL12 and CXCR4 to fulfill this 
role as the chemokine ligand was found to cause proliferation in Ishikawa cell lines 
(Tsutsumi et al., 2011).
CXCL12 was found to be expressed at the mRNA level throughout the cycle but its 
expression did not change during menstrual cycle phases, which has not previously 
been shown and is in agreement with unpublished protein studies from our laboratory. 
This suggests that CXCR4 expression is regulated independently of CXCL12 as they 
show different expression profiles. There is evidence that CXCR4 may be regulated by 
oestrogen either directly or indirectly and both this and Dominguez's study (2003) 
showed a decrease in CXCR4 mRNA expression as oestrogen increases through the 
proliferative phase of the cycle.
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Recruitment of leukocytes and particularly uNK cells seems like an unlikely function of 
CXCL12 in the endometrium as there is a large increase in the numbers of leukocytes 
and particularly uNK cells in the endometrium during the secretory phase of the cycle. 
If CXCL12 was important in recruiting uNK cells to the endometrium an increase in 
CXCL12 levels would be expected during the secretory phase of the cycle but this was 
not observed.
The microarray study identified possible new effects of CXCL12 and showed that 
CXCL12 could increase the expression of unidentified genes, genes for which there is 
no available information in the endometrium and genes such as ghrelin and Etsl which 
have been been linked to endometrial processes such as decidualisation and 
angiogenesis. Also, several factors such as EBI3, BIRC7 and PDCD4 were identified as 
being upregulated at the mRNA level by CXCL12. These factors could potentially play 
roles in controlling cell proliferation and apoptosis in the endometrium. Coupled with 
the knowledge that CXCR4 mRNA expression is maximal in the endometrium during 
the proliferative the early proliferative phase of the cycle when the endometrium is 
undergoing rapid growth and CXCL12 has been shown to act as a growth factor in 
Ishikawa cells (Tsutsumi et al., 2011), it may be the case that CXCL12 acts as a 
paracrine growth factor in the endometrium.
Many investigations into the functions of CXCL12 and CXCR4 in the human have 
focused on the roles of the receptor CXCR4 in HIV infection and in the metastases of 
many types of cancer (Busillo and Benovic, 2007). While normal physiological roles 
have received less attention, studies in cancer cells have suggested that CXCL12 and 
CXCR4 may be important in controlling the spread of cancer cells throughout the body 
(Kucia et al., 2005). It is thought that CXCR4 positive cancer cells are recruited to 
tissues by the presence of a CXCL12 gradient, causing the infiltration and 
establishment of cancer cells within new tissues and allowing secondary tumour 
development (Gargett, 2006; Gargett et al., 2009 and Maruyama et al., 2010). This 
process has been linked to an emerging physiological role for CXCL12 and CXCR4 in the 
recruitment of stem cells to tissues where they are required throughout the body. 
CXCR4 is a known stem cell marker and it has been suggested that a CXCL12 gradient 
could be responsible for recruiting stem cells to tissues and has been shown to occur in 
the pathological metastases of cancer cells (Figure 6.2).
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The endometrium has a remarkable regenerative capacity, cycling through periods of 
rapid proliferation, differentiation and shedding. It is thought that adult 
stem/progenitor cells reside within the endometrium to allow this process to occur. 
There are several pieces of indirect evidence suggesting the presence of stem cells in 
the endometrium and while adult stem cells provide few markers to distinguish them 
from other cell populations, methods are being established to specifically identify their 
presence and function in the endometrium. It is conceivable that a constant level of 
CXCL12 expression in endometrial tissues may play a role in recruiting and maintaining 
the presence of adult stem/progenitor cells in the endometrium throughout the cycle.
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Figure 6.2: Diagram showing the potential of CXCL12 to recruit metastatic 
cancer cells and adult stem cells via CXCR4. (Taken from Kucia et al., 2005)
A parallel between the recruitment of stem cells via CXCL12 gradients and cancer cell 
metastasis can be made.
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6.9 Future studies
A number of further studies need to be carried out to confirm the findings of this study 
and establish a role for CXCL12 and CXCR4 in the human endometrium. Validation of 
the effects of CXCL12 seen in the analysis of the microarray data from the Ishikawa cell 
lines needs to be carried by repeating this type of analysis in primary epithelial and 
stromal cells and the hypotheses summarised in Table 5.3 could be tested using the 
techniques suggested. Effects of CXCL12 on factors that are shown to be altered in the 
primary cell cultures needs to be confirmed by further real-time RT-PCR and protein 
studies using western blotting, immunostaining or analysis of secreted protein. 
Identification of the signaling pathways through which CXCL12/CXCR4 is functioning in 
the endometrium, could be studied, particularly in primary cell cultures using western 
blotting with antibodies specific for phosphorylated signaling proteins. Attempts could 
be made to represent the in vivo endometrium more accurately in cell culture 
experiments. For example, inclusion of steroid hormones may represent the in vivo 
endomtrium more accurately. A co-culture of endometrial epithelial and stromal cells 
may be able to determine the direction of secretion for all the paracrine factors 
investigated giving further information as to their mode of function. As the in vivo 
endometrium contains vascular cells and immune cell populations including uNK cells, 
protein studies such as immunohistochemistry may reveal the distribution of CXCL12 
and CXCR4 in all endometrial cell types. As FCS can potentially alter the behaviour of 
cells in culture, attempts could be made to successfully grow cultures without using 
FCS as a cell supplement and cell culture n numbers could be increased to reduce the 
effect of experimental variation during statistical analysis of the results.
This study concentrated on the effects of one isoform of CXCL12. Several other 
functional isoforms of CXCL12 produced by alternative splicing have been identified 
(Yu et al., 2006). Studying the effects of these isoforms in the endometrial cells could 
give more detailed information on the function of CXCL12 and CXCR4 in the 
endometrium. Recent studies have shown that CXCL12 may possibly function through 
an alternative chemokine receptor called CXCR7 (Mahabaleshwa et al., 2008). 
Identification of this receptor in the endometrium and if present, measuring 
expression throughout the menstrual cycle and identifying the cell types which express 
CXCR7 might also help understand the roles of CXCL12 in endometrial function.
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The evidence generated by this study suggests CXCR4 expression is maximal during the 
early proliferative phase of the endometrium and in ishikawa cells that CXCL12 may act 
as an endometrial cell growth factor (Tsutsumi et al., 2011). As the microarray study 
showed CXCL12 could regulate genes involved in cell proliferation and apoptosis, 
primary cell cultures could be used to further investigate the potential for CXCL12 to 
act as a growth factor in endometrium via CXCR4. As cell differentiation and 
angiogenesis are also important processes occurring in the endometrium during the 
proliferative phase of the menstrual cycle, primary cell culture models could also be 
used to investigate to what extent, if at all, CXCL12 and CXCR4 contribute to this 
process in the endometrium. Using antagonists to CXCR4 and inhibiting its activity 
through intracellular signaling could be of key importance to elucidating the precise 
actions of this chemokine and receptor in the endometrium.
6.10 General conclusions
This study has identified the expression of CXCL12 and CXCR4 mRNA in the 
endometrium through the menstrual cycle and suggested little change in CXCL12 
expression, but increased expression of CXCR4 in the early proliferative phase. The 
effects of CXCL12 on IL6, IL8, MMP2, MMP9 and VEGFA were measured in endometrial 
epithelial, stromal, Ishikawa and HEC-l-B cells. Despite CXCL12 affecting expression of 
these factors in non-endometrial cells, this effect was not observed in endometrial 
cells. The differential expression of CXCL12, IL6, IL8, MMP2, MMP9 and VEGFA 
between primary epithelial cells and HEC-l-B and Ishikawa cell lines, with low levels 
being expressed by the cell lines suggest that these cell lines are not good models for 
studying endometrial function. Microarray expression analysis showed that CXCL12 
up-regulated unknown gene transcripts, known genes transcripts that have not 
previously shown to be importance in endometrial cell types and transcripts that have 
previously been shown to be of importance in the endometrium but have not been 
linked to CXCL12. The study therefore indicates directions of further study in order to 
further understand the role of CXCL12 and CXCR4 in the endometrium.
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